

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number
WO 03/101400 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number: PCT/US03/17559
- (22) International Filing Date: 4 June 2003 (04.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/385,505 4 June 2002 (04.06.2002) US
- (71) Applicant (for all designated States except US): **AVALON PHARMACEUTICALS, INC.** [US/US]; 20358 Seneca Meadows Parkway, Germantown, MD 20876 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SHEA, Martin** [US/US]; 345 Market Street West #316, Gaithersburg, MD 20878 (US). **EBNER, Reinhard** [US/US]; 9906 Shelburn Terrace #316, Gaithersburg, MD 20878 (US).
- (74) Agents: **GRANT, Alan, J.** et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/101400 A2

(54) Title: CANCER-LINKED GENE AS TARGET FOR CHEMOTHERAPY

(57) Abstract: Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with processes for assaying potential antitumor agents based on their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as by using the antibody to target cancerous cells *in vivo* for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing using the gene sequences.

CANCER-LINKED GENE AS TARGET FOR CHEMOTHERAPY

5

This application claims priority of U.S. Provisional Patent Application 60/385,505, filed 4 June 2002, the disclosure of which is hereby incorporated
10 by reference in its entirety.

15

FIELD OF THE INVENTION

The present invention relates to methods of screening cancer-linked genes and expression products for involvement in the cancer initiation and
20 facilitation process as a means of cancer diagnosis as well as the use of such genes for screening potential anti-cancer agents, including small organic compounds and other molecules, and development of therapeutic agents.

25

BACKGROUND OF THE INVENTION

Cancer-linked genes are valuable in that they indicate genetic differences between cancer cells and normal cells, such as where a gene is expressed in a cancer cell but not in a non-cancer cell, or where said gene is over-expressed or expressed at a higher level in a cancer as opposed to normal or non-cancer cell. In addition, the expression of such a gene in a normal cell but not in a cancer cell, especially of the same type of tissue, can indicate important functions in the cancerous process. For example, screening
30 assays for novel drugs are based on the response of model cell based
35

systems *in vitro* to treatment with specific compounds. Such genes are also useful in the diagnosis of cancer and the identification of a cell as cancerous. Gene activity is readily measured by measuring the rate of production of gene products, such as RNAs and polypeptides encoded by such genes. Where 5 genes encode cell surface proteins, appearance of, or alterations in, such proteins, as cell surface markers, are an indication of neoplastic activity. Some such screens rely on specific genes, such as oncogenes (or gene mutations). In accordance with the present invention, a cancer-linked gene has been identified and its putative amino acid sequence worked out. Such 10 gene is useful in the diagnosing of cancer, the screening of anticancer agents and the treatment of cancer using such agents, especially in that these genes encode polypeptides that can act as markers, such as cell surface markers, thereby providing ready targets for anti-tumor agents such as antibodies, preferably antibodies complexed to cytotoxic agents, including apoptotic 15 agents.

BRIEF SUMMARY OF THE INVENTION

20

In accordance with the present invention, there is provided herein a cancer specific gene, linked especially to kidney cancer, or otherwise involved in the cancer initiating and facilitating process and the derived amino acid sequence thereof, including a number of different transcripts derived from said 25 gene.

In one aspect, the present invention relates to a process for identifying an agent that modulates the activity of a cancer-related gene comprising:

(a) contacting a compound with a cell containing a gene that 30 corresponds to a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1-7, 14-20 and 27-33, and under conditions promoting the expression of said gene; and

(b) detecting a difference in expression of said gene relative to when said compound is not present

thereby identifying an agent that modulates the activity of a cancer-related gene.

5

In various embodiments of such a process, the cell is a cancer cell and the difference in expression is a decrease in expression. Such polynucleotides may also include those that have sequences identical to SEQ ID NO: 1-7, 14-20 and 27-33.

10

In another aspect, the present invention relates to a process for identifying an anti-neoplastic agent comprising contacting a cell exhibiting neoplastic activity with a compound first identified as a cancer related gene modulator using an assay process disclosed herein and detecting a decrease 15 in said neoplastic activity after said contacting compared to when said contacting does not occur. Such neoplastic activity may include accelerated cellular replication and/or metastasis, and the decrease in neoplastic activity preferably results from the death of the cell, or senescence, terminal differentiation or growth inhibition.

20

The present invention also relates to a process for identifying an anti-neoplastic agent comprising administering to an animal exhibiting a cancer condition an effective amount of an agent first identified according to a process of one of one of the assays disclosed according to the invention and 25 detecting a decrease in said cancerous condition.

The present invention further relates to a process for determining the cancerous status of a cell, comprising determining an increase in the level of expression in said cell of at least one gene that corresponds to a 30 polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1-7, 14-20 and 27-33 wherein an elevated expression relative to a known non-cancerous cell indicates a cancerous state or potentially

cancerous state. Such elevated expression may be due to an increased copy number.

The present invention additionally relates to an isolated polypeptide,
5 encoded by one of the polynucleotide transcripts disclosed herein, comprising
an amino acid sequence homologous to an amino acid sequence selected
from the group consisting of SEQ ID NO: 8-13, 21-26 and 34-39, wherein any
difference between said amino acid sequence and the sequence of SEQ ID
NO: 8-13, 21-26 and 34-39 is due solely to conservative amino acid
10 substitutions and wherein said isolated polypeptide comprises at least one
immunogenic fragment. In a preferred embodiment, the present invention
encompasses an isolated polypeptide comprising an amino acid sequence
homologous to an amino acid sequence selected from the group consisting of
SEQ ID NO: 8-13, 21-26 and 34-39. These represent kidney cell surface
15 antigens.

The present invention also relates to an antibody that reacts with a
polypeptide as disclosed herein, preferably a polypeptide comprising an
amino acid sequence selected from the group consisting of SEQ ID NO: 8-13,
20 21-26 and 34-39. Such an antibody may be polyclonal, monoclonal,
recombinant or synthetic in origin.

In one such embodiment, said antibody is associated, either
covalently or non-covalently, with a cytotoxic agent, for example, an
apoptotic agent. Thus, the present invention relates to an
25 immunoconjugate comprising an antibody of the invention and a cytotoxic
agent.

The present invention also relates to a process for treating cancer
30 comprising contacting a cancerous cell with an agent having activity against
an expression product encoded by a gene sequence selected from the group
consisting of SEQ ID NO: 1-7, 14-20 and 27-33. In one such embodiment, the

cancerous cell is contacted *in vivo*. In another such embodiment, said agent has affinity for said expression product. In a preferred embodiment, such agent is an antibody disclosed herein, such as an antibody that is specific or selective for, or otherwise reacts with, a polypeptide of the invention. In a 5 preferred embodiment, the expression product is a polypeptide incorporating an amino acid sequence selected from SEQ ID NO: 8-13, 21-26 and 34-39.

The present invention further encompasses an immunogenic composition comprising a polypeptide disclosed herein, as well as 10 compositions formed using antibodies specific for these polypeptides.

The present invention is also directed to uses of such compositions. Such uses include a method for treating cancer in an animal afflicted therewith comprising administering to said animal an amount of an 15 immunogenic composition of one or more of the polypeptides disclosed herein where such amount is an amount sufficient to elicit the production of cytotoxic T lymphocytes specific for a polypeptide of the invention, preferably a polypeptide incorporating a sequence of SEQ ID NO: 8-13, 21-26 and 34-39. In a preferred embodiment, the animal to be so treated is a human patient.

20

DEFINITIONS

As used herein, the terms "portion," "segment," and "fragment," when 25 used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides 30 resulting from such treatment would represent portions, segments or fragments of the starting polypeptide. When used in relation to a polynucleotides, such

terms refer to the products produced by treatment of said polynucleotides with any of the common endonucleases.

As used herein, the term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). It could also be produced recombinantly and subsequently purified. For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides, for example, those prepared recombinantly, could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment. In one embodiment of the present invention, such isolated, or purified, polypeptide is useful in generating antibodies for practicing the invention, or where said antibody is attached to a cytotoxic or cytolytic agent, such as an apoptotic agent.

The term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

25 Percent Identity = 100 [1-(C/R)]

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence

that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted
5 as a base or amino acid.

If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the
10 Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity.

15 As known in the art "similarity" between two polypeptides is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide.

In accordance with the present invention, the term "DNA segment" or
20 "DNA sequence" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its
25 component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame,
30 where the same do not interfere with manipulation or expression of the coding regions.

The term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding *in vivo* for the native expression product of the gene. The coding region can be from a normal, 5 mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

In accordance with the present invention, the term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. Generally, DNA segments encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory 10 elements derived from a microbial, eukaryotic or viral operon.

The term "expression product" means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding 15 for the same amino acid(s).

The term "active fragment," when referring to a coding sequence, means a portion comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.

The term "primer" means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'-OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

30 The term "promoter" means a region of DNA involved in binding of RNA polymerase to initiate transcription. The term "enhancer" refers to a region of DNA that, when present and active, has the effect of increasing expression of

a different DNA sequence that is being expressed, thereby increasing the amount of expression product formed from said different DNA sequence.

The term "open reading frame (ORF)" means a series of triplets coding 5 for amino acids without any termination codons and is a sequence (potentially) translatable into protein.

As used herein, reference to a "DNA sequence" includes both single stranded and double stranded DNA. Thus, the specific sequence, unless the 10 context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded DNA) and the complement of such sequence.

As used herein, "corresponding genes" refers to genes that encode an 15 RNA that is at least 90% identical, preferably at least 95% identical, most preferably at least 98% identical, and especially identical, to an RNA encoded by one of the nucleotide sequences disclosed herein (i.e., SEQ ID NO: 1-7, 14-20 and 27-33). Such genes will also encode the same polypeptide sequence as any of the sequences disclosed herein, preferably SEQ ID NO: 20 1-7, 14-20 and 27-33, but may include differences in such amino acid sequences where such differences are limited to conservative amino acid substitutions, such as where the same overall three dimensional structure, and thus the same antigenic character, is maintained. Thus, amino acid sequences may be within the scope of the present invention where they react 25 with the same antibodies that react with polypeptides comprising the sequences of SEQ ID NO: 8-13, 21-26 and 34-39. A "corresponding gene" includes splice variants thereof.

The genes identified by the present disclosure are considered "cancer-related" genes, as this term is used herein, and include genes expressed at 30 higher levels (due, for example, to elevated rates of expression, elevated extent of expression or increased copy number) in cancer cells relative to

expression of these genes in normal (i.e., non-cancerous) cells where said cancerous state or status of test cells or tissues has been determined by methods known in the art, such as by reverse transcriptase polymerase chain reaction (RT-PCR) as described in the Examples herein. In specific 5 embodiments, this relates to the genes whose sequences correspond to the sequences of SEQ ID NO: 1-7, 14-20 and 27-33.

As used herein, the term "conservative amino acid substitutions" are defined herein as exchanges within one of the following five groups:

- 10 I. Small aliphatic, nonpolar or slightly polar residues:
 Ala, Ser, Thr, Pro, Gly;
- II. Polar, negatively charged residues and their amides:
 Asp, Asn, Glu, Gln;
- III. Polar, positively charged residues:
 His, Arg, Lys;
- 15 IV. Large, aliphatic, nonpolar residues:
 Met Leu, Ile, Val, Cys
- V. Large, aromatic residues:
 Phe, Tyr, Trp

20

DETAILED SUMMARY OF THE INVENTION

- 25 The present invention relates to processes for utilizing a nucleotide sequence for a cancer-linked gene, polypeptides encoded by such sequences and antibodies reactive with such polypeptides in methods of treating and diagnosing cancer, preferably kidney cancer, and in carrying out screening assays for agents effective in reducing the activity of cancer-linked genes and
30 thereby treating a cancerous condition.

The polypeptides disclosed herein incorporate various polynucleotide transcripts (SEQ ID NO: 1-7, 14-20 and 27-33) and the derived amino acid sequence (SEQ ID NO: 8-13, 21-26 and 34-39) from said transcripts are available as targets for chemotherapeutic agents, especially anti-cancer agents, including antibodies specific for said polypeptides.

The cancer-related polynucleotide sequences disclosed herein correspond to gene sequences whose expression is indicative of the cancerous status of a given cell. Such sequences are substantially identical to SEQ ID NO: 1-7, 14-20 and 27-33, which represent different transcripts identified from the GenBank EST database and which exhibit cancer-specific expression. The polynucleotides of the invention are those that correspond to a sequence of SEQ ID NO: 1-7, 14-20 and 27-33. Such sequences have been searched within the GenBank database, especially the EST database, with results as follows:

Type:	cell-surface tumor antigen therapeutic antibody target
Tissue:	kidney
Accession(s):	AI479935, AI479935, AI186520
Unigene cluster-ID(s):	Hs.61384
Chromosomal location:	3

The nucleotides and polypeptides, as gene products, used in the processes of the present invention may comprise a recombinant polynucleotide or polypeptide, a natural polynucleotide or polypeptide, or a synthetic polynucleotide or polypeptide, or a recombinant polynucleotide or polypeptide.

Fragments of such polynucleotides and polypeptides as are disclosed herein may also be useful in practicing the processes of the present invention.

For example, a fragment, derivative or analog of the polypeptide (SEQ ID NO: 8-13, 21-26 and 34-39) may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid 5 residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature 10 polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide (such as a histidine hexapeptide) or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

15

In another aspect, the present invention relates to an isolated polypeptide, including a purified polypeptide, comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 8-13 and/or 21-26 and/or 34-39. In preferred embodiments, said isolated 20 polypeptide comprises an amino acid sequence having sequence identity of at least 95%, preferably at least about 98%, and especially is identical to, the sequence of SEQ ID NO: 8-13 and/or 21-26 and/or 34-39. The present invention also includes isolated active fragments of such polypeptides where said fragments retain the biological activity of the polypeptide or where such 25 active fragments are useful as specific targets for cancer treatment, prevention or diagnosis. Thus, the present invention relates to any polypeptides, or fragments thereof, with sufficient sequence homology to the sequences disclosed herein as to be useful in the production of antibodies that react with (i.e., are selective or specific for) the polypeptides of SEQ ID NO: 8-13, 21-26 30 and 34-39 so as to be useful in targeting cells that exhibit such polypeptides, or fragments, on their surfaces, thereby providing targets for such antibodies and therapeutic agents associated with such antibodies.

The polynucleotides and polypeptides useful in practicing the processes of the present invention may likewise be obtained in an isolated or purified form. In addition, the polypeptide disclosed herein as being useful in practicing the processes of the invention are believed to be surface proteins present on cells, such as cancerous cells. Precisely how such cancer-linked proteins are used in the processes of the invention may thus differ depending on the therapeutic approach used. For example, cell-surface proteins, such as receptors, are desirable targets for cytotoxic antibodies that can be generated against the polypeptides disclosed herein.

The sequence information disclosed herein, as derived from the GenBank submissions, can readily be utilized by those skilled in the art to prepare the corresponding full-length polypeptide by peptide synthesis. The same is true for either the polynucleotides or polypeptides disclosed herein for use in the methods of the invention.

The present invention relates to an isolated polypeptide, encoded by one of the polynucleotide transcripts disclosed herein, comprising an amino acid sequence homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 8-13, 21-26 and 34-39, wherein any difference between amino acid sequence in the isolated polypeptide and the sequence of SEQ ID NO: 8-13, 21-26 and 34-39 is due solely to conservative amino acid substitutions and wherein said isolated polypeptide comprises at least one immunogenic fragment. In a preferred embodiment, the present invention encompasses an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8-13, 21-26 and 34-39.

Methods of producing recombinant cells and vectors useful in preparing the polynucleotides and polypeptides disclosed herein are well known to those skilled in the molecular biology art. See, for example,

Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), Wu et al., *Methods in Gene Biotechnology* (CRC Press, New York, NY, 1997), and *Recombinant Gene Expression Protocols*, in *Methods in Molecular Biology*, Vol. 62, (Tuan, ed., Humana Press, Totowa, NJ, 1997), the disclosures of which are hereby incorporated by reference.

In one aspect, the present invention relates to a process for identifying an agent that modulates the activity of a cancer-related gene comprising:

- (a) contacting a compound with a cell containing a gene that corresponds to a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1-7, 14-20 and 27-33 and under conditions promoting the expression of said gene; and
- (b) detecting a difference in expression of said gene relative to when said compound is not present
- 15 thereby identifying an agent that modulates the activity of a cancer-related gene.

In specific embodiments of such process the cell is a cancer cell and the difference in expression is a decrease in expression. Such 20 polynucleotides may also include those that have sequences identical to SEQ ID NO: 1-7, 14-20 and 27-33.

In another aspect, the present invention relates to a process for identifying an anti-neoplastic agent comprising contacting a cell exhibiting neoplastic activity with a compound first identified as a cancer related gene modulator using an assay process disclosed herein and detecting a decrease 25 in said neoplastic activity after said contacting compared to when said contacting does not occur. Such neoplastic activity may include accelerated cellular replication and/or metastasis, and the decrease in neoplastic activity 30 preferably results from the death of the cell.

The present invention also relates to a process for identifying an anti-neoplastic agent comprising administering to an animal exhibiting a cancer condition an effective amount of an agent first identified according to a process of one of one of the assays disclosed according to the invention and
5 detecting a decrease in said cancerous condition.

In specific embodiments of the present invention, the genes useful for the invention comprise genes that correspond to polynucleotides having a sequence selected from SEQ ID NO: 1-7, 14-20 and 27-33, or may comprise
10 the sequence of any of the polynucleotides disclosed herein (where the latter are cDNA sequences).

In accordance with the present invention, such assays rely on methods of determining the activity of the gene in question. Such assays are
15 advantageously based on model cellular systems using cancer cell lines, primary cancer cells, or cancerous tissue samples that are maintained in growth medium and treated with compounds at a single concentration or at a range of concentrations. At specific times after treatment, cellular RNAs are conveniently isolated from the treated cells or tissues, which RNAs are
20 indicative of expression of selected genes. The cellular RNA is then divided and subjected to differential analysis that detects the presence and/or quantity of specific RNA transcripts, which transcripts may then be amplified for detection purposes using standard methodologies, such as, for example, reverse transcriptase polymerase chain reaction (RT-PCR), etc. The presence
25 or absence, or concentration levels, of specific RNA transcripts are determined from these measurements. The polynucleotide sequences disclosed herein are readily used as probes for the detection of such RNA transcripts and thus the measurement of gene activity and expression.

30 The polynucleotides of the invention can include fully operational genes with attendant control or regulatory sequences or merely a polynucleotide

sequence encoding the corresponding polypeptide or an active fragment or analog thereof.

Because expression of the polynucleotide sequences disclosed herein
5 are specific to the cancerous state, useful gene modulation is downward
modulation, so that, as a result of exposure to an antineoplastic agent
identified by the screening assays herein, the corresponding gene of the
cancerous cell is expressed at a lower level (or not expressed at all) when
exposed to the agent as compared to the expression when not exposed to the
10 agent. For example, the gene sequences disclosed herein (SEQ ID NO: 1-7,
14-20 and 27-33) correspond to a gene expressed at a higher level in cells of
kidney cancer than in normal kidney cells. Thus, where said chemical agent
causes this gene of the tested cell to be expressed at a lower level than the
same genes of the reference, this is indicative of downward modulation and
15 indicates that the chemical agent to be tested has anti-neoplastic activity.

In carrying out the assays disclosed herein, relative antineoplastic activity
may be ascertained by the extent to which a given chemical agent modulates
the expression of genes present in a cancerous cell. Thus, a first chemical agent
20 that modulates the expression of a gene associated with the cancerous state
(i.e., a gene corresponding to one or more of the polynucleotide transcripts
disclosed herein) to a larger degree than a second chemical agent tested by the
assays of the invention is thereby deemed to have higher, or more desirable, or
more advantageous, anti-neoplastic activity than said second chemical agent.
25

The gene expression to be measured is commonly assayed using RNA
expression as an indicator. Thus, the greater the level of RNA (for example,
messenger RNA or mRNA) detected the higher the level of expression of the
corresponding gene. Thus, gene expression, either absolute or relative, is
30 determined by the relative expression of the RNAs encoded by such genes.

RNA may be isolated from samples in a variety of ways, including lysis and denaturation with a phenolic solution containing a chaotropic agent (e.g., trizol) followed by isopropanol precipitation, ethanol wash, and resuspension in aqueous solution; or lysis and denaturation followed by isolation on solid support, such as a Qiagen resin and reconstitution in aqueous solution; or lysis and denaturation in non-phenolic, aqueous solutions followed by enzymatic conversion of RNA to DNA template copies.

Normally, prior to applying the processes of the invention, steady state RNA expression levels for the genes, and sets of genes, disclosed herein will have been obtained. It is the steady state level of such expression that is affected by potential anti-neoplastic agents as determined herein. Such steady state levels of expression are easily determined by any methods that are sensitive, specific and accurate. Such methods include, but are in no way limited to, real time quantitative polymerase chain reaction (PCR), for example, using a Perkin-Elmer 7700 sequence detection system with gene specific primer probe combinations as designed using any of several commercially available software packages, such as Primer Express software., solid support based hybridization array technology using appropriate internal controls for quantitation, including filter, bead, or microchip based arrays, solid support based hybridization arrays using, for example, chemiluminescent, fluorescent, or electrochemical reaction based detection systems.

The gene expression indicative of a cancerous state need not be characteristic of every cell of a given tissue. Thus, the methods disclosed herein are useful for detecting the presence of a cancerous condition within a tissue where less than all cells exhibit the complete pattern. Thus, for example, a selected gene corresponding to the sequence of SEQ ID NO: 1, may be found, using appropriate probes, either DNA or RNA, to be present in as little as 60% of cells derived from a sample of tumorous, or malignant, tissue. In a highly preferred embodiment, such gene pattern is found to be

present in at least 100% of cells drawn from a cancerous tissue and absent from at least 100% of a corresponding normal, non-cancerous, tissue sample.

Expression of a gene may be related to copy number, and changes in expression may be measured by determining copy number. Such change in gene copy number may be determined by determining a change in expression of messenger RNA encoded by a particular gene sequence, especially that of SEQ ID NO: 1-7, 14-20 and 27-33. Also in accordance with the present invention, said gene may be a cancer initiating or facilitating gene. In carrying out the methods of the present invention, a cancer facilitating gene is a gene that, while not directly initiating tumor formation or growth, acts, such as through the actions of its expression product, to direct, enhance, or otherwise facilitate the progress of the cancerous condition, including where such gene acts against genes, or gene expression products, that would otherwise have the effect of decreasing tumor formation and/or growth.

Although the expression of a gene corresponding to a sequence of SEQ ID NO: 1-7, 14-20 and 27-33 may be indicative of a cancerous status for a given cell, the mere presence of such a gene may not alone be sufficient to achieve a malignant condition and thus the level of expression of such gene may also be a significant factor in determining the attainment of a cancerous state. Thus, it becomes essential to also determine the level of expression of a gene as disclosed herein, including substantially similar sequences, as a separate means of diagnosing the presence of a cancerous status for a given cell, groups of cells, or tissues, either in culture or *in situ*.

The level of expression of the polypeptides disclosed herein is also a measure of gene expression, such as polypeptides having sequence identical, or similar to, any polypeptide encoded by a sequence of SEQ ID NO: 1-7, 14-20 and 27-33, especially a polypeptide whose amino acid sequence is the sequence of SEQ ID NO: 8-13, 21-26 and 34-39.

In accordance with the foregoing, the present invention specifically contemplates a method for determining the cancerous status of a cell to be tested, comprising determining the level of expression in said cell of a gene that includes one of the nucleotide sequences selected from the sequences of
5 SEQ ID NO: 1-7, 14-20 and 27-33, including sequences substantially identical to said sequences, or characteristic fragments thereof, or the complements of any of the foregoing and then comparing said expression to that of a cell known to be non-cancerous whereby the difference in said expression indicates that said cell to be tested is cancerous.

10

In accordance with the invention, although gene expression for a gene that includes as a portion thereof one of the sequences of SEQ ID NO: 1-7, 14-20 and 27-33, is preferably determined by use of a probe that is a fragment of such nucleotide sequence, it is to be understood that the probe
15 may be formed from a different portion of the gene. Expression of the gene may be determined by use of a nucleotide probe that hybridizes to messenger RNA (mRNA) transcribed from a portion of the gene other than the specific nucleotide sequence disclosed herein.

20

It should be noted that there are a variety of different contexts in which genes have been evaluated as being involved in the cancerous process. Thus, some genes may be oncogenes and encode proteins that are directly involved in the cancerous process and thereby promote the occurrence of cancer in an animal. In addition, other genes may serve to suppress the
25 cancerous state in a given cell or cell type and thereby work against a cancerous condition forming in an animal. Other genes may simply be involved either directly or indirectly in the cancerous process or condition and may serve in an ancillary capacity with respect to the cancerous state. All such types of genes are deemed with those to be determined in accordance
30 with the invention as disclosed herein. Thus, the gene determined by said process of the invention may be an oncogene, or the gene determined by said process may be a cancer facilitating gene, the latter including a gene that

directly or indirectly affects the cancerous process, either in the promotion of a cancerous condition or in facilitating the progress of cancerous growth or otherwise modulating the growth of cancer cells, either *in vivo* or *ex vivo*. In addition, the gene determined by said process may be a cancer suppressor 5 gene, which gene works either directly or indirectly to suppress the initiation or progress of a cancerous condition. Such genes may work indirectly where their expression alters the activity of some other gene or gene expression product that is itself directly involved in initiating or facilitating the progress of a cancerous condition. For example, a gene that encodes a polypeptide, 10 either wild or mutant in type, which polypeptide acts to suppress of tumor suppressor gene, or its expression product, will thereby act indirectly to promote tumor growth.

As noted previously, polynucleotides encoding the same proteins as 15 any of SEQ ID NO: 1-7, 14-20 and 27-33, regardless of the percent identity of such sequences, are also specifically contemplated by any of the methods of the present invention that rely on any or all of said sequences, regardless of how they are otherwise described or limited. Thus, any such sequences are available for use in carrying out any of the methods disclosed according to the 20 invention. Such sequences also include any open reading frames, as defined herein, present within the sequence of SEQ ID NO: 1-7, 14-20 and 27-33.

Because a gene disclosed according to the invention "corresponds to" a polynucleotide having a sequence of SEQ ID NO: 1-7, 14-20 and 27-33, 25 said gene encodes an RNA (processed or unprocessed, including naturally occurring splice variants and alleles) that is at least 90% identical, preferably at least 95% identical, most preferably at least 98% identical to, and especially identical to, an RNA that would be encoded by, or be complementary to, such as by hybridization with, a polynucleotide having the indicated sequence. In addition, genes including sequences at least 90% 30 identical to a sequence selected from SEQ ID NO: 1-7, 14-20 and 27-33, preferably at least about 95% identical to such a sequence, more preferably at

least about 98% identical to such sequence and most preferably comprising such sequence are specifically contemplated by all of the processes of the present invention. Sequences encoding the same proteins as any of these sequences, regardless of the percent identity of such sequences, are also 5 specifically contemplated by any of the methods of the present invention that rely on any or all of said sequences, regardless of how they are otherwise described or limited. The polynucleotide sequences of the invention also include any open reading frames, as defined herein, present within any of the sequences of SEQ ID NO: 1-7, 14-20 and 27-33.

10

The sequences disclosed herein may be genomic in nature and thus represent the sequence of an actual gene, such as a human gene, or may be a cDNA sequence derived from a messenger RNA (mRNA) and thus represent contiguous exonic sequences derived from a corresponding 15 genomic sequence, or they may be wholly synthetic in origin for purposes of practicing the processes of the invention. Because of the processing that may take place in transforming the initial RNA transcript into the final mRNA, the sequences disclosed herein may represent less than the full genomic sequence. They may also represent sequences derived from ribosomal and 20 transfer RNAs. Consequently, the gene as present in the cell (and representing the genomic sequence) and the polynucleotide transcripts disclosed herein, including cDNA sequences, may be identical or may be such that the cDNAs contain less than the full genomic sequence. Such genes and cDNA sequences are still considered "corresponding sequences" 25 (as defined elsewhere herein) because they both encode the same or related RNA sequences (i.e., related in the sense of being splice variants or RNAs at different stages of processing). Thus, by way of non-limiting example only, a gene that encodes an RNA transcript, which is then processed into a shorter mRNA, is deemed to encode both such RNAs and therefore encodes an RNA 30 complementary to (using the usual Watson-Crick complementarity rules), or that would otherwise be encoded by, a cDNA (for example, a sequence as disclosed herein). Thus, the sequences disclosed herein correspond to genes

- contained in the cancerous cells (here, kidney cancer) and are used to determine gene activity or expression because they represent the same sequence or are complementary to RNAs encoded by the gene. Such a gene also includes different alleles and splice variants that may occur in the cells
- 5 used in the methods of the invention, such as where recombinant cells are used to assay for anti-neoplastic agents and such cells have been engineered to express a polynucleotide as disclosed herein, including cells that have been engineered to express such polynucleotides at a higher level than is found in non-engineered cancerous cells or where such recombinant cells
- 10 express such polynucleotides only after having been engineered to do so. Such engineering includes genetic engineering, such as where one or more of the polynucleotides disclosed herein has been inserted into the genome of such cell or is present in a vector.
- 15 Such cells, especially mammalian cells, may also be engineered to express on their surfaces one or more of the polypeptides of the invention for testing with antibodies or other agents capable of masking such polypeptides and thereby removing the cancerous nature of the cell. Such engineering includes both genetic engineering, where the genetic complement of the cells
- 20 is engineered to express the polypeptide, as well as non-genetic engineering, whereby the cell has been physically manipulated to incorporate a polypeptide of the invention in its plasma membrane, such as by direct insertion using chemical and/or other agents to achieve this result.
- 25 In accordance with the foregoing, the present invention includes anti-cancer agents that are themselves either polypeptides, or small chemical entities, that affect the cancerous process, including initiation, suppression or facilitation of tumor growth, either *in vivo* or *ex vivo*. Said cancer modulating agent will have the effect of decreasing gene expression.
- 30 The present invention thus also relates to a method for treating cancer comprising contacting a cancerous cell with an agent having activity against

an expression product encoded by a gene or polynucleotide sequence as disclosed herein, such as one having, or corresponding to, the nucleotide sequence of SEQ ID NO: 1-7, 14-20 and 27-33. The present invention also relates to a process for treating cancer comprising contacting a cancerous cell
5 with an agent having activity against an expression product encoded by a gene or polynucleotide sequence corresponding to a sequence selected from the group consisting of SEQ ID NO: 1-7, 14-20 and 27-33. In one such embodiment, the cancerous cell is contacted *in vivo*. In another such embodiment, said agent has affinity for said expression product. In a preferred
10 embodiment, such agent is an antibody disclosed herein, such as an antibody that is specific or selective for, or otherwise reacts with, a polypeptide of the invention. In a preferred embodiment, the expression product is a polypeptide incorporating an amino acid sequence selected from SEQ ID NO: 8-13, 21-26 and 34-39.

15

The present invention is also directed to such uses of the compositions of polypeptides and antibodies disclosed herein. Such uses include a process for treating cancer in an animal afflicted therewith comprising administering to said animal an amount of an immunogenic composition of one or more of the
20 polypeptides disclosed herein where such amount if an amount sufficient to elicit the production of cytotoxic T lymphocytes specific for a polypeptide of the invention, preferably a polypeptide incorporating a sequence of SEQ ID NO: 8-13, 21-26 and 34-39. In a preferred embodiment, the animal to be so treated is a human patient.

25

The proteins encoded by the genes disclosed herein due to their expression, or elevated expression, in cancer cells, represent highly useful therapeutic targets for "targeted therapies" utilizing such affinity structures as, for example, antibodies coupled to some cytotoxic agent. In such
30 methodology, it is advantageous that nothing need be known about the endogenous ligands or binding partners for such cell surface molecules. Rather, an antibody or equivalent molecule that can specifically recognize the

cell surface molecule (which could include an artificial peptide, a surrogate ligand, and the like) that is coupled to some agent that can induce cell death or a block in cell cycling offers therapeutic promise against these proteins. Thus, such approaches include the use of so-called suicide "bullets" against 5 intracellular proteins. For example, monoclonal antibodies may readily be produced by methods well known in the art, for example, the method of Kohler and Milstein (see: *Nature*, 256:495 (1975)).

With the advent of methods of molecular biology and recombinant 10 technology, it is now possible to produce antibody molecules by recombinant means and thereby generate gene sequences that code for specific amino acid sequences found in the polypeptide structure of the antibodies. Such antibodies can be produced by either cloning the gene sequences encoding the polypeptide chains of said antibodies or by direct synthesis of said 15 polypeptide chains, with *in vitro* assembly of the synthesized chains to form active tetrameric (H_2L_2) structures with affinity for specific epitopes and antigenic determinants. This has permitted the ready production of antibodies having sequences characteristic of neutralizing antibodies from different species and sources.

20 Regardless of the source of the antibodies, or how they are recombinantly constructed, or how they are synthesized, *in vitro* or *in vivo*, using transgenic animals, such as cows, goats and sheep, using large cell cultures of laboratory or commercial size, in bioreactors or by direct chemical synthesis employing no living organisms at any stage of the process, all 25 antibodies have a similar overall 3 dimensional structure. This structure is often given as H_2L_2 and refers to the fact that antibodies commonly comprise 2 light (L) amino acid chains and 2 heavy (H) amino acid chains. Both chains have regions capable of interacting with a structurally complementary antigenic target. The regions interacting with the target are referred to as 30 "variable" or "V" regions and are characterized by differences in amino acid sequence from antibodies of different antigenic specificity.

The variable regions of either H or L chains contains the amino acid sequences capable of specifically binding to antigenic targets. Within these sequences are smaller sequences dubbed "hypervariable" because of their extreme variability between antibodies of differing specificity. Such 5 hypervariable regions are also referred to as "complementarity determining regions" or "CDR" regions. These CDR regions account for the basic specificity of the antibody for a particular antigenic determinant structure.

The CDRs represent non-contiguous stretches of amino acids within 10 the variable regions but, regardless of species, the positional locations of these critical amino acid sequences within the variable heavy and light chain regions have been found to have similar locations within the amino acid sequences of the variable chains. The variable heavy and light chains of all 15 antibodies each have 3 CDR regions, each non-contiguous with the others (termed L1, L2, L3, H1, H2, H3) for the respective light (L) and heavy (H) chains. The accepted CDR regions have been described by Kabat et al., *J. Biol. Chem.* **252**:6609-6616 (1977).

In all mammalian species, antibody polypeptides contain constant (i.e., 20 highly conserved) and variable regions, and, within the latter, there are the CDRs and the so-called "framework regions" made up of amino acid sequences within the variable region of the heavy or light chain but outside the CDRs.

25 The antibodies disclosed according to the invention may also be wholly synthetic, wherein the polypeptide chains of the antibodies are synthesized and, possibly, optimized for binding to the polypeptides disclosed herein as being receptors. Such antibodies may be chimeric or humanized antibodies and may be fully tetrameric in structure, or may be dimeric and comprise only 30 a single heavy and a single light chain. Such antibodies may also include fragments, such as Fab and F(ab₂)' fragments, capable of reacting with and binding to any of the polypeptides disclosed herein as being receptors.

In one aspect, the present invention relates to immunoglobulins, or antibodies, as described herein, that react with, especially where they are specific for, the polypeptides having amino acid sequences as disclosed herein, preferably those having an amino acid sequence of one of SEQ ID NO: 8-13, 21-26 and 34-39. Such antibodies may commonly be in the form of a composition, especially a pharmaceutical composition. Such antibodies, by themselves, may have therapeutic value in that they are able to bind to, and thereby tie up, surface sites on cancerous cells. Where such sites have some type of function to perform (i.e., where they are surface enzymes, or channel structures, or structures that otherwise facilitate, actively or passively, the transport of nutrients and other vital materials to the cell. Such nutrients serve to facilitate the growth and replication of the cell and molecules that bind to such sites and thereby interfere with such activities can prove to have a therapeutic effect in that the result of such binding is to remove sources of nutrients from such cells, thereby interfering with growth and replication. In like manner, such binding may serve to remove vital enzyme activities from the cell's functional repertoire, thereby also interfering with viability and/or the ability of the cell to multiply or metastasize. In addition, by binding to such surface sites, the antibodies may serve to prevent the cells from reacting to environmental agents, such as cytokines and the like, that may facilitate growth, replication and metastasis, thereby further reducing the cancerous status of such cell and ameliorating the cancerous condition in a patient, even without proving fatal to the cell or cells so affected.

The methods of the present invention also include processes wherein the cancer cell is contacted *in vivo* as well as *ex vivo* with an agent that comprises a portion, or is part of an overall molecular structure, having affinity for an expression product of a gene corresponding to a polynucleotide sequence as disclosed herein, preferably where the expression product is a cell surface structure, most preferably a polypeptide as disclosed herein, such as one that comprises an amino acid sequence of SEQ ID NO: 8-13, 21-26 and 34-39. In one such embodiment, said portion having affinity for said

expression product is an antibody, especially where said expression product is a polypeptide or oligopeptide or comprises an oligopeptide portion, or comprises a polypeptide.

5 In another aspect, the present invention also relates to an antibody that reacts with a polypeptide as disclosed herein, preferably a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8-13, 21-26 and 34-39. Such an antibody may be polyclonal, monoclonal, recombinant or synthetic in origin. In one such embodiment, said 10 antibody is associated, either covalently or non-covalently, with a cytotoxic agent, for example, an apoptotic agent. It is thus contemplated that the antibody acts a targeted vector for guiding an associated therapeutic agent to a cancerous cell, such as a cell expressing a polypeptide homologous to, if not identical to, a polypeptide as disclosed herein.

15

Where the cytotoxic agent is itself a polypeptide, said may be linked directly to an antibody specific for a surface target on a cancer cell, such as where the polypeptide represents an extension of the amino acid chain of the antibody. In alternative embodiments, such molecules may be covalently 20 linked through a linker sequence of long or short duration, such as an amino acid sequence of 5 to 10 residues in length. Where the cytotoxic agents is some small organic molecule, such as a small organic compound, or some type of apoptotic agent, this may be covalently bonded to the antibody molecule or may be attached by some other type of non-covalent linkage, 25 including hydrophobic and electrostatic linkages. Methods for forming such linkages, especially covalent linkages, are well known to those skilled in the art.

The antibodies disclosed herein may also serve as targeting vectors for 30 much larger structures, such as liposomes. In one such embodiment, an antibody is part of, or otherwise linked to, or associated with, a membranous structure, preferably a liposome or possibly some type of cellular organelle,

which acts as a reservoir for a cytotoxic agent, such as ricin. The antibody then acts to target said liposome to a cancerous tissue in an animal, whereupon the liposome provides a source of cytotoxic agents for localized treatment of a solid tumor or other type of neoplasm.

5

The present invention further encompasses an immunogenic composition comprising a polypeptide disclosed herein, as well as compositions formed using antibodies specific for these polypeptides.

10

Methods well known in the art for making formulations are found in, for example, *Remington: The Science and Practice of Pharmacy*, (19th ed.) Ed. A.R. Gennaro, 1995, Mack Publishing Company, Easton, PA. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for agonists of the invention include ethylenevinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, or example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel. It should be noted that, where the therapeutic agent to be administered is an immunoconjugate, these sometimes contain chemical linkages that are somewhat labile in aqueous media and therefore must be stored prior to administration in a more stable environment, such as in the form of a lyophilized powder.

20

Such an agent can be a single molecular structure, comprising both affinity portion and anti-cancer activity portions, wherein said portions are derived from separate molecules, or molecular structures, possessing such

activity when separated and wherein such agent has been formed by combining said portions into one larger molecular structure, such as where said portions are combined into the form of an adduct. Said anti-cancer and affinity portions may be joined covalently, such as in the form of a single
5 polypeptide, or polypeptide-like, structure or may be joined non-covalently, such as by hydrophobic or electrostatic interactions, such structures having been formed by means well known in the chemical arts. Alternatively, the anti-cancer and affinity portions may be formed from separate domains of a single molecule that exhibits, as part of the same chemical structure, more than one
10 activity wherein one of the activities is against cancer cells, or tumor formation or growth, and the other activity is affinity for an expression product produced by expression of genes related to the cancerous process or condition.

In one embodiment of the present invention, a chemical agent, such as
15 a protein or other polypeptide, is joined to an agent, such as an antibody, having affinity for an expression product of a cancerous cell, such as a polypeptide or protein encoded by a gene related to the cancerous process, preferably a gene as disclosed herein according to the present invention, most preferably a polypeptide sequence disclosed herein. Thus, where the
20 presence of said expression product is essential to tumor initiation and/or growth, binding of said agent to said expression product will have the effect of negating said tumor promoting activity. In one such embodiment, said agent is an apoptosis-inducing agent that induces cell suicide, thereby killing the cancer cell and halting tumor growth.

25 Other genes within the cancer cell that are regulated in a manner similar to that of the genes disclosed herein and thus change their expression in a coordinated way in response to chemical compounds represent genes that are located within a common metabolic, signaling, physiological, or functional pathway so that by analyzing and identifying such commonly
30 regulated groups of genes (groups that include the gene, or similar sequences, disclosed according to the invention, one can (a) assign known genes and novel genes to specific pathways and (b) identify specific functions

and functional roles for novel genes that are grouped into pathways with genes for which their functions are already characterized or described. For example, one might identify a group of 10 genes, at least one of which is the gene as disclosed herein, that change expression in a coordinated fashion

5 and for which the function of one, such as the polypeptide encoded by the sequence disclosed herein, is known then the other genes are thereby implicated in a similar function or pathway and may thus play a role in the cancer-initiating or cancer-facilitating process. In the same way, if a gene were found in normal cells but not in cancer cells, or happens to be expressed

10 at a higher level in normal as opposed to cancer cells, then a similar conclusion may be drawn as to its involvement in cancer, or other diseases. Therefore, the processes disclosed according to the present invention at once provide a novel means of assigning function to genes, i.e. a novel method of functional genomics, and a means for identifying chemical compounds that

15 have potential therapeutic effects on specific cellular pathways. Such chemical compounds may have therapeutic relevance to a variety of diseases outside of cancer as well, in cases where such diseases are known or are demonstrated to involve the specific cellular pathway that is affected.

20 The polypeptides disclosed herein, preferably those of SEQ ID NO: 8-13, 21-26 and 34-39, also find use as vaccines in that, where the polypeptide represents a surface protein present on a cancer cell, such polypeptide may be administered to an animal, especially a human being, for purposes of activating cytotoxic T lymphocytes (CTLs) that will be specific for, and act to

25 lyze, cancer cells in said animal. Where used as vaccines, such polypeptides are present in the form of a pharmaceutical composition. The present invention may also employ polypeptides that have the same, or similar, immunogenic character as the polypeptides of SEQ ID NO: 8-13, 21-26 and 34-39 and thereby elicit the same, or similar, immunogenic response after

30 administration to an animal, such as an animal at risk of developing cancer, or afflicted therewith. Thus, the polypeptides disclosed according to the invention will commonly find use as immunogenic compositions.

Expression of a gene corresponding to a polynucleotide disclosed herein, when in normal tissues, may indicate a predisposition towards development of kidney cancer. The encoded polypeptide might then present a 5 potentially useful cell surface target for therapeutic molecules such as cytolytic antibodies, or antibodies attached to cytotoxic, or cytolytic, agents. .

The present invention specifically contemplates use of antibodies against the polypeptides encoded by the polynucleotides corresponding to the 10 genes disclosed herein, whereby said antibodies are conjugates to one or more cytotoxic agents so that the antibodies serve to target the conjugated immunotoxins to a region of cancerous activity, such as a solid tumor. For many known cytotoxic agents, lack of selectivity has presented a drawback to their use as therapeutic agents in the treatment of malignancies. For example, 15 the class of two-chain toxins, consisting of a binding subunit (or B-chain) linked to a toxic subunit (A-chain) are extremely cytotoxic. Thus, such agents as ricin, a protein isolated from castor beans, kills cells at very low concentrations (even less than 10^{-11} M) by inactivating ribosomes in said cells (see, for example, Lord et al., Ricin: structure, mode of action, and some 20 current applications. *Faseb J*, 8: 201-208 (1994), and Blättler et al., Realizing the full potential of immunotoxins. *Cancer Cells*, 1: 50-55 (1989)). While isolated A-chains of protein toxins that functionally resemble ricin A-chain are only weakly cytotoxic for intact cells (in the concentration range of 10^{-7} to 10^{-6} M), they are very potent cytotoxic agents inside the cells. Thus, a single 25 molecule of the A-subunit of diphtheria toxin can kill a cell once inside (see: Yamaizumi et al., One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. *Cell*, 15: 245-250, 1978).

The present invention solves this selectivity problem by using 30 antibodies specific for antigens present on cancer cells to target the cytotoxins to said cells. In addition, use of antibodies decreases toxicity because the antibodies are non-toxic until they reach the tumor and, because the cytotoxin

is bound to the antibody, it is presented with less opportunity to cause damage to non-targeted tissues.

In addition, use of such antibodies alone can provide therapeutic effects on the tumor through the antibody-dependent cellular cytotoxic response (ADCC) and complement-mediated cell lysis mechanisms.

A number of recombinant immunotoxins (for example, consisting of Fv regions of cancer specific antibodies fused to truncated bacterial toxins) are well known (see, for example, Smyth et al., Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies, *J. Natl. Cancer Inst.*, **76**(3):503-510 (1986); Cho et al., Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells, *Bioconjug. Chem.*, **8**(3):338-346 (1997)). As noted in the literature, these may contain, for example, a truncated version of *Pseudomonas* exotoxin as a toxic moiety but the toxin is modified in such a manner that by itself it does not bind to normal human cells, but it retains all other functions of cytotoxicity. Here, recombinant antibody fragments target the modified toxin to cancer cells which are killed, such as by direct inhibition of protein synthesis, or by concomitant induction of apoptosis. Cells that are not recognized by the antibody fragment, because they do not carry the cancer antigen, are not affected. Good activity and specificity has been observed for many recombinant immunotoxins in *in vitro* assays using cultured cancer cells as well as in animal tumor models. Ongoing clinical trials provide examples where the promising pre-clinical data correlate with successful results in experimental cancer therapy. (see, for example, Brinkmann U., Recombinant antibody fragments and immunotoxin fusions for cancer therapy, *In Vivo* (2000) **14**:21-27).

While the safety of employing immunoconjugates in humans has been established, *in vivo* therapeutic results have been less impressive. Because clinical use of mouse MAbs in humans is limited by the development of a foreign anti-globulin immune response by the human host, genetically

engineered chimeric human-mouse MAbs have been developed by replacing the mouse Fc region with the human constant region. In other cases, the mouse antibodies have been "humanized" by replacing the framework regions of variable domains of rodent antibodies by their human equivalents. Such 5 humanized and engineered antibodies can even be structurally arranged to have specificities and effector functions determined by design and which characteristics do not appear in nature. The development of bispecific antibodies, having different binding ends so that more than one antigenic site can be bound, have proven useful in targeting cancer cells. Thus, such 10 antibody specificity has been improved by chemical coupling to various agents such as bacterial or plant toxins, radionuclides or cytotoxic drugs and other agents. (see, for example, Bodey, B. et al). Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. *Curr Pharm Des* (2000) 15 Feb;6(3):261-76). See also, Garnett, M. C., Targeted drug conjugates: principles and progress. *Adv. Drug Deliv. Rev.* (2001 Dec 17) 53(2):171-216; Brinkmann et al., Recombinant immunotoxins for cancer therapy. *Expert Opin Biol Ther.* (2001) 1(4):693-702.

20 Among the cytotoxic agents specifically contemplated for use as immunoconjugates according to the present invention are Calicheamicin, a highly toxic enediyne antibiotic isolated from *Micromonospora echinospora* ssp. *Calichensis*, and which binds to the minor groove of DNA to induce double strand breaks and cell death (see: Lee et al., 25 Calicheamicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calicheamicin g₁. *J Am Chem Soc*, **109**: 3464-3466 (1987); Zein et al., Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically, *Science*, **240**: 1198-1201 (1988)). Useful derivatives of the calicheamicins include mylotarg and 138H11-Camθ. 30 Mylotarg is an immunoconjugate of a humanized anti-CD33 antibody (CD33 being found in leukemic cells of most patients with acute myeloid leukemia) and N-acetyl gamma colicheamicin dimethyl hydrazide, the latter of which is

readily coupled to an antibody of the present invention (in place of the anti-CD33 but which can also be humanized by substitution of human framework regions into the antibody during production as described elsewhere herein) to form an immunoconjugate of the invention. (see: Hamann et al. Gemtuzumab
5 Ozogamicin, A Potent and Selective Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia, *Bioconjug. Chem.* **13**, 47-58 (2002)) For use with 138H11-Camθ, 138H11 is an anti- γ -glutamyl transferase antibody coupled to theta calicheamicin through a disulfide linkage and found useful *in vitro* against cultured renal cell carcinoma cells.
10 (see: Knoll et al., Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin θ₁, *Cancer Res.* **60**: 6089-6094 (2000) The same linkage may be utilized to link this cytotoxic agent to an antibody of the present invention, thereby forming a targeting structure for kidney cancer cells.

15

Also useful in forming the immunoconjugates of the invention is DC1, a disulfide-containing analog of adozelesin, that kills cells by binding to the minor groove of DNA, followed by alkylation of adenine bases. Adozelesin is a structural analog of CC-1065, an anti-tumor antibiotic isolated from microbial fermentation of *Streptomyces zelensis*, and is about 1,000 fold more toxic to cultured cell lines than other DNA interacting agents, such as cis-platin and doxorubicin. This agent is readily linked to antibodies through the disulfide bond of adozelesin. (see: Chari et al., Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation, *Cancer Res.* **55**: 4079-4084 (1995)).

Maytansine, a highly cytotoxic microtubular inhibitor isolated from the shrub *Maytenus serrata* found to have little value in human clinical trials, is much more effective in its derivatized form, denoted DM1, containing a disulfide bond to facilitate linkage to antibodies, is up to 10-fold more cytotoxic
30 (see: Chari et al., Immunoconjugates containing novel maytansinoids: promising anticancer drugs, *Cancer Res.* **52**: 127-131 (1992)). These same *in vitro* studies showed that up to four DM1 molecules could be linked to a single

immunoglobulin without destroying the binding affinity. Such conjugates have been used against breast cancer antigens, such as the *neu/HER2/erbB-2* antigen. (see: Goldmacher et al., Immunogen, Inc., (2002) *in press*); also see Liu, C. et al., Eradication of large colon tumor xenografts by targeted delivery 5 of maytansinoids, *Proc. Natl. Acad. Sci. USA*, **93**, 8618-8623 (1996)). For example, Liu et al. (1996) describes formation of an immunoconjugate of the maytansinoid cytotoxin DM1 and C242 antibody, a murine IgG1 immunoglobulin, available from Pharmacia and which has affinity for a mucin-like glycoprotein variably expressed by human colorectal cancers. The latter 10 immunoconjugate was prepared according to Chari et al., *Cancer Res.*, **52**:127-131 (1992) and was found to be highly cytotoxic against cultured colon cancer cells as well as showing anti-tumor effects *in vivo* in mice bearing subcutaneous COLO 205 human colon tumor xenografts using doses well below the maximum tolerated dose.

15

In addition, there are a variety of protein toxins (cytotoxic proteins), which include a number of different classes, such as those that inhibit protein synthesis: ribosome-inactivating proteins of plant origin, such as ricin, abrin, gelonin, and a number of others, and bacterial toxins such as pseudomonas 20 exotoxin and diphtheria toxin.

Another useful class is the one including taxol, taxotere, and taxoids. Specific examples include paclitaxel (taxol), its analog docetaxel (taxotere), and derivatives thereof. The first two are clinical drugs used in treating a 25 number of tumors while the taxoids act to induce cell death by inhibiting the de-polymerization of tubulin. Such agents are readily linked to antibodies through disulfide bonds without disadvantageous effects on binding specificity.

30

In one instance, a truncated Pseudomonas exotoxin was fused to an anti-CD22 variable fragment and used successfully to treat patients with chemotherapy-resistant hairy-cell leukemia. (see: Kreitman et al., Efficacy of

the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia, *N Engl J Med*, **345**: 241-247 (2001)) Conversely, the cancer-linked peptides of the present invention offer the opportunity to prepare antibodies, recombinant or otherwise, against the appropriate 5 antigens to target solid tumors, preferably those of malignancies of kidney tissue, using the same or similar cytotoxic conjugates. Thus, many of the previously used immunoconjugates have been formed using antibodies against general antigenic sites linked to cancers whereas the antibodies formed using the peptides disclosed herein are more specific and target the 10 antibody-cytotoxic agent to a particular tissue or organ, thus further reducing toxicity and other undesirable side effects.

In addition, the immunoconjugates formed using the antibodies prepared against the cancer-linked antigens disclosed herein can be formed 15 by any type of chemical coupling. Thus, the cytotoxic agent of choice, along with the immunoglobulin, can be coupled by any type of chemical linkage, covalent or non-covalent, including electrostatic linkage, to form the immunoconjugates of the present invention.

20 When used as immunoconjugates, the antitumor agents of the present invention represent a class of pro-drugs that are relatively non-toxic when first administered to an animal (due mostly to the stability of the immunoconjugate), such as a human patient, but which are targeted by the conjugated immunoglobulin to a cancer cell where they then exhibit good 25 toxicity. The tumor-related, associated, or linked, antigens, preferably those presented herein, serve as targets for the antibodies (monoclonal, recombinant, and the like) specific for said antigens. The end result is the release of active cytotoxic agent inside the cell after binding of the immunoglobulin portion of the immunoconjugate.

30

The cited references describe a number of useful procedures for the chemical linkage of cytotoxic agents to immunoglobulins and the disclosures

of all such references cited herein are hereby incorporated by reference in their entirety. For other reviews see Ghetie et al., Immunotoxins in the therapy of cancer: from bench to clinic, *Pharmacol Ther*, **63**: 209-234 (1994), Pietersz et al. The use of monoclonal antibody immunoconjugates in cancer therapy, 5 *Adv Exp Med Biol*, **353**:169-179 (1994), and Pietersz, G. A. The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer, *Bioconjug Chem*, **1**:89-95 (1990).

Thus, the present invention provides highly useful cancer-associated 10 antigens for generation of antibodies for linkage to a number of different cytotoxic agents which are already known to have some *in vitro* toxicity and possess chemical groups available for linkage to antibodies.

The present invention also relates to a process that comprises a 15 method for producing a product, such as test data, comprising identifying an agent according to one of the disclosed processes for identifying such an agent (i.e., the therapeutic agents identified according to the assay procedures disclosed herein) wherein said product is the data collected with respect to said agent as a result of said identification process, or assay, and 20 wherein said data is sufficient to convey the chemical character and/or structure and/or properties of said agent. For example, the present invention specifically contemplates a situation whereby a user of an assay of the invention may use the assay to screen for compounds having the desired enzyme modulating activity and, having identified the compound, then 25 conveys that information (i.e., information as to structure, dosage, etc) to another user who then utilizes the information to reproduce the agent and administer it for therapeutic or research purposes according to the invention. For example, the user of the assay (user 1) may screen a number of test 30 compounds without knowing the structure or identity of the compounds (such as where a number of code numbers are used the first user is simply given samples labeled with said code numbers) and, after performing the screening process, using one or more assay processes of the present invention, then

imparts to a second user (user 2), verbally or in writing or some equivalent fashion, sufficient information to identify the compounds having a particular modulating activity (for example, the code number with the corresponding results). This transmission of information from user 1 to user 2 is specifically
5 contemplated by the present invention.

It should be cautioned that, in carrying out the procedures of the present invention as disclosed herein, whether to form immunoconjugates or screen for other antitumor agents using the genes and polypeptides disclosed
10 herein, any reference to particular buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one
15 buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make such substitutions as will optimally serve their purposes in using the methods and procedures disclosed herein.

20 The present invention will now be further described by way of the following non-limiting example. In applying the disclosure of the example, it should be kept clearly in mind that other and different embodiments of the methods disclosed according to the present invention will no doubt suggest
25 themselves to those of skill in the relevant art. The following example shows how a potential anti-neoplastic agent may be identified using one or more of the genes disclosed herein.

30

EXAMPLE**Determination of Gene Inhibitory Activity of an Anti-neoplastic Agent**

5 SW480 cells are grown to a density of 10^5 cells/cm² in Leibovitz's L-15 medium supplemented with 2 mM L-glutamine (90%) and 10% fetal bovine serum. The cells are collected after treatment with 0.25% trypsin, 0.02% EDTA at 37°C for 2 to 5 minutes. The trypsinized cells are then diluted with 30 ml growth medium and plated at a density of 50,000 cells per well in a 96 well plate (100 µl/well). The following day, cells are treated with either compound buffer alone, or compound buffer containing a chemical agent to be tested, for 10 24 hours. The media is then removed, the cells lysed and the RNA recovered using the RNAeasy reagents and protocol obtained from Qiagen. RNA is quantitated and 10 ng of sample in 1 µl are added to 24 µl of Taqman reaction 15 mix containing 1X PCR buffer, RNAsin, reverse transcriptase, nucleoside triphosphates, ampliTaq gold, tween 20, glycerol, bovine serum albumin (BSA) and specific PCR primers and probes for a reference gene (18S RNA) and a test gene (Gene X). Reverse transcription is then carried out at 48°C for 30 minutes. The sample is then applied to a Perkin Elmer 7700 sequence 20 detector and heat denatured for 10 minutes at 95°C. Amplification is performed through 40 cycles using 15 seconds annealing at 60°C followed by a 60 second extension at 72°C and 30 second denaturation at 95°C. Data files are then captured and the data analyzed with the appropriate baseline windows and thresholds.

25

The quantitative difference between the target and reference gene is then calculated and a relative expression value determined for all of the samples used. In this way, the ability of a chemotherapeutic agent to effectively and selectively reduce the activity of a cancer-specific gene is 30 readily ascertained. The overall expression of the cancer-specific gene, as modulated by one chemical agent relative to another, is also determined.

Chemical agents having the most effect in reducing gene activity are thereby identified as the most anti-neoplastic.

5

References:

- Walter A. Blättler and Ravi Chari: Drugs to enhance the therapeutic potency of anti-cancer antibodies: antibody-drug conjugates as tumor-activated prodrugs. In *Anticancer Agents - Frontiers in Cancer Chemotherapy* (Iwao Ojima, Gregory D. Vite, Karl-Heinz Altmann, Eds.), American Chemical Society, pp. 317-338 (2001).
- Dan L. Longo, Patricia L. Duffey, John G. Gibben, Elaine S. Jaffe, Brendan D. Curti, Barry L. Gause, John E. Janik, Virginia M. Braman, Dixie Esseltine, Wyndham H. Wilson, Dwight Kaufman, Robert E. Wittes, Lee M. Nadler, and Walter J. Urba: Combination chemotherapy followed by an Immunotoxin (Anti-B4-blocked Ricin) in patients with indolent lymphoma: results of a Phase II study. *Cancer J.* 6, 146-150 (2000).
- Walter A. Blättler and John M. Lambert: Preclinical immunotoxin development. In *Monoclonal Antibody-Based Therapy of Cancer* (M. Grossbard, Ed.), Marcel Dekker, Inc. NY, NY, pp. 1-22 (1998).
- Ravi V. J. Chari: Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. In *Advanced Drug Delivery Reviews*, Elsevier Science B.V., pp. 89-104 (1998).
- David T. Scadden, David P. Schenkein, Zale Bernstein, Barry Luskey, John Doweiko, Anil Tulpule, and Alexandra M. Levine: Immunotoxin combined with chemotherapy for patients with AIDS-related Non-Hodgkin's Lymphoma. *Cancer* 83, 2580-2587 (1998).
- Changnian Liu and Ravi VJ Chari: The development of antibody delivery systems to target cancer with highly potent maytansinoids. *Exp. Op. Invest. Drugs* 6, 169-172 (1997).
- A. C. Goulet, Viktor S. Goldmacher, John M. Lambert, C. Baron, Dennis C. Roy and E. Kouassi: Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization. *Blood* 90, 2364-2375 (1997).
- Changnian Liu, John M. Lambert, Beverly A. Teicher, Walter A. Blättler, and Rosemary O'Connor: Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. *Blood* 87, 3892-3898 (1996).

- Rajeeva Singh, Lana Kats, Walter A. Blättler, and John M. Lambert: Formation of N-Substituted 2-Iminothiolanes when amino groups in proteins and peptides are modified by 2-Iminothiolane. *Anal. Biochem.* 236, 114-125 (1996).
- 5 Changnian Liu, B. Mitra Tadayoni, Lizabeth A. Bourret, Kristin M. Mattocks, Susan M. Derr, Wayne C. Widdison, Nancy L. Kedersha, Pamela D. Ariniello, Victor S. Goldmacher, John M. Lambert, Walter A. Blättler, and Ravi V.J. Chari: Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. *Proc. Natl. Acad. Sci. USA* 93, 8618-8623 (1996).
- 10 Denis C. Roy, Sophie Ouellet, Christiane Le Houiller, Pamela D. Ariniello, Claude Perreault and John M. Lambert: Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. *J. Natl. Cancer Inst.* 88, 1136-1145 (1996).
- 15 Walter A. Blättler, Ravi V.J. Chari and John M. Lambert: Immunoconjugates. In *Cancer Therapeutics: Experimental and Clinical Agents*. (B. Teicher, Ed.), Humana Press, Totowa, NJ, pp. 371-394 (1996).
- 20 Michael L Grossbard, John M. Lambert, Victor S. Goldmacher, Arnold S. Freedman, Jeanne Kinsella, Danny P. Ducello, Susan N. Rabinowe, Laura Elisea, Felice Carol, James A. Taylor, Walter A. Blättler, Carol L. Epstein, and Lee M. Nadler: Anti-B4-blocked Ricin: A phase I trial of 7 day continuous infusion in patients with B-cell neoplasms. *J. Clin. Oncol.* 11, 726-737 (1993).
- 25 Michael L. Grossbard, John G. Gribben, Arnold S. Freedman, John M. Lambert, Jeanne Kinsella, Susan N. Rabinowe, Laura Eliseo, James A. Taylor, Walter A. Blättler, Carol L. Epstein, and Lee M. Nadler: Adjuvant immunotoxin therapy with anti-B4-blocked ricin following autologous bone marrow transplantation for patients with B-cell Non-Hodgkin's lymphoma. *Blood* 81, 2263-2271 (1993).
- 30 Sudhir A. Shah, Patricia M. Halloran, Cynthia A. Ferris, Beth A. Levine, Lizabeth A. Bourret, Victor S. Goldmacher, and Walter A. Blättler: Anti-B4-blocked Ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. *Cancer Res.* 53, 1360-1367 (1993).
- 35 Ravi V.J. Chari, Bridget A. Martell, Jonathan L. Gross, Sherilyn B. Cook, Sudhir A. Shah, Walter A. Blättler, Sara J. McKenzie, and Victor S. Goldmacher: Immunoconjugates containing novel maytansinoids: promising anti-cancer drugs. *Cancer Res.* 52, 127-131 (1992).
- John M. Lambert, Peter D. Senter, Annie Yau-Young, Walter A. Blättler, and Victor S. Goldmacher: Purified immunotoxins that are reactive with human lymphoid cells. *J. Biol. Chem.* 250, 12035-12041 (1985).

WHAT IS CLAIMED IS:

1. A process for identifying an agent that modulates the activity of a cancer-related gene comprising:
 - 5 (a) contacting a compound with a cell containing a gene that corresponds to a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1-7, 14-20 and 27-33 and under conditions promoting the expression of said gene; and
10 (b) detecting a difference in expression of said gene relative to when said compound is not present thereby identifying an agent that modulates the activity of a cancer-related gene.
- 2 The process of claim 1 wherein said gene has a sequence selected
15 from the group consisting of SEQ ID NO: 1-7, 14-20 and 27-33.
3. The process of claim 2 wherein the cell is a cancer cell and the difference in expression is a decrease in expression.
- 20 4. The process of claim 3 wherein said cancer cell is a kidney cancer cell.
5. A process for identifying an anti-neoplastic agent comprising contacting a cell exhibiting neoplastic activity with a compound first identified
25 as a cancer related gene modulator using the process of one of claim 1 and detecting a decrease in said neoplastic activity after said contacting compared to when said contacting does not occur.
- 30 6. The process of claim 5 wherein said neoplastic activity is accelerated cellular replication.

7. The process of claim 5 wherein said decrease in neoplastic activity results from the death of the cell.

8. A process for identifying an anti-neoplastic agent comprising
5 administering to an animal exhibiting a cancer condition an effective amount of an agent first identified according to the process of one of claim 1 and detecting a decrease in said cancerous condition.

9. A process for determining the cancerous status of a cell, comprising
10 determining an increase in the level of expression in said cell of a gene that corresponds to a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1-7, 14-20 and 27-33 wherein an elevated expression relative to a known non-cancerous cell indicates a cancerous state or potentially cancerous state.

15

10. The process of claim 9 wherein said elevated expression is due to an increased copy number.

11. An isolated polypeptide comprising an amino acid sequence
20 homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 8-13, 21-26 and 34-39 wherein any difference between said amino acid sequence and the sequence of SEQ ID NO: 8-13, 21-26 and 34-39 is due solely to conservative amino acid substitutions and wherein said isolated polypeptide comprises at least one immunogenic fragment.

25

12. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8-13, 21-26 and 34-39.

30

13. An antibody that reacts with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8-13, 21-26 and 34-39.

5 14. The antibody of claim 13 wherein said antibody is a recombinant antibody.

15. The antibody of claim 13 wherein said antibody is a synthetic antibody.

10

16. The antibody of claim 13 wherein said antibody is a humanized antibody.

15

17. An immunoconjugate comprising the antibody of claim 13 and a cytotoxic agent.

18. The antibody of claim 17 wherein said cytotoxic agent is a member selected from the group consisting of a calicheamicin, a maytansinoid, an adozelesin, a cytotoxic protein, a taxol, a taxotere, a taxoid and DC1.

20

19. The immunoconjugate of claim 18 wherein said calicheamicin is calicheamicin γ_1^1 , N-acetyl gamma calicheamicin dimethyl hydrazide or calicheamicin θ_1^1 .

25

20. The immunoconjugate of claim 18 wherein said maytansinoid is DM1.

21. The immunoconjugate of claim 18 wherein said cytotoxic protein is ricin, abrin, gelonin, pseudomonas exotoxin or diphtheria toxin.

30

22. The immunoconjugate of claim 18 wherein said taxol is paclitaxel.

23. The immunoconjugate of claim 18 wherein said taxotere is docetaxel.

24. A process for treating cancer comprising contacting a cancerous cell *in vivo* with an agent having activity against an expression product encoded by a gene sequence selected from the group consisting of SEQ ID NO: 1-7, 14-20 and 27-33.

25. The process of claim 24 wherein said agent is the antibody of claim
10 13.

26. The process of claim 24 wherein said agent is an immunoconjugate of claim 17.

15 27. An immunogenic composition comprising a polypeptide of claim 11.

28. An immunogenic composition comprising a polypeptide of claim 12.

29. The process of claim 24 wherein said cancer is kidney cancer.
20

30. A process for treating cancer in an animal afflicted therewith comprising administering to said animal an amount of an immunogenic composition of claim 27 sufficient to elicit the production of cytotoxic T lymphocytes specific for the polypeptide of claim 11.

25 31. A process for treating cancer in an animal afflicted therewith comprising administering to said animal an amount of an immunogenic composition of claim 28 sufficient to elicit the production of cytotoxic T lymphocytes specific for the polypeptide of claim 12.

30 32. A process for treating a cancerous condition in an animal afflicted therewith comprising administering to said animal a therapeutically effective

amount of an agent first identified as having anti-neoplastic activity using the process of claim 8.

33. A process for protecting an animal against cancer comprising administering to an animal at risk of developing cancer a therapeutically effective amount of an agent first identified as having anti-neoplastic activity using the process of claim 8.

34. The process of claim 30 wherein said animal is a human being.

10 35. The process of claim 30 wherein said cancer is kidney cancer.

36. A method for producing test data with respect to the gene modulating activity of a compound comprising:

15 (a) contacting a compound with one or more cells containing a polynucleotide comprising a nucleotide sequence corresponding to a gene whose expression is increased in a cancerous cell over that in a non-cancerous cell or a gene whose expression is elevated in a non-cancerous cell over that in a cancerous cell under conditions wherein said polynucleotide is being expressed, and

20 (b) determining a change in expression of more than one of said polynucleotides, and

25 (c) producing test data with respect to the gene modulating activity of said compound based on an increase in the expression of the determined genes whose expression is otherwise elevated in a non-cancerous cell over that in a cancerous cell and a decrease in the expression of the determined genes whose expression is otherwise increased in a cancerous cell over that in a non-cancerous cell indicating gene modulating activity.

SEQUENCE LISTING

<110> Avalon Pharmaceuticals

<120> Cancer-Linked Gene as Target for Chemotherapy

<130> 689290-165

<140>

<141>

<150> US/60/385,505

<151> 2002-06-04

<160> 39

<170> PatentIn version 3.0

<210> 1

<211> 4567

<212> DNA

<213> Homo sapiens

<400> 1

gcggccgccc cattcccaga ccggccgcca gcccacatctgg ttagctcccg ccgcgtccgcg	60
ccggccggga gtcggagacc gcggggaaacc gggcacctgc acccgccctct gggagtgagt	120
ggttccagct ggtgcctggc ctgtgtctct tggatgcctt gtggcttcag tccgtctcct	180
gttgcccacc acctcggtccc tggggccgcct gataccccag cccaaacagct aaggtgtgga	240
tggacagtag ggggtctggct tctctactg gtcagggggtc ttctccctgt tctgcctccc	300
ggagcttagga ctgcagaggg gcctatcatg gtgcttgcag gccccctggc tgtctcgctg	360
ttgctgcccgcctc gcctcacact gctggtgtcc cacctctcca gctcccagga tgtctccagt	420
gagccccagca gtgagcagca gctgtgcgcc cttagcaagc acccccaccgt ggcctttgaa	480
gacctgcagc cgtgggtctc taacttcacc tacccctggag cccgggattt ctcccagctg	540
gctttggacc cctccgggaa ccagctcatc gtgggagcca ggaactacact cttcagactc	600
agccttgccca atgtctctct tcttcaggccc acagagtggg cctccagtgaa ggacacgcgc	660
cgtctctgccc aaagcaaagg gaagacttag gaggagtgtc agaactacgt gcgagtcctg	720
atcgtcggcc gccggaaagggt gttcatgtgt ggaaccaatg ctttttcccc catgtgcacc	780
agcagacagg tggggAACCT cagccggact actgagaaga tcaatgggtt ggcccgctgc	840
cccttatgacc cacggccacaa ctccacacact gtcatctctt cccagggggaa gctctatgca	900
gccacggta tcgacttctc aggtcgggac cttccatctt accgcagccct gggcagtggtt	960
ccaccgcttc gcactgcccataataactcc aagtggctta atgagccaaa cttcgtggca	1020
gcctatgata ttgggtgtt tgcataacttc ttccctgggg agaacgcagt ggagcagcag	1080
tgtggacgca ccgtgtactc tcgcgtggcc cgctgtgtca agaatgcagt gggggggccga	1140
ttccctgtgg aggacacatg gaccacattt atgaaggccc ggctcaactg cttccggccg	1200
ggcgaggtcc ctttctacta taacgagctg cagagtgcct tccacttgcc agagcaggac	1260
ctcatctatg gagtttccac aaccaacgtt aacagcatcg cggcttctgc tgtctcgcc	1320
ttcaaacctca gtgctatctc ccaggcttc aatggccat ttgcgttacca ggagaaccccc	1380
agggtctgcct ggctccccat agccaacccc atccccattt tccagtgtgg caccctgcct	1440
gagaccgggtc ccaacagagaa cctgacggag cgacgcctgc aggacgcgca ggcgcctttc	1500
ctgtatgagcg aggccgtgca gccgggtaca cccgagccct gtgtcacccca ggacagcgtg	1560
cgtttctcac acctcggtgtt ggacctgggt caggctaaag acacgcctta ccatgtactc	1620
tacattggca ccgagtcggg caccatctt aaggcgctgt ccacggcgag cgcgcgcctc	1680
cacggctgtc acctggagga gtcgcacgtg ctgcgggggg ggcgcgcgca gcccctgcgc	1740
agcctgcgca tcctgcacag cgccgcgcg ctcttcgtgg ggctgagaga cggcgtccgt	1800
cgggtcccac tggagaggtg cgccgcctac cgacgcagg gggcatgcct gggggccgg	1860
gaccggactt gtggctggga cgggaagcag caacgttgca gcacactcgaa ggacagctcc	1920
aacatgagcc tctggaccca gaacatcacc gcctgtcctt tgccgaaatgt gacacggat	1980
gggggcttgc gccccatggc accatggcaa ccatgtgagc acttggatgg ggacaactca	2040
ggctcttgcc tgtgtcgagc tcgatcctgt gattccctc gaccccgctg tggggccctt	2100
gactgcctgg ggccagccat ccacatcgcc aactgctcca ggaatggggc gtggaccccg	2160

tggtcatgt	ggcgctgt	cagcacgtcc	tgtggcatcg	gcttccaggt	ccgcacgcga	2220
agttgcagca	accctgctcc	ccgccacggg	ggccgcacatc	gcgtggcaa	gagccgggag	2280
gaacggttct	gtaatgagaa	cacgccttg	ccgggtcccc	tcttctggc	ttccctgggc	2340
tcctggagca	agtgcagcag	caactgtgga	gggggcattgc	agtcgcggcg	tcgggcctgc	2400
gagaacggca	actcctgcct	gggctgcggc	gtggagttca	agacgtgca	ccccgaggc	2460
tgcggcgaag	tgcggcga	cacccctgg	acgcgtggc	tgcccgtgaa	cgtgacgcag	2520
ggcggggcac	ggcaggagca	gcggtccgc	ttcacctg	gcgcgc	ccccct	2580
caaggcctgc	agttcggcag	gagaaggacc	gagacgagga	cctgtcccgc	ggacggctcc	2640
ggctcctgc	acaccgacgc	cctggggag	gtcctcctgc	gcagcggag	cacotcccc	2700
cacacggtga	gccccggctg	ggccgcctgg	ggcccggtg	cgctcgtc	ccggactgc	2760
gagctggct	tccgcgtcc	caagagaacg	tgcactaacc	cggagcccc	caacggggc	2820
ctgcccgtcg	tgggcgtgc	tgccgagttac	caggactgca	accccccaggc	ttgcccagtt	2880
cgggggtgctt	ggtcctgctg	gacctcatgg	tctccatg	cagttcctg	tggtgggggt	2940
cactatcaac	gcacccttc	ctgcaccacgc	cccgacccct	ccccaggtg	ggacatctgt	3000
ctcgggctgc	acacggagga	ggcactatgt	gccacacagg	cctgcccaga	aggctggctg	3060
ccctggtctg	agtggagtaa	gtgcactgac	gacggagccc	agagccgaa	ccggcactgt	3120
gaggagctcc	tcccagggtc	cagcgcmtgt	gctggaaaca	gcagccagag	ccgcgcctgc	3180
ccctacagcg	agattcscgt	cattctgcca	gcctccagca	tggaggaggc	caccgactgt	3240
gcagggttca	atctcatcca	cttggggccc	acgggcatct	cctgcttctt	gggctctggg	3300
ctcctgaccc	tagcagtgt	cctgtcttgc	cagcactg	agcgtcagtc	ccaggagtc	3360
acactggtcc	atcctgccac	ccccaaaccat	ttgcactaca	aggcggagg	caccccgaa	3420
aatgaaaagt	acacacccat	gaaattcaag	accctgaaca	agaataactt	gatccctgat	3480
gacagagcca	acttctaccc	attgcagcag	accaatgtgt	acacgactac	ttactaccca	3540
agccccctga	acaaacacag	cttccggccc	gaggcctc	ctggacaacg	gtgcttcccc	3600
aacagctgt	accgcgtcc	tggggactt	ggcttcttgc	cttcataagg	cacagagcag	3660
atggagatgg	gacagtggag	ccagtttgt	tttctcc	tgca	cttgc	3720
ctgccttgcc	tgtgggggt	ccatccgc	ttcagagac	tctggcttgc	attgaccatg	3780
ggggaaagg	ctgggttcag	gctgacat	ggccgcagg	ccagttc	ccaggtctmt	3840
catggttatc	ttccaaccca	ctgtcacgt	gacactatgc	tgccatgc	gggtgttgg	3900
cctactgggc	atttgggaa	ytggagaatg	gagatggca	gagggcagg	ttttaa	3960
gggttggaga	caacttcctg	tggcccccac	aagctgagtc	tggccttc	cagctggccc	4020
caaaaaaggc	cttgc	taca	tcctgattat	ctctgaa	aatcaatcaa	4080
tagctctgga	ttttctgcca	gggctgggccc	attgtgg	tgccc	aggta	4140
ccaaaggccag	cgcagttat	ccacctctgc	ctggaa	gtc	atactctacc	4200
ctctggtca	aggcagttag	tactgggac	tggaggct	cctgt	tc	4260
aatctgggc	gttacaggcc	tcagccttgc	cctcaatg	ca	cgaaagg	4320
aggatcaatg	ccataggagg	cagaagtctg	gcctctgt	ctctatgg	actatcttcc	4380
agttgtctgt	caacagagtt	gttggctg	acctgctt	gagtct	tc	4440
tctgttctagg	aacacacaca	cacacacact	cacacacg	caca	caat	4500
cacgcacaca	caatcacaat	ttgctacagc	aacaaaaa	aa	gatgat	4560
caccaacaaa	aaagacattt	ggctgtgg	ttattaatt	aa	ccagtcaaaa	4567
aaaaactt						

<210> 2
<211> 453
<212> DNA
<213> Homo sapiens

<400> 2

agtaatcagc	tcggtaccgg	catgtgt	agccagcgca	ggttatccac	ctctgcctgg	60
aagtctatac	tctaccagg	gatccct	ggtcagaggc	agttagtact	ggaaactgg	120
ggctgacctg	tgcttagaag	tcctttaatc	tgggtgt	caggcctc	ccttgc	180
aatgcacgaa	aggtggccca	ggagagagga	tcaatgc	aggaggcaga	agtctgg	240
ctgtgcctct	atggagacta	tcttcc	gctg	caac	agatgtt	300
gcttgggagt	ctctgc	tgc	ttcagga	caca	cacactcaca	360
cacgcacaca	caatcacaat	ttgctacagc	aacaaaaa	acattgg	gtggcattat	420
taattaaaga	tgatatccag	tcaaaaaaaa	act			453

<210> 3
<211> 4675

<212> DNA

<213> Homo sapiens

<400> 3

gcggccgccc cattcccaga ccggccgcca gcccacatctgg ttagctcccg ccgcgtcccg	60
ccgccccggga gtcgggagcc gcggggaaacc gggcacctgc acccgccctct gggagttagt	120
ggttccagct ggtgcctggc ctgtgtctct tggatgcctt gtggcttcag tccgtctcct	180
gttgcccacc acctcgtccc tggggccgcct gataccccag cccaacagct aagggtgtgga	240
tggacagtag ggggctggct tctctcaactg gtcaggggca ggaagccaag tggagacttt	300
gaatggaggc aaggatggag gggacactggg gaagaggact ggcctgaatc accttccccca	360
aagggtccta tggactgagc tggaggtctt ctcccctgtc tgcctccccc agctaggact	420
gcagaggggc ctatcatgtt gcttgcagc cccctggctg tctcgctgtt gctgcccagc	480
ctcacactgc tggtgtccca cctctccagc tcccaggatg tctccagtgta gcccagcagt	540
gagcagcagc tgtgcctct tagcaagcac cccaccgtgg cctttaagaaga cctgcagccg	600
tgggtctcta acttcaccta ccctggagcc cgggatttct cccagctggc tttggacccc	660
tccgggaacc agctcatgtt gggagccagg aactacctct tcagactcag ccttgccaaat	720
gtctctcttc ttcaaggccac agagtgggccc tccagtgagg acacgcgcgc ctcctgccaa	780
agcaaaggga agactgagga ggagtgttag aactacgtgc gagtcctgtat cgtgcggc	840
cggaaagggt tcatgtgtgg aaccaatgcc ttttcccca tttgtcaccagg cagacagggt	900
gggaaccta gccggactac tgagaagatc aatgggtgtgg cccgctgccc ctatgaccca	960
cggccacaact ccacagctgt catctcctcc cagggggagc tctatgcagc cacgtcatc	1020
gacttctca gtcgggaccc tgccatctac cgcagcctgg gcagtgggccc accgcttcgc	1080
actgccccaa ataaactccaa gtggcttaat gagccaaact tcgtggcagc ctatgatatt	1140
gggctgtttt cataacttctt cctgcgggag aacgcagtgg agcacgactg tggacgcacc	1200
gtgtactctc gctgtggcccg ctgtgtcaag aatgcagtgg gggggccatt cctgtgtggag	1260
gacacatgga ccacattcat gaaggccccgg ctcaactgtc cccggccggg cgaggtcccc	1320
ttctactata acgagctgca gagtgccttc cacttgcagc agcaggacct catctatgga	1380
gttttcacaa ccaacgtaaa cagcatcgcg gcttctgtc tctgcgcctt caacctcagt	1440
gctatctccc aggcttcaa tggccattt cgcttaccagg agaaccccaag ggctgcctgg	1500
ctccccatag ccaacccat ccccaatttc cagttgtggca ccctgcctga gaccgggtccc	1560
aacgagaacc tgacggagcg cagccctgcag gacgcgcagc gcctttccct gatgagcgag	1620
gccgtgcagc cggtgacacc cgagccctgt gtcacccagg acagcgtgcg ctctcacac	1680
ctctgtgtgg acctgggtca ggcctaaagac acgctctacc atgtactcta cattggcacc	1740
gagtcgggca ccattctgaa ggcgtgttcc acggcgagcc gcagccttca cggctgtac	1800
ctggaggagc tgcacgtgtt gccccccggg cggccgcagc ccctgcgcag cctgcgcate	1860
ctgcacagcg cccgcgcgtt ctctgtgggg ctgagagacg gcgtctgcg ggtcccaactg	1920
gagagggtcg cgccttaccg cagccagggg gcatgcctgg gggccgggaa cccgtactgt	1980
ggctgggacg ggaagcagca acgttgcagc acactcgagg acagctccaa catgagcctc	2040
tggaccaga acatcaccgc ctgtcctgtc cggaatgtga cacggatgg gggcttcggc	2100
ccatggtcac catggcaacc atgtgagcac ttggatgggg acaactcagg ctctgcctg	2160
tgtcgagctc gatcctgtga tccccctcga ccccgctgtg ggggccttga ctgcctgggg	2220
ccagccatcc acatcgccaa ctgctccagg aatggggcgat gggcccccgt gtcatcgtgg	2280
gcgcgtgtca gcacgtcctg tggcatcgcc ttccagggtcc gccagcgaag ttgcagcaac	2340
cctgctcccc gccacggggg cgcgcattgc gtcggcaaga gcccggagga acggttctgt	2400
aatgagaaca cgccttgccc ggtgcccattt ttctgggctt cctggggctc ctggagcaag	2460
tgcagcagca actgtggagg gggcatgcag tcgcggcgcc gggcctgcga gaacggcaac	2520
tcctgcctgg gctgcggcgtt ggagttcaag acgtgcacacc cgcaggggctg ccccaagtg	2580
cggcgcaaca cccctggac gccgtggctg cccgtaaacg tgacgcaggg cggggcacgg	2640
caggagcagc ggttccgctt cacatgcgcg cgcgcctt cagacccgc cggcctgcag	2700
ttcggcagga gaaggaccga gacgaggacc tgcgtccgcgg acggctccgg ctctgcgac	2760
accgacgccc tggtgaggt cctctgcgc agcggagacg cctcccccgc acgggtgagc	2820
gggggctggg cgcctgggg cccgtggctg tcctgtctcc gggactgcga gctgggcttc	2880
cgcgtccgca agagaacgtg cactaaccgc gagcccccga acgggggctt gcccgtcg	2940
ggcgatgtg cgcgtatcca ggactgcac ccccaaggctt gcccgttc ggggtcttgg	3000
tcctgctggc cctcatgttc tccatgtca gtttctgtg gtgggggtca ctatcaacgc	3060
acccgttctt gcaccagccc cgcacccctcc ccaggtgagg acatctgtct cgggctgcac	3120
acggaggagg cactatgtgc cacacaggcc tgcctcagaag gtcggcgtcc ctggcttgag	3180
tggagtaagt gcaactgacga cggagccagg agccgaagcc ggcactgtga ggagctccctc	3240
ccagggtcca ggcgcmtgtc tggaaacacgc agccagagcc gcccctgccc ctacagcgag	3300
attcscgtca tcctgcgcagc ctccagcatg gaggaggcca ccgactgtgc agggttcaat	3360
ctcatccact tggtgccac gggcatctcc tgcttcttgg gctctggctt cctgacccta	3420

gcagtgtacc	tgtctgccca	gcactgcccag	cgtcagtccc	aggagtccac	actggtccat	3480
cctgccaccc	ccaaccattt	gcactacaag	ggcgaggca	ccccgaagaa	tgaaaagtac	3540
acacccatgg	aattcaagac	cctgaacaag	aataactga	tccctgatga	cagagccaac	3600
ttctacccat	tgcagcagac	caatgtgtac	acgactactt	actacccaag	ccccctgaac	3660
aaacacagct	tccggccgaa	gcccctcacct	ggacaacggt	gctcccaa	cagtgatac	3720
cggcgtcctg	gggacttggg	cttcttgctt	tcataaggca	cagagcagat	ggagatggaa	3780
catgtggagcc	agtttggttt	tctccctctg	cactaggca	agaacttgct	gccttgctg	3840
tggggggtcc	catccggctt	cagagagctc	tggctggcat	tgaccatggg	ggaaagggct	3900
ggtttcaggc	tgacatatgg	ccgcaggctc	agttcagccc	aggtctmtca	tggttatctt	3960
ccaaacccact	gtcacgctga	cactatgtc	ccatgctgg	gctgtggacc	tactgggcat	4020
ttgaggaayt	ggagaatgga	gatggcaaga	gggcaggctt	ttaagtttg	gttggagaca	4080
acttcctgtg	gccccacaa	gctgagtc	gccttctcca	gctggccca	aaaaaggcct	4140
ttgctacatc	ctgattatct	ctgaaagtaa	tcaatcaagt	ggctccagta	gctctggatt	4200
ttctgccagg	gctggccat	tgtgtgctg	ccccagttatg	acatgggacc	aaggccagcg	4260
caggttatcc	acctctgcct	gaaagtctat	actctaccca	gggcatccct	ctggcagag	4320
gcagttagta	ctggaaactg	gaggctgacc	tgtgcttaga	agtcccttaa	tctgggctgg	4380
tacaggcctc	agcctgccc	tcaatgcacg	aaaggtgccc	caggagagag	gatcaatgcc	4440
ataggaggca	gaagtctggc	ctctgtgcct	ctatggagac	tatcttccag	ttgctgctca	4500
acagagttgt	tggctgagac	ctgcttggg	gtctctgc	gcccttcatc	tgttcaggaa	4560
cacacacaca	cacacactca	cacacgcaca	cacaatcaca	atttgctaca	gcaacaaaaaa	4620
agacattggg	ctgtggcatt	attaattaaa	gatgatatcc	agtcaaaaaaa	aaact	4675

<210> 4
<211> 4731
<212> DNA
<213> Homo sapiens

<400> 4						
attggagatg	ctcgaaaa	ggctgcccgc	ttgtgtcctg	cttttctgcg	gccagaccaa	60
gccgtctgg	gctgctggc	aggtttctt	gctgaccta	cctgaccaca	gtggccctggg	120
tggactctac	aggaaatgt	tgtttctcc	ctggagcag	tagcagcagt	cctggctccc	180
ctggactgag	aactcctcat	cagccccagg	aagccggac	ccccttcag	ggatctggaa	240
ccgggtgtcc	tgtggccca	ggtctgcctc	caggcgtgg	ctgaagtct	gacttctgtc	300
gctggggca	aggagtggg	gagccagct	gctgcctgg	cttggcaga	cagcaggctg	360
atggtgcgg	cttccccgg	actgcttc	ctgcctgc	tctgatttcc	ctgcatggtg	420
cccgcagctg	agctgctacg	ggtcttc	cctgctgc	tcccgagct	aggactgcag	480
aggggcctat	catggtgctt	gcaggcccc	tggctgtc	gctgttgc	cccaagctca	540
cactgctgt	gtccccaccc	tccagctcc	aggatgtc	cagtgagccc	agcaagtgagc	600
agcagctgt	cggcccttagc	aagcaccca	ccgtggc	tgaagacctg	cagccgtgg	660
tctctaactt	cacctaccct	ggagccccc	atttctcc	gctggctt	gaccctccg	720
ggaaccagct	catcggtgg	gccaggaact	acctcttc	actcagcctt	gccaatgtct	780
ctcttctca	ggccacagag	tgggcctca	gtgaggacac	gcccgc	tgccaaagca	840
aaggaaagac	tgaggaggag	tgtcagaact	acgtgc	ctgtatgc	gccggccgga	900
aggtgttcat	gtgtgaaacc	aatgcctt	ccccatgt	caccagcaga	cagggtggg	960
acctcagccg	gactactgag	aagatcaatg	gtgtggcc	ctgcccctat	gaccacagcc	1020
acaactccac	agctgtc	tcctcccagg	gggagctct	tgcaagccac	gtcatcgact	1080
tctcaggctg	ggaccctgtc	atctaccgca	gcctggc	tggccacc	cttcgcact	1140
cccaatataa	ctccaagtgg	cttaatgagc	caaacttc	ggcagcctat	gatattggc	1200
tgtttgcata	cttcttc	cgggagaacg	cagtgagca	cgactgtg	cgcaccgtgt	1260
actctcgcgt	ggcccgctg	tgcaagaatg	acgtgggg	ccgattc	ctggaggaca	1320
catggaccac	attcatgaag	gcccggctca	actgtccc	cccgccg	gtcccttct	1380
actataacga	gctgcagagt	gccttccact	tgccagagca	ggacctcatc	tatggagttt	1440
tcacaaccaa	cgtaaacagc	atcgccg	ctgctgtc	cgccctca	ctcagtgc	1500
tctcccaggc	tttcaatggc	ccatttc	accaggaga	ccccagg	gcctggctcc	1560
ccatagccaa	ccccatcccc	aatttcc	gtggacc	gcctgagacc	ggtcccaacg	1620
agaacctgac	ggagcgc	ctgcaggac	cgcagcgc	cttcc	tgatc	1680
tgcagccggt	gacacccgag	ccctgtgtca	cccaggacag	cgtgcgc	tcacac	1740
tggtggaccc	ggtgcaggt	aaagacacgc	tctaccatgt	actctacatt	ggcaccg	1800
cggcaccat	cctgaaggcg	ctgtccacgg	cgagccgc	cctccacggc	tgctac	1860
aggagctgca	cgtgcgtccc	cccgccgccc	gcgcagcc	gcgcagc	cgcac	1920

acagcgcccc	cgcgtcttc	gtggggctga	gagacggcgt	cctgcgggtc	ccactggaga	1980
ggtgcgccgc	ctaccgcagc	cagggggcat	gcctggggc	ccgggacccg	tactgtggct	2040
gggacggaa	gcagcaacgt	tgcagcacac	tcgaggacag	ctccaacatg	agcctctgga	2100
cccagaacat	caccgcctgt	cctgtgcgga	atgtacacg	ggatggggc	ttcggccat	2160
ggtcaccatg	gcaaccatgt	gagcaacttgg	atggggacaa	ctcaggctc	tgcctgtgtc	2220
gagctcgatc	ctgtgattcc	cctcgacccc	gctgtgggg	ccttactgc	ctggggccag	2280
ccatccacat	cgcgaactgc	tccaggaatg	gggcgtggac	cccgtggta	tcgtgggcgc	2340
tgtgcagcac	gtcctgtggc	atcggtttcc	aggtaacccca	gcaagttgc	agcaaccctg	2400
ctccccggca	cggggccgc	atctgctggg	gcaagagccg	ggaggaacgg	ttctgtaatg	2460
agaacacgccc	ttgcccggtg	ccatcttct	gggcttctg	gggctcctgg	agcaagtgc	2520
gcagcaactg	tggagggggc	atgcagtgc	ggcgtgggc	ctgcgagaac	ggcaactcct	2580
gcctgggctg	cggcgtggag	tcaagacgt	gcaacccca	gggctgccc	gaagtgcggc	2640
gcaacacccccc	ctggacgccc	tggctgccc	tgaacgtgac	gcagggcggg	gcacggcagg	2700
agcagcggtt	ccgcgttcacc	tgccgcgcgc	cccttgcaga	ccgcacggc	ctgcagttcg	2760
gcaggagaag	gaccgagacg	aggacctgtc	ccgcggacgg	ctccggctcc	tgcgacacccg	2820
acgcctgtgt	ggaggtcctc	ctgcgcagcg	ggagcacctc	ccgcacacg	gtgagcgggg	2880
gctggggccgc	ctggggcccc	tggctgtctt	gctcccggg	ctgcgagctg	ggctccgcg	2940
tccgcaagag	aacgtgcact	aacccggagc	ccgcacacgg	gggcctgccc	tgcgtggcg	3000
atgcgtccga	gtaccaggac	tgcaacccccc	aggcttgc	attcgggg	gcttggctct	3060
gttggaccc	atggcttcca	tgctcagtt	cctgtggg	gggtcactat	caacgcaccc	3120
gttccctgcac	cagccccgca	ccctccccag	gtgaggacat	ctgtctcggg	ctgcacacgg	3180
aggaggcact	atgtgccaca	caggcctgcc	cagaaggctg	gtgcctctgg	tctgagtgga	3240
gttaagtgcac	tgacgacgga	gcccagagcc	gaagccggca	ctgtgaggag	ctcctccca	3300
ggtccagcgc	mtgtgctgga	aacagcagcc	agagccggcc	ctgcccctac	agcagattc	3360
scgtcatcc	gccagcctcc	agcatggagg	aggccaccga	ctgtcaggg	ttcaatctca	3420
tccacttgg	ggccacgggc	atctcctgt	tcttggg	ctggctcctg	acccttagcag	3480
tgtacctgtc	ttgcccagcac	tgccagcgtc	agtcccagga	gtccacactg	gtccatcctg	3540
ccaccccaaa	ccatttgac	tacaaggggc	gaggcacccc	gaagaatgaa	aagtacacac	3600
ccatggaaatt	caagaccctg	aacaagaata	acttgatccc	tgatgacaga	gccaacttct	3660
accatttgca	gcagaccaat	gtgtacacga	ctacttacta	cccaagcccc	ctgaacaaac	3720
acagcttccg	gcccggggcc	tcacctggac	aacggtgctt	ccccaaacagc	tgataaccgcc	3780
gtccctggga	cttggcttc	ttgccttcat	aaggcacaga	gcagatggag	atggacagat	3840
ggagccagtt	tggtttctc	cctctgcact	aggccaagaa	cttgctgcct	tgcctgtggg	3900
gggtcccatc	cggcttcaga	gagctctgc	tggcattgac	catgggggaa	agggctgggt	3960
tcaggctgac	atatggccgc	aggtccagg	cagcccaggt	ctmtcatggt	tatcttccaa	4020
cccaactgtca	cgctgacact	atgctgcat	gcctggctg	tggacctact	ggcatttga	4080
ggaaytggag	aatggagatg	gcaagagggc	aggctttaa	gttggggtt	gagacaactt	4140
cctgtggccc	ccacaagctg	agtctggc	tctcagctg	ccccaaaaaa	aggcctttgc	4200
tacatcctga	ttatctctga	aagtaatcaa	tcaagtggt	ccagtagctc	tggatttct	4260
gccagggctg	ggccattgtg	gtgctgcccc	agtatgacat	gggaccaagg	ccagcgcagg	4320
ttatccacct	ctgcctggaa	gtctatactc	taccaggc	atccctctgg	tcaagggcag	4380
tgagtaactgg	gaactggagg	ctgacctgt	cttagaagtc	ctttaatctg	ggctgggtaca	4440
ggcctcagcc	ttgcccctaa	tgcacgaaag	gtggccagg	agagaggatc	aatgccatag	4500
gaggcagaag	tctggctct	gtgcctctat	ggagactatc	ttccagttgc	tgctcaacag	4560
agttgttggc	tgagacactc	ttggggatct	ctgctggccc	ttcatctgtt	caggaacaca	4620
cacacacaca	cactcacaca	cgcacacaca	atcacaattt	gctacagcaa	caaaaaagac	4680
attgggctgt	ggcatttata	attaaagatc	atatccagtc	aaaaaaaaac	t	4731

<210> 5
<211> 4703
<212> DNA
<213> Homo sapiens

<400> 5						
gcggccgccc	cattccaga	ccggccgcca	gcccatctgg	ttagctccc	ccgcgtccgc	60
ccgccccggg	gtcgggagcc	gccccggaa	gggcacctgc	acccgcctc	gggagccagc	120
ttgggtccgg	gttgcactgg	gcccgtccag	ggctgtggc	ggcgcacatc	ggctgcagcg	180
gcgatgggg	cccgggaccc	aggcctggag	aaggagacgg	acgagtggagg	ctgagggacg	240
gagggacaga	gtgagtgg	ccagctgg	cctggcctgt	gtcttctgg	tgccctgtgg	300
cttcagtcc	tctcgtt	cccaccac	cgtccctgg	ccgcctgata	ccccagccca	360

acagctaagg	tgtggatgga	cagttaggggg	ctggcttctc	tcactggtca	ggggcttct	420	
cccctgtctg	cctcccgag	ctaggactgc	agaggggcct	atcatggtgc	ttgcaggccc	480	
cctggctgtc	tcgctgtgc	tgcccagcct	cacactgctg	gtgtcccacc	tctcagctc	540	
ccaggatgtc	tccagtgagc	ccagcagtga	gcagcagctg	tgccctta	gcaagcaccc	600	
caccgtggcc	tttgaagacc	tgcagccgt	ggtctcta	ttcacctacc	ctggagcccg	660	
ggatttctcc	cagctggc	ttgaccctc	cgggaaaccag	ctcatcg	gagcaggaa	720	
ctacctcttc	agactcagcc	ttgccaatgt	ctctcttctt	caggccacag	agtggccctc	780	
caigtgaggac	acgcggcgct	cctgccaaag	caaaggaaag	actgaggagg	agtgtcagaa	840	
ctacgtgcga	gtcctgatcg	tcgcccggcc	gaagggtt	atgtgtggaa	ccaatgcctt	900	
ttccccatg	tgcaccagca	gacaggtggg	gaac	ctc	ggactactg	960	
tggtgtggcc	cgctggccct	atgaccac	ccacaactcc	acagctgtca	tctcctccca	1020	
gggggagctc	tatgcagcca	cggtcatcg	cttctcaggt	cgggaccctg	ccatctaccg	1080	
cagcctgggc	agtggccac	cgcttcgac	tgcccaat	aactcca	ggcttaatga	1140	
gccaaacttc	gtggcagcct	atgatattgg	gctgtttgca	tacttcttcc	tgcgggagaa	1200	
cgcagtggag	cacgactgt	gacgcaccgt	gtactctcg	gtggcccg	tgtcaagaa	1260	
tgacgtgggg	ggccgattcc	tgctggagga	cacatggacc	acattcatga	aggcccggct	1320	
caactgctcc	cggccggcg	aggtccc	ctactataac	gagctgcaga	gtgccttcca	1380	
ctgccagag	caggac	ctatggagt	tttcacaacc	aacgtaa	gcatcgccgc	1440	
ttctgtgtc	tgcccttca	acctcagtc	tatctccag	gcttcaatg	gcccatttcg	1500	
ctaccaggag	aacccaggg	ctgctggc	ccccatagcc	aacccatcc	ccaatttcca	1560	
gtgtggcacc	tgcctgaga	ccgg	ccaa	cgagaac	acggagcgc	1620	
cgcgcagcgc	cttccctga	tgagcgaggc	cg	tgacacc	agccctgtgt	1680	
cacccaggac	agcgtgcgt	tctcacac	ctggtggac	ctgg	tgcagg	ctaaagacac	1740
gcttaccat	gtacttaca	ttggcaccga	gtcggg	cacc	atcctgaagg	cgctgtccac	1800
ggcgagccgc	agc	cttccac	g	gaggag	acgtgt	ccccggcg	1860
ccgcgagccc	ctgcgcagcc	tg	gac	gg	cccc	ctg	1920
gagagacggc	gtcctgcggg	tccactg	gaggtgc	cc	ca	gggg	1980
atgcctgggg	gcccggacc	ctgactgt	ctgg	gac	a	ggcaac	2040
actcgaggac	agtc	ccaaca	t	gac	tc	ctgt	2100
aatgtgaca	cg	ggatgggg	g	ttc	cc	gtg	2160
ggatggggac	aactcagg	cttgc	tc	gac	tc	ctgtgt	2220
ccgctgtggg	ggc	cttgact	gc	ccat	ccac	atc	2280
tggggcgtgg	accc	ctgtgg	g	tc	tc	cc	2340
ccaggtccgc	cag	cgaa	gt	ct	cc	cg	2400
ggcaagagc	cg	ggag	gaa	tc	cc	cc	2460
ctgggcttcc	tggg	ctt	gg	tc	cc	cc	2520
goggcgtcg	gc	ctgc	gaga	tc	cc	cc	2580
gtgcaacccc	gagg	gctg	cc	ca	cc	cc	2640
ctgttcccg	gact	tcg	gag	cc	tc	cc	2700
gcccccttgc	gac	cc	tc	gg	cc	cc	2760
tcccgcggac	gg	ctc	gg	cc	cc	cc	2820
cgggagcacc	tccc	cc	gg	cc	cc	cc	2880
ctgttcttgc	gact	tcg	gag	cc	tc	cc	2940
gcccccaac	gggg	cc	gg	cc	cc	cc	3000
ccaggcttc	ccag	tcg	gg	cc	tc	cc	3060
ttcctgttgt	gggg	ct	tc	cc	cc	cc	3120
aggtgaggac	atct	gtc	tc	cc	cc	cc	3180
cccaagaaggc	tgg	tc	cc	gg	cc	cc	3240
ccgaagccgg	cact	gt	tc	gg	cc	cc	3300
ccagagccgc	cc	ct	gg	cc	cc	cc	3360
ggaggccacc	gact	gt	tc	gg	cc	cc	3420
cttcttggcc	tct	gg	ct	cc	cc	cc	3480
tcagtc	gag	tcc	ac	cc	cc	cc	3540
ataaggcaca	gag	cac	at	cc	cc	cc	3600
taacttgatc	cct	gt	tc	gg	cc	cc	3660
gactacttac	tac	cc	aa	cc	cc	cc	3720
acaacgggtc	tt	cc	aa	cc	cc	cc	3780
ataaggcaca	gag	cac	at	cc	cc	cc	3840
ctaggccaag	aact	tg	tc	gg	cc	cc	3900
getggcattt	accat	gggg	aa	gggg	cc	cc	3960
ttcagcc	gt	ct	mt	ca	cc	cc	4020
ttcagcc	gt	ct	at	tt	cc	cc	

atgcctggc	tgtggaccta	ctgggcattt	gaggaaytgg	agaatggaga	tggcaagagg	4080
gcaggcttt	aagttgggt	tgagacaac	ttcctgtggc	ccccacaagc	tgagtctggc	4140
cttctccagc	tggcccaa	aaaggcctt	gctacatcct	gattatct	gaaagtaatc	4200
aatcaagtgg	ctccagtagc	tctggatttt	ctgccaggc	tggccattt	tggtgctgcc	4260
ccagtatgac	atggaccaa	gcccagcgca	ggttatccac	ctctgcctgg	aagtctatac	4320
tctaccagg	gcatccctt	ggtcagaggc	agtgactt	gggaactgga	ggctgacact	4380
tgcttagaa	tccttaatc	tggctggta	caggcctag	ccttgcctc	aatgcacgaa	4440
aggtggccca	ggagagagga	tcaatgccat	aggaggcaga	agtctggct	ctgtgcctct	4500
atggagacta	tcttcagtt	gctgctcaac	agagttgtt	gctgagac	gttgggaggt	4560
ctctgctggc	ccttcatctg	ttcaggaaca	cacacacaca	cacactcaca	cacgcacacaca	4620
caatcacaat	ttgctacagc	aacaaaaaaag	acattggct	gtggcattat	taattaaaga	4680
tatatccag	tcaaaaaaaaaa	act				4703

<210> 6
<211> 4405
<212> DNA
<213> Homo sapiens

<400> 6						
gccccggccc	cattcccaga	ccggccgcca	gcccacatctgg	ttagctcccg	ccgctccg	60
ccgccccggga	gtcgaggagcc	gcggggaaacc	gggcacatgc	acccgcctt	gggagggttt	120
ctccccctgtc	tgcctcccg	agctaggact	gcagagggc	cstatcatgg	gcttgcaggc	180
cccccggctg	tctcgctgtt	gctgcccagc	ctcacactgc	tggtgtccca	ccttcacagc	240
tcccaggatg	tetccagtga	gcccagca	gagcagcagc	tgtgcgcct	tagaagcac	300
cccacccgtgg	ccttgaaga	cctgcagccg	tgggtctcta	acttcaccta	ccctggagcc	360
cgggatttct	cccagctggc	tttggacccc	tccggaaacc	agctcatgt	gggagccagg	420
aactacctct	tcagactcag	ccttgccaaat	gtctcttcc	ttcaggccac	agagtggcc	480
tccagtgagg	acacgcgccc	ctcctgccaa	agcaaaggga	agactgagga	ggagtgtcag	540
aactacgtgc	gagtctgtat	cgtcgcggc	cggaagggtt	tcatgtgtt	aaccaatgcc	600
ttttccccc	tgtgcaccag	cagacaggt	gggaacctca	gccggactac	tgagaagatc	660
aatgggtgtgg	cccgctgccc	ctatgaccca	cgccacaact	ccacagctgt	catctcc	720
cagggggagc	tctatgcagc	cacggtcatc	gacttctcag	gtcgggaccc	tgccatctac	780
cgcagcctgg	gcagtgggcc	accgcctcgc	actgcacaa	ataactccaa	gtggcttaat	840
gagccaaact	tcgtggcagc	ctatgatatt	gggctgttt	catacttctt	cctgcgggag	900
aacgcagtg	agcagactg	tggacgcacc	gtgtactctc	gcgtggcccg	cgtgtgcaag	960
aatgacgtgg	ggggccgatt	cctgctggag	gacacatgga	ccacattcat	gaaggccccgg	1020
ctcaactgtc	cccgccccgg	cgaggtcccc	ttctactata	acgagctgca	gagtgccttc	1080
cacttgccag	agcagacac	catctatgga	gtttcacaa	ccaacgtaaa	cagcatcg	1140
gcttctgtc	tctgcgcctt	caacctca	gctatctccc	aggcttcaa	tggccattt	1200
cgctaccagg	agaacccag	ggctgcctgg	ctccccatag	ccaacccat	ccccaaattc	1260
cagtgtggca	ccctgcctga	gaccggccc	aacgagaacc	tgacggagcg	cagcctgcag	1320
gacgcgcagc	gcctttcc	gatgagcag	gccgtgcagc	cggtgacacc	cgagccctgt	1380
gtcacccagg	acagcgtgc	cttctcacac	ctcgtggtgg	acctggtgc	ggctaaagac	1440
acgctctacc	atgtactcta	cattggcacc	gagtcgggca	ccatctgaa	ggcgctgtcc	1500
acggcgagcc	gcagcctcca	cggtctctac	ctggaggagc	tgcacgtgt	gccccccggg	1560
cgccgcgagc	ccctgcgcag	cctgcgcac	ctgcacagcg	cccgcgcgct	cttcgtgggg	1620
ctgagagac	gcgtcctgc	ggtcccactg	gagaggtgc	ccgcctaccg	cagccagggg	1680
gcatgcctgg	ggggccggga	cccgtagt	ggctgggacg	ggaagcagca	acgttgca	1740
acactcgagg	acagctcaa	catgaccc	tggacccaga	acatcaccgc	ctgtccgt	1800
cggaatgtga	cacggatgg	gggctcgc	ccatggtcac	catggcaacc	atgtgac	1860
ttggatgggg	acaactcagg	ctcttgcctt	tgtcagatc	gatctgtt	ttccctcga	1920
ccccgcgtt	ggggccttga	ctgcctgggg	ccagccatcc	acatgc	ctgtccagg	1980
aatggggcgt	ggaccccg	gtcatgtt	gctgtgtt	gcacgtct	tggatcg	2040
ttccaggtcc	gccagcga	ttgcagca	cctgtctccc	gccacgggg	ccgcatctgc	2100
gtgggcaaga	gccgggagga	acggttctgt	aatgagaaca	cgccttgc	ggtgc	2160
ttctgggctt	cctggggctc	ctggagca	tgcagcagc	actgtggagg	gggcacatgc	2220
tcgcggcgtc	gggcctgc	gaacggca	tcctgcctt	gctgcggcgt	ggagttca	2280
acgtgcaacc	ccgagggt	ccccga	cggcgaaca	ccccctggac	gccgtggct	2340
cccggtgaac	tgacgcaggg	cggggcacgg	caggagcagc	ggttccg	cacctgccc	2400
gcgc	cccttgc	ca	ggcgcagga	gaaggacc	gacgaggacc	2460

tgtccccggc	acggctccgg	ctcctgcgac	accgacgccc	tggtgaggt	cctcctgcgc	2520
agcgggagca	cctcccgca	cacggtgagc	gggggctggg	ccgcctgggg	cccgtggtcg	2580
tcctgtccc	gggactgcga	gctgggcttc	cgcgccgca	agagaacgtg	cactaacccg	2640
gagccccgca	acgggggcct	gccctgcgtg	ggcgatgtc	ccgagttacca	ggactgcaac	2700
ccccaggctt	gcccagttcg	gggtgcttgg	tcctgttgc	cctcatggtc	tccatgctca	2760
gttccctgtt	gtgggggtca	ctatcaacgc	accggttcct	gcaccagccc	cgcaccctcc	2820
ccaggtgagg	acatctgtct	cgggctgcac	acggaggagg	cactatgtgc	cacacaggcc	2880
tgcccagaag	gctggcgcc	ctgggtctgag	tggagtaagt	gcactgacga	cggagcccg	2940
agccgaagcc	ggcactgtga	ggagctcctc	ccaggggtcca	gcmcmtgtgc	tggaaacacgc	3000
agccagagcc	gcccctgccc	ctacagcgag	attcscgtca	tcctgcccag	ctccagcatg	3060
gaggaggcca	ccgactgtgc	agggttcaat	ctcatccact	tggtgccac	gggcatctcc	3120
tgcttcttgg	gctctggct	cctgacccta	gcagtgtaacc	tgtcttgc	gcactgcccag	3180
cgtcagtccc	aggagtccac	actggtccat	cctggcacccc	ccaaccattt	gcactacaag	3240
ggcggaggca	ccccgaagaa	tggaaaagtac	acacccatgg	aattcaagac	cctgaacaag	3300
aataacttga	tccctgtatga	cagagccaa	ttcttaccat	tgcagcagac	aatgtgtac	3360
acgactactt	actacccaag	ccccctgaac	aaacacagct	tccggcccg	ggcctcacct	3420
ggacaacgg	gcttccccaa	cagctgatac	cgccgtcctg	gggacttggg	cttcttgcct	3480
tcataaggca	cagagcagat	ggagatggg	cagtggagcc	agtttggttt	tctccctctg	3540
caactaggca	agaacttgct	gccttgcctg	tgggggtcc	catccggctt	cagagagctc	3600
tggctggcat	tgaccatggg	ggaaagggt	ggtttcaggc	tgacatatgg	ccgcagggtcc	3660
agttcagccc	aggtctmtca	tggttatctt	ccaacccact	gtcacgctga	cactatgtcg	3720
ccatgcctgg	gctgtggacc	tactggcat	ttgaggaayt	ggagaatgg	gatggcaaga	3780
ggcaggctt	ttaagtttgg	gttggagaca	acttctgtg	gcccccacaa	gctgagctg	3840
gccttctcca	gctggcccca	aaaaaggcct	ttgctacatc	ctgattatct	ctgaaagtaa	3900
tcaatcaagt	ggctccagta	gctctggatt	ttctgcccagg	gctggccat	tgtgtgctg	3960
ccccagtagt	acatgggacc	aaggccagcg	caggttatcc	acctctgcct	ggaagtctat	4020
actctaccca	gggcattccct	ctgggtcagag	gcagtgagta	ctgggaactg	gaggctgacc	4080
tgtgcttaga	agtcctttaa	tctgggctgg	tacaggcctc	agccttgc	tcaatgcacg	4140
aaagggtggc	caggagagag	gatcaatggc	ataggaggca	gaagtctggc	ctctgtgcct	4200
ctatggagac	tatctccag	ttgctgtc	acagagttgt	tggctgagac	ctgottggg	4260
gtctctgt	gcccttc	tgttcaggaa	cacacacaca	cacacactca	cacacgcaca	4320
cacaatcaca	atttgctaca	gcaacaaaaaa	agacattggg	ctgtggcatt	attaattaaa	4380
gatgatatacc	agtcaaaaaaa	aaact				4405

<210> 7
<211> 3938
<212> DNA
<213> Homo sapiens

<400> 7						
gcggccgccc	cattcccaga	ccggccgcca	gcccatctgg	ttagctccc	ccgctccg	60
ccgccccggg	gtcgaggacc	gcggggaaacc	gggcacctgc	acccgcctt	gggagtgt	120
gttccagct	gttgcttggc	ctgtgtctt	tggatgcct	gtggcttc	tccgtctc	180
gttcccacc	acctcg	tggccgcct	gataccca	ccaaacagct	aagggtgg	240
tggacagtag	ggggctgg	tctctcact	gtcagggtc	ttctccct	tctgcctccc	300
ggagcttaga	ctgcagaggg	gcctatcat	gtgcttgc	gccccctgg	tgtctcg	360
ttgctggca	gcctcacact	gtctgtgt	cacccatc	gctcccagg	tgtctcc	420
gagccca	gtgagcagca	gtctgtgc	cttagca	accccac	ggcctt	480
gacctgc	cgtgggt	tacttca	taccctgg	ccgggattt	ctcc	540
gttttggacc	cctccgggaa	ccagctcat	gtggagcc	gaaactac	cttca	600
agccttgc	atgtctct	tcttcagg	acagatgg	cctcc	ggacac	660
cgtctctgc	aaagcaaagg	gaagactg	gagggtgt	agaactac	gtcg	720
atcgctgc	gccggaa	gttcatgt	gaaaccaat	ccttt	catgt	780
agcagacagg	tgggaa	cagccggact	actgaga	tcaatgg	ggcc	840
ccctatgacc	cacgcacaa	ctccacag	gtcatct	cccagg	gctat	900
gccacgg	tcgactt	aggcgg	cctccat	accgcag	ggcag	960
ccaccg	gactg	atataact	aagggtt	atgagcc	cttgc	1020
gcctatgata	ttgggt	tgcata	ttcc	ggagc	ggact	1080
tgtggacgca	ccgtgt	tgcgtgg	cgcg	agaatgac	ggggggccg	1140
ttcctgt	aggac	gaccat	atgaagg	ggctca	act	1200

ggcgagggtcc	ccttctacta	taacgagctg	cagagtgcct	tccacttgcc	agagcaggac	1260
ctcatctatg	gagtttcac	aaccaacgt	aacagcatcg	cggttctgc	tgtctgcgcc	1320
ttcaacctca	gtgctatctc	ccaggcttc	aatggccat	ttcgctacca	ggagaacccc	1380
agggctgcct	ggctccccat	agccaacccc	atcccaatt	tccagtgtgg	caccctgcct	1440
gagaccggtc	ccaacgagaa	cctgacggag	cgcagcctgc	aggacgcga	gccccttc	1500
ctgatgagcg	aggccgtgca	gccggtgaca	cccgagccct	gtgtcaccca	ggacagcgtg	1560
cgttctcac	acctcggtt	gjacctggg	caggtaaag	acacgctcta	ccatgtactc	1620
tacattggca	ccgagtcggg	caccatctg	aaggcgctgt	ccacggcgag	ccgcagcctc	1680
cacggctgct	acctggagga	gctgacgtg	ctgccccccg	ggcgccgcga	gcccctgcgc	1740
agcctgcgca	tcctgcacag	ccccggcg	ctcttcgtgg	ggctgagaga	cgccgtctcg	1800
cgggtcccac	tggagagggt	ccccgcctac	cgcagccagg	ggcatgct	gggggcccgg	1860
gaccctgta	gtggctggga	ccccggcg	caacgttgca	gcacactoga	ggacagctcc	1920
aacatgagcc	tctggaccca	gaacatcacc	gcctgtcctg	tgcggaaatgt	gacacgggat	1980
gggggcttcg	gccccatggc	accatggcaa	ccatgtgagc	acttggatgg	ggacaactca	2040
ggctcttgcc	tgtgtcgagc	tcgatcctgt	gattcccctc	gaccccgctg	tgggggcctt	2100
gactgcctgg	ggccagccat	ccacatcgcc	aactgctcca	ggaatggggc	gtggaccccg	2160
tgttcatcg	gggcgtgtg	cagcacgtcc	tgtggcatcg	gcttccaggt	ccgcagcga	2220
agttgcagca	accctgctcc	ccgcccacggg	ggccgcacatc	gcgtgggca	gagccgggag	2280
gaacggttct	gtaatgagaa	cacgccttc	ccgggtgccc	tcttctggc	ttccctgggc	2340
tcctggagca	agtgcagcag	caactgtgga	gggggcatgc	agtgcggcg	tcgggcctgc	2400
gagaacggca	actccctgcct	gggctgcggc	gtggagttca	agacgtgca	ccccgaggc	2460
tgccccgaa	tgcggcgca	cacccctgg	acgcccgtgc	tgcccgtgaa	cgtacgcag	2520
ggcggggcac	ggcaggagca	gcgggtccgc	ttcacctgca	gcgcgc	ttgcagacccg	2580
cacggcctgc	agttcggcag	gagaaggacc	gagacgagga	cctgtcccgc	ggacggctcc	2640
ggctcctgcg	acacccgacgc	cctgggtggg	gtcctcctgc	gcagcgggag	cacccccc	2700
cacacgggt	gcggggctg	ccccgcctgg	ggccctgtgt	cgtcctgc	ccggactgc	2760
gagctgggt	tccgcgtcc	caagagaacg	tgcactaacc	cggagccccc	caacggggc	2820
ctgcctgcg	tgggcgtatgc	tgccgagttac	caggactgca	accccccaggc	ttgcccagtt	2880
cgggggtgtt	gttcctgt	gacctcatgg	tctccatgt	cagttccctg	tgggggggt	2940
cactatcaac	gcacccgttc	ctgcaccaggc	ccgcacccct	ccccaggtg	ggacatctgt	3000
ctcgggctgc	acacggagga	ggcactatgt	gccacacagg	cctgcccaga	aggctggc	3060
ccctggtctg	agtggagtaa	gtgcactgac	gacggagccc	agagccga	ccggcactgt	3120
gaggagctcc	tcccagggtc	cagcgcmtgt	gctggaaaca	gcagccagag	ccgcctgc	3180
ccctacagcg	agattcscgt	catcctgcca	gcctccagca	tggaggaggc	caccgactgt	3240
gcagggttca	atctcatcca	cttgggtggc	acgggcacatc	cctgcttctt	gggctctggg	3300
ctcctgaccc	tagca	ctgtcttgc	cagca	gcgtcagtc	ccaggagtcc	3360
acactggtcc	atccgtccac	ccccaa	ttgcactaca	aggcgggagg	caccccaag	3420
aatgaaaagt	acacacccat	gaaattcaag	accctgaaca	agaataactt	gatccctgtat	3480
gacagagcca	acttctaccc	attgcagcag	accaatgca	gcgcaggtt	tccacctctg	3540
cctggaa	acttctac	ccaggc	cctctgg	gaggcagtg	gtactggaa	3600
ctggaggctg	acctgtgctt	agaagtcctt	taatctggc	tggtagggc	ctcagccttg	3660
ccctcaatgc	acgaaagggt	ccccaggaga	gaggatca	gccataggag	gcagaagtct	3720
ggcctctgt	cctctatgg	gactatctc	cagttgctgc	tcaacagagt	tgttgctga	3780
gacctgtt	ggagtc	ctggcccttc	atctgttca	gaacacacac	acacacacac	3840
tcacacacgc	acacacaatc	acaatttgc	acagaacaa	aaaagacatt	gggctgtggc	3900
attattaatt	aaagatgata	tccagtcaaa	aaaaaact			3938

<210> 8
<211> 1095
<212> PRT
<213> Homo sapiens

<400> 8
Met Val Leu Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser Leu
1 5 10 15

Thr Leu Leu Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser Glu
20 25 30

Pro Ser Ser Glu Gln Gln Leu Cys Ala Leu Ser Lys His Pro Thr Val

35	40	45
Ala Phe Glu Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly		
50	55	60
Ala Arg Asp Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu		
65	70	75
80		
Ile Val Gly Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val		
85	90	95
Ser Leu Leu Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg		
100	105	110
Ser Cys Gln Ser Lys Gly Lys Thr Glu Glu Glu Cys Gln Asn Tyr Val		
115	120	125
Arg Val Leu Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr Asn		
130	135	140
Ala Phe Ser Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser Arg		
145	150	155
160		
Thr Thr Glu Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg		
165	170	175
His Asn Ser Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala		
180	185	190
Thr Val Ile Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu		
195	200	205
Gly Ser Gly Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu		
210	215	220
Asn Glu Pro Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr		
225	230	235
240		
Phe Phe Leu Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr Val		
245	250	255
Tyr Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly Arg Phe		
260	265	270
Leu Leu Glu Asp Thr Trp Thr Phe Met Lys Ala Arg Leu Asn Cys		
275	280	285
Ser Arg Pro Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala		
290	295	300
300		
Phe His Leu Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn		
305	310	315
320		
Val Asn Ser Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser Ala		
325	330	335
335		
Ile Ser Gln Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg		
340	345	350
350		
Ala Ala Trp Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly		
355	360	365

Thr Leu Pro Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu
 370 375 380

Gln Asp Ala Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro Val
 385 390 395 400

Thr Pro Glu Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His Leu
 405 410 415

Val Val Asp Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu Tyr
 420 425 430

Ile Gly Thr Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser
 435 440 445

Arg Ser Leu His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro Pro
 450 455 460

Gly Arg Arg Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala Arg
 465 470 475 480

Ala Leu Phe Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu Glu
 485 490 495

Arg Cys Ala Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp
 500 505 510

Pro Tyr Cys Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu
 515 520 525

Asp Ser Ser Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro
 530 535 540

Val Arg Asn Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp
 545 550 555 560

Gln Pro Cys Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys
 565 570 575

Arg Ala Arg Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp
 580 585 590

Cys Leu Gly Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly Gly
 595 600 605

Arg Gly Pro Arg Gly Ala Ser Trp Ala Ala Val Gln Ala Arg Pro Val
 610 615 620

Ala Ser Gly Phe Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro
 625 630 635 640

Arg His Gly Gly Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe
 645 650 655

Cys Asn Glu Asn Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp
 660 665 670

Gly Ser Trp Ser Lys Cys Ser Ser Asn Cys Gly Gly Met Gln Ser
 675 680 685

Arg Arg Arg Ala Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly Val
 690 695 700

 Glu Phe Lys Thr Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg Asn
 705 710 715 720

 Thr Pro Trp Thr Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly Ala
 725 730 735

 Arg Gln Glu Gln Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala Asp
 740 745 750

 Pro His Gly Leu Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr Cys
 755 760 765

 Pro Ala Asp Gly Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu Val
 770 775 780

 Leu Leu Arg Ser Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly Trp
 785 790 795 800

 Ala Ala Trp Gly Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu Gly
 805 810 815

 Phe Arg Val Arg Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn Gly
 820 825 830

 Gly Leu Pro Cys Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn Pro
 835 840 845

 Gln Ala Cys Pro Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp Ser
 850 855 860

 Pro Cys Ser Ala Ser Cys Gly Gly His Tyr Gln Arg Thr Arg Ser
 865 870 875 880

 Cys Thr Ser Pro Ala Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu
 885 890 895

 His Thr Glu Glu Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp
 900 905 910

 Ser Pro Trp Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser
 915 920 925

 Arg Ser Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala
 930 935 940

 Gly Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val
 945 950 955 960

 Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly Phe
 965 970 975

 Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu Gly Ser
 980 985 990

 Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His Cys Gln Arg
 995 1000 1005

 Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr Pro Asn His

1010	1015	1020
------	------	------

Leu His Tyr Lys Gly Gly	Gly Thr Pro Lys Asn Glu	Lys Tyr Thr
1025	1030	1035

Pro Met Glu Phe Lys Thr	Leu Asn Lys Asn Asn Leu	Ile Pro Asp
1040	1045	1050

Asp Arg Ala Asn Phe Tyr	Pro Leu Gln Gln Thr Asn	Val Tyr Thr
1055	1060	1065

Thr Thr Tyr Tyr Pro Ser	Pro Leu Asn Lys His Ser	Phe Arg Pro
1070	1075	1080

Glu Ala Ser Pro Gly Gln Arg	Cys Phe Pro Asn Ser	
1085	1090	1095

<210> 9

<211> 1248

<212> PRT

<213> Homo sapiens

<400> 9

Arg Pro Pro His Ser Gln Thr	Gly Arg Gln Pro Ile Trp	Leu Ala Pro	
1	5	10	15

Ala Ala Pro Arg Arg Pro	Gly Val Gly Ser Arg Gly	Glu Pro Gly Thr
20	25	30

Cys Thr Arg Leu Trp Glu	Pro Ala Trp Val Arg Val	Ala Leu Gly Pro
35	40	45

Ala Arg Ala Val Val Gly	Ala Ser Gly Leu Gln Arg	Arg Trp Gly Pro
50	55	60

Gly Thr Gln Ala Trp Arg	Arg Arg Arg Arg Thr Ser	Glu Ala Gly Arg	
65	70	75	80

Arg Asp Arg Val Ser Gly	Ser Ser Trp Cys Leu Ala	Cys Val Ser Trp
85	90	95

Met Pro Cys Gly Phe Ser	Pro Ser Pro Val Ala His	His Leu Val Pro
100	105	110

Gly Pro Pro Asp Thr Pro	Ala Gln Gln Leu Arg Cys	Gly Trp Thr Val
115	120	125

Gly Gly Trp Leu Leu Ser	Leu Val Arg Gly Leu	Leu Pro Cys Leu Pro
130	135	140

Pro Gly Ala Arg Thr Ala	Glu Gly Pro Ile Met Val	Leu Ala Gly Pro	
145	150	155	160

Leu Ala Val Ser Leu Leu	Leu Pro Ser Leu Thr	Leu Leu Val Ser His
165	170	175

Leu Ser Ser Ser Gln Asp	Val Ser Ser Glu Pro Ser	Ser Glu Gln Gln
180	185	190

Leu Cys Ala Leu Ser Lys His Pro Thr Val Ala Phe Glu Asp Leu Gln

195	200	205
Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp Phe Ser Gln		
210	215	220
Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu Ile Val Gly Ala Arg Asn		
225	230	235
Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val Ser Leu Leu Gln Ala Thr		
245	250	255
Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln Ser Lys Gly		
260	265	270
Lys Thr Glu Glu Glu Cys Gln Asn Tyr Val Arg Val Leu Ile Val Ala		
275	280	285
Gly Arg Lys Val Phe Met Cys Gly Thr Asn Ala Phe Ser Pro Met Cys		
290	295	300
Thr Ser Arg Gln Val Gly Asn Leu Ser Arg Thr Thr Glu Lys Ile Asn		
305	310	315
Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg His Asn Ser Thr Ala Val		
325	330	335
Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile Asp Phe Ser		
340	345	350
Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly Pro Pro Leu		
355	360	365
Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro Asn Phe Val		
370	375	380
Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu Arg Glu Asn		
385	390	395
Ala Val Glu His Asp Cys Gly Arg Thr Val Tyr Ser Arg Val Ala Arg		
405	410	415
Val Cys Lys Asn Asp Val Gly Arg Phe Leu Leu Glu Asp Thr Trp		
420	425	430
Thr Thr Phe Met Lys Ala Arg Leu Asn Cys Ser Arg Pro Gly Glu Val		
435	440	445
Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala Phe His Leu Pro Glu Gln		
450	455	460
Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn Val Asn Ser Ile Ala Ala		
465	470	475
Ser Ala Val Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln Ala Phe Asn		
485	490	495
Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp Leu Pro Ile		
500	505	510
Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro Glu Thr Gly		
515	520	525

Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala Gln Arg Leu
 530 535 540

Phe Leu Met Ser Glu Ala Val Gln Pro Val Thr Pro Glu Pro Cys Val
 545 550 555 560

Thr Gln Asp Ser Val Arg Phe Ser His Leu Val Val Asp Leu Val Gln
 565 570 575

Ala Lys Asp Thr Leu Tyr His Val Leu Tyr Ile Gly Thr Glu Ser Gly
 580 585 590

Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu His Gly Cys
 595 600 605

Tyr Leu Glu Glu Leu His Val Leu Pro Pro Gly Arg Arg Glu Pro Leu
 610 615 620

Arg Ser Leu Arg Ile Leu His Ser Ala Arg Ala Leu Phe Val Gly Leu
 625 630 635 640

Arg Asp Gly Val Leu Arg Val Pro Leu Glu Arg Cys Ala Ala Tyr Arg
 645 650 655

Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys Gly Trp Asp
 660 665 670

Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser Asn Met Ser
 675 680 685

Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro Val Arg Asn Val Thr Arg
 690 695 700

Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys Glu His Leu
 705 710 715 720

Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg Ser Cys Asp
 725 730 735

Ser Pro Arg Pro Arg Cys Gly Leu Asp Cys Leu Gly Pro Ala Ile
 740 745 750

His Ile Ala Asn Cys Ser Arg Asn Gly Ala Val Asp Pro Val Val Ile
 755 760 765

Val Gly Arg Cys Ala Ala Thr Ser Cys Gly Ile Gly Phe Gln Val Arg
 770 775 780

Gln Arg Ser Cys Ser Asn Pro Ala Pro Arg His Gly Gly Arg Ile Cys
 785 790 795 800

Val Gly Lys Ser Arg Glu Glu Arg Phe Cys Asn Glu Asn Thr Pro Cys
 805 810 815

Pro Val Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser Lys Cys Ser
 820 825 830

Ser Asn Cys Gly Gly Met Gln Ser Arg Arg Arg Ala Cys Glu Asn
 835 840 845

Gly Asn Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr Cys Asn Pro
850 855 860

Glu Gly Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr Pro Trp Leu
865 870 875 880

Pro Val Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln Arg Phe Arg
885 890 895

Phe Thr Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu Gln Phe Gly
900 905 910

Arg Arg Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly Ser Gly Ser
915 920 925

Cys Asp Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser Gly Ser Thr
930 935 940

Ser Pro His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly Pro Trp Ser
945 950 955 960

Ser Cys Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg Lys Arg Thr
965 970 975

Cys Thr Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys Val Gly Asp
980 985 990

Ala Ala Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro Val Arg Gly
995 1000 1005

Ala Trp Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala Ser Cys
1010 1015 1020

Gly Gly Gly His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro Ala
1025 1030 1035

Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu
1040 1045 1050

Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp
1055 1060 1065

Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser Arg Ser
1070 1075 1080

Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala Gly
1085 1090 1095

Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val
1100 1105 1110

Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly
1115 1120 1125

Phe Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu
1130 1135 1140

Gly Ser Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His
1145 1150 1155

Cys Gln Arg Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr

1160	1165	1170
Pro Asn His Leu His Tyr Lys	Gly Gly Gly Thr Pro	Lys Asn Glu
1175	1180	1185
Lys Tyr Thr Pro Met Glu Phe	Lys Thr Leu Asn Lys	Asn Asn Leu
1190	1195	1200
Ile Pro Asp Asp Arg Ala Asn	Phe Tyr Pro Leu Gln	Gln Thr Asn
1205	1210	1215
Val Tyr Thr Thr Tyr Tyr	Pro Ser Pro Leu Asn	Lys His Ser
1220	1225	1230
Phe Arg Pro Glu Ala Ser Pro	Gly Gln Arg Cys Phe	Pro Asn Ser
1235	1240	1245

<210> 10
<211> 1150
<212> PRT
<213> Homo sapiens

<400> 10			
Ala Ala Ala Pro Phe Pro Asp Arg Pro	Pro Ala His Leu Val Ser Ser		
1	5	10	15
Arg Arg Ser Ala Pro Pro Gly Ser Arg	Glu Pro Arg Gly Thr Gly His		
20	25	30	
Leu His Pro Pro Leu Gly Gly	Leu Leu Pro Cys Leu Pro Pro Gly Ala		
35	40	45	
Arg Thr Ala Glu Gly Pro Ile Met Val	Leu Ala Gly Pro Leu Ala Val		
50	55	60	
Ser Leu Leu Leu Pro Ser Leu Thr Leu Leu Val	Ser His Leu Ser Ser		
65	70	75	80
Ser Gln Asp Val Ser Ser Glu Pro Ser Ser	Glu Gln Gln Leu Cys Ala		
85	90	95	
Leu Ser Lys His Pro Thr Val Ala Phe	Glu Asp Leu Gln Pro Trp Val		
100	105	110	
Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp Phe	Ser Gln Leu Ala Leu		
115	120	125	
Asp Pro Ser Gly Asn Gln Leu Ile Val Gly	Ala Arg Asn Tyr Leu Phe		
130	135	140	
Arg Leu Ser Leu Ala Asn Val Ser Leu Leu Gln	Ala Thr Glu Trp Ala		
145	150	155	160
Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln	Ser Lys Gly Lys Thr Glu		
165	170	175	
Glu Glu Cys Gln Asn Tyr Val Arg Val	Leu Ile Val Ala Gly Arg Lys		
180	185	190	
Val Phe Met Cys Gly Thr Asn Ala Phe	Ser Pro Met Cys Thr Ser Arg		

195	200	205
Gln Val Gly Asn Leu Ser Arg Thr Thr Glu Lys Ile Asn Gly Val Ala		
210	215	220
Arg Cys Pro Tyr Asp Pro Arg His Asn Ser Thr Ala Val Ile Ser Ser		
225	230	235
240		
Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile Asp Phe Ser Gly Arg Asp		
245	250	255
Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly Pro Pro Leu Arg Thr Ala		
260	265	270
Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro Asn Phe Val Ala Ala Tyr		
275	280	285
Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu Arg Glu Asn Ala Val Glu		
290	295	300
His Asp Cys Gly Arg Thr Val Tyr Ser Arg Val Ala Arg Val Cys Lys		
305	310	315
320		
Asn Asp Val Gly Gly Arg Phe Leu Leu Glu Asp Thr Trp Thr Thr Phe		
325	330	335
Met Lys Ala Arg Leu Asn Cys Ser Arg Pro Gly Glu Val Pro Phe Tyr		
340	345	350
Tyr Asn Glu Leu Gln Ser Ala Phe His Leu Pro Glu Gln Asp Leu Ile		
355	360	365
Tyr Gly Val Phe Thr Thr Asn Val Asn Ser Ile Ala Ala Ser Ala Val		
370	375	380
Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln Ala Phe Asn Gly Pro Phe		
385	390	395
400		
Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp Leu Pro Ile Ala Asn Pro		
405	410	415
Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro Glu Thr Gly Pro Asn Glu		
420	425	430
Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala Gln Arg Leu Phe Leu Met		
435	440	445
Ser Glu Ala Val Gln Pro Val Thr Pro Glu Pro Cys Val Thr Gln Asp		
450	455	460
Ser Val Arg Phe Ser His Leu Val Val Asp Leu Val Gln Ala Lys Asp		
465	470	475
480		
Thr Leu Tyr His Val Leu Tyr Ile Gly Thr Glu Ser Gly Thr Ile Leu		
485	490	495
Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu His Gly Cys Tyr Leu Glu		
500	505	510
Glu Leu His Val Leu Pro Pro Gly Arg Arg Glu Pro Leu Arg Ser Leu		
515	520	525

Arg Ile Leu His Ser Ala Arg Ala Leu Phe Val Gly Leu Arg Asp Gly
 530 535 540

Val Leu Arg Val Pro Leu Glu Arg Cys Ala Ala Tyr Arg Ser Gln Gly
 545 550 555 560

Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys Gly Trp Asp Gly Lys Gln
 565 570 575

Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser Asn Met Ser Leu Trp Thr
 580 585 590

Gln Asn Ile Thr Ala Cys Pro Val Arg Asn Val Thr Arg Asp Gly Gly
 595 600 605

Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys Glu His Leu Asp Gly Asp
 610 615 620

Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg Ser Cys Asp Ser Pro Arg
 625 630 635 640

Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly Pro Ala Ile His Ile Ala
 645 650 655

Asn Cys Ser Arg Asn Gly Ala Val Asp Pro Val Val His Arg Gly Pro
 660 665 670

Leu Cys Ser His Val Leu Trp His Ala Ala Ser Arg Ser Ala Ser Glu
 675 680 685

Val Ala Ala Thr Leu Leu Pro Ala Thr Gly Ala Ala Ser Ala Trp Ala
 690 695 700

Arg Ala Trp Glu Glu Arg Phe Cys Asn Glu Asn Thr Pro Cys Pro Val
 705 710 715 720

Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser Lys Cys Ser Ser Asn
 725 730 735

Cys Gly Gly Gly Met Gln Ser Arg Arg Arg Ala Cys Glu Asn Gly Asn
 740 745 750

Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr Cys Asn Pro Glu Gly
 755 760 765

Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr Pro Trp Leu Pro Val
 770 775 780

Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln Arg Phe Arg Phe Thr
 785 790 795 800

Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu Gln Phe Gly Arg Arg
 805 810 815

Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly Ser Gly Ser Cys Asp
 820 825 830

Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser Gly Ser Thr Ser Pro
 835 840 845

His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly Pro Trp Ser Ser Cys
 850 855 860
 Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg Lys Arg Thr Cys Thr
 865 870 875 880
 Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys Val Gly Asp Ala Ala
 885 890 895
 Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro Val Arg Gly Ala Trp
 900 905 910
 Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala Ser Cys Gly Gly Gly
 915 920 925
 His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro Ala Pro Ser Pro Gly
 930 935 940
 Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu Ala Leu Cys Ala Thr
 945 950 955 960
 Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp Ser Glu Trp Ser Lys Cys
 965 970 975
 Thr Asp Asp Gly Ala Gln Ser Arg Ser Arg His Cys Glu Glu Leu Leu
 980 985 990
 Pro Gly Ser Ser Ala Cys Ala Gly Asn Ser Ser Gln Ser Arg Pro Cys
 995 1000 1005
 Pro Tyr Ser Glu Ile Arg Val Ile Leu Pro Ala Ser Ser Met Glu
 1010 1015 1020
 Glu Ala Thr Asp Cys Ala Gly Phe Asn Leu Ile His Leu Val Ala
 1025 1030 1035
 Thr Gly Ile Ser Cys Phe Leu Gly Ser Gly Leu Leu Thr Leu Ala
 1040 1045 1050
 Val Tyr Leu Ser Cys Gln His Cys Gln Arg Gln Ser Gln Glu Ser
 1055 1060 1065
 Thr Leu Val His Pro Ala Thr Pro Asn His Leu His Tyr Lys Gly
 1070 1075 1080
 Gly Gly Thr Pro Lys Asn Glu Lys Tyr Thr Pro Met Glu Phe Lys
 1085 1090 1095
 Thr Leu Asn Lys Asn Asn Leu Ile Pro Asp Asp Arg Ala Asn Phe
 1100 1105 1110
 Tyr Pro Leu Gln Gln Thr Asn Val Tyr Thr Thr Thr Tyr Tyr Pro
 1115 1120 1125
 Ser Pro Leu Asn Lys His Ser Phe Arg Pro Glu Ala Ser Pro Gly
 1130 1135 1140
 Gln Arg Cys Phe Pro Asn Ser
 1145 1150

<210> 11
 <211> 1211
 <212> PRT
 <213> Homo sapiens

<400> 11
 Ala Ala Ala Pro Phe Pro Asp Arg Pro Pro Ala His Leu Val Ser Ser
 1 5 10 15

Arg Arg Ser Ala Pro Pro Gly Ser Arg Glu Pro Arg Gly Thr Gly His
 20 25 30

Leu His Pro Pro Leu Gly Val Ser Gly Ser Ser Trp Cys Leu Ala Cys
 35 40 45

Val Ser Trp Met Pro Cys Gly Phe Ser Pro Ser Pro Val Ala His His
 50 55 60

Leu Val Pro Gly Pro Pro Asp Thr Pro Ala Gln Gln Leu Arg Cys Gly
 65 70 75 80

Trp Thr Val Gly Gly Trp Leu Leu Ser Leu Val Arg Gly Leu Leu Pro
 85 90 95

Cys Leu Pro Pro Gly Ala Arg Thr Ala Glu Gly Pro Ile Met Val Leu
 100 105 110

Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser Leu Thr Leu Leu
 115 120 125

Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser Glu Pro Ser Ser
 130 135 140

Glu Gln Gln Leu Cys Ala Leu Ser Lys His Pro Thr Val Ala Phe Glu
 145 150 155 160

Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp
 165 170 175

Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu Ile Val Gly
 180 185 190

Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val Ser Leu Leu
 195 200 205

Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln
 210 215 220

Ser Lys Gly Lys Thr Glu Glu Glu Cys Gln Asn Tyr Val Arg Val Leu
 225 230 235 240

Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr Asn Ala Phe Ser
 245 250 255

Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser Arg Thr Thr Glu
 260 265 270

Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg His Asn Ser
 275 280 285

Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile

290	295	300
Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly		
305	310	315
320		
Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro		
325	330	335
Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu		
340	345	350
Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr Val Tyr Ser Arg		
355	360	365
Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg Phe Leu Leu Glu		
370	375	380
Asp Thr Trp Thr Thr Phe Met Lys Ala Arg Leu Asn Cys Ser Arg Pro		
385	390	395
400		
Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala Phe His Leu		
405	410	415
Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn Val Asn Ser		
420	425	430
Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln		
435	440	445
Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp		
450	455	460
Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro		
465	470	475
480		
Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala		
485	490	495
Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro Val Thr Pro Glu		
500	505	510
Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His Leu Val Val Asp		
515	520	525
Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu Tyr Ile Gly Thr		
530	535	540
Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu		
545	550	555
560		
His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro Pro Gly Arg Arg		
565	570	575
Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala Arg Ala Leu Phe		
580	585	590
Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu Glu Arg Cys Ala		
595	600	605
Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys		
610	615	620

Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser
 625 630 635 640

Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro Val Arg Asn
 645 650 655

Val Thr Arg Asp Gly Gly Pro Trp Ser Pro Trp Gln Pro Cys
 660 665 670

Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg
 675 680 685

Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly
 690 695 700

Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly Ala Val Asp Pro
 705 710 715 720

Val Val Ile Val Gly Arg Cys Ala Ala Thr Ser Cys Gly Ile Gly Phe
 725 730 735

Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro Arg His Gly Gly
 740 745 750

Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe Cys Asn Glu Asn
 755 760 765

Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser
 770 775 780

Lys Cys Ser Ser Asn Cys Gly Gly Met Gln Ser Arg Arg Arg Ala
 785 790 795 800

Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr
 805 810 815

Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr
 820 825 830

Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln
 835 840 845

Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu
 850 855 860

Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly
 865 870 875 880

Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser
 885 890 895

Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly
 900 905 910

Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg
 915 920 925

Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys
 930 935 940

Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro
 945 950 955 960

Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala
 965 970 975

Ser Cys Gly Gly His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro
 980 985 990

Ala Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu
 995 1000 1005

Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp
 1010 1015 1020

Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser Arg Ser
 1025 1030 1035

Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala Gly
 1040 1045 1050

Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val
 1055 1060 1065

Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly
 1070 1075 1080

Phe Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu
 1085 1090 1095

Gly Ser Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His
 1100 1105 1110

Cys Gln Arg Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr
 1115 1120 1125

Pro Asn His Leu His Tyr Lys Gly Gly Gly Thr Pro Lys Asn Glu
 1130 1135 1140

Lys Tyr Thr Pro Met Glu Phe Lys Thr Leu Asn Lys Asn Asn Leu
 1145 1150 1155

Ile Pro Asp Asp Arg Ala Asn Phe Tyr Pro Leu Gln Gln Thr Asn
 1160 1165 1170

Ala Ser Ala Gly Tyr Pro Pro Leu Pro Gly Ser Leu Tyr Ser Thr
 1175 1180 1185

Gln Gly Ile Pro Leu Val Arg Gly Ser Glu Tyr Trp Glu Leu Glu
 1190 1195 1200

Ala Asp Leu Cys Leu Glu Val Leu
 1205 1210

<210> 12
<211> 1203
<212> PRT
<213> Homo sapiens

<400> 12

Ala Ala Ala Pro Phe Pro Asp Arg Pro Pro Ala His Leu Val Ser Ser
 1 5 10 15

Arg Arg Ser Ala Pro Pro Gly Ser Arg Glu Pro Arg Gly Thr Gly His
 20 25 30

Leu His Pro Pro Leu Gly Val Ser Gly Ser Ser Trp Cys Leu Ala Cys
 35 40 45

Val Ser Trp Met Pro Cys Gly Phe Ser Pro Ser Pro Val Ala His His
 50 55 60

Leu Val Pro Gly Pro Pro Asp Thr Pro Ala Gln Gln Leu Arg Cys Gly
 65 70 75 80

Trp Thr Val Gly Gly Trp Leu Leu Ser Leu Val Arg Gly Leu Leu Pro
 85 90 95

Cys Leu Pro Pro Gly Ala Arg Thr Ala Glu Gly Pro Ile Met Val Leu
 100 105 110

Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser Leu Thr Leu Leu
 115 120 125

Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser Glu Pro Ser Ser
 130 135 140

Glu Gln Gln Leu Cys Ala Leu Ser Lys His Pro Thr Val Ala Phe Glu
 145 150 155 160

Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp
 165 170 175

Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu Ile Val Gly
 180 185 190

Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val Ser Leu Leu
 195 200 205

Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln
 210 215 220

Ser Lys Gly Lys Thr Glu Glu Glu Cys Gln Asn Tyr Val Arg Val Leu
 225 230 235 240

Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr Asn Ala Phe Ser
 245 250 255

Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser Arg Thr Thr Glu
 260 265 270

Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg His Asn Ser
 275 280 285

Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile
 290 295 300

Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly
 305 310 315 320

Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro

325	330	335	
Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu			
340	345	350	
Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr Val Tyr Ser Arg			
355	360	365	
Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg Phe Leu Leu Glu			
370	375	380	
Asp Thr Trp Thr Thr Phe Met Lys Ala Arg Leu Asn Cys Ser Arg Pro			
385	390	395	400
Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala Phe His Leu			
405	410	415	
Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn Val Asn Ser			
420	425	430	
Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln			
435	440	445	
Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp			
450	455	460	
Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro			
465	470	475	480
Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala			
485	490	495	
Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro Val Thr Pro Glu			
500	505	510	
Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His Leu Val Val Asp			
515	520	525	
Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu Tyr Ile Gly Thr			
530	535	540	
Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu			
545	550	555	560
His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro Pro Gly Arg Arg			
565	570	575	
Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala Arg Ala Leu Phe			
580	585	590	
Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu Glu Arg Cys Ala			
595	600	605	
Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys			
610	615	620	
Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser			
625	630	635	640
Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro Val Arg Asn			
645	650	655	

Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys
 660 665 670
 Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg
 675 680 685
 Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly
 690 695 700
 Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly Ala Val Asp Pro
 705 710 715 720
 Val Val Ile Val Gly Arg Cys Ala Ala Thr Ser Cys Gly Ile Gly Phe
 725 730 735
 Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro Arg His Gly Gly
 740 745 750
 Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe Cys Asn Glu Asn
 755 760 765
 Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser
 770 775 780
 Lys Cys Ser Ser Asn Cys Gly Gly Met Gln Ser Arg Arg Arg Ala
 785 790 795 800
 Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr
 805 810 815
 Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr
 820 825 830
 Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln
 835 840 845
 Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu
 850 855 860
 Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly
 865 870 875 880
 Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser
 885 890 895
 Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly
 900 905 910
 Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg
 915 920 925
 Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys
 930 935 940
 Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro
 945 950 955 960
 Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala
 965 970 975

Ser Cys Gly Gly His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro
 980 985 990

Ala Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu
 995 1000 1005

Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp
 1010 1015 1020

Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser Arg Ser
 1025 1030 1035

Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala Gly
 1040 1045 1050

Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val
 1055 1060 1065

Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly
 1070 1075 1080

Phe Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu
 1085 1090 1095

Gly Ser Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His
 1100 1105 1110

Cys Gln Arg Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr
 1115 1120 1125

Pro Asn His Leu His Tyr Lys Gly Gly Gly Thr Pro Lys Asn Glu
 1130 1135 1140

Lys Tyr Thr Pro Met Glu Phe Lys Thr Leu Asn Lys Asn Asn Leu
 1145 1150 1155

Ile Pro Asp Asp Arg Ala Asn Phe Tyr Pro Leu Gln Gln Thr Asn
 1160 1165 1170

Val Tyr Thr Thr Tyr Tyr Pro Ser Pro Leu Asn Lys His Ser
 1175 1180 1185

Phe Arg Pro Glu Ala Ser Pro Gly Gln Arg Cys Phe Pro Asn Ser
 1190 1195 1200

<210> 13
<211> 1240
<212> PRT
<213> Homo sapiens

<400> 13
Ala Ala Ala Pro Phe Pro Asp Arg Pro Pro Ala His Leu Val Ser Ser
1 5 10 15

Arg Arg Ser Ala Pro Pro Gly Ser Arg Glu Pro Arg Gly Thr Gly His
20 25 30

Leu His Pro Pro Leu Gly Val Ser Gly Ser Ser Trp Cys Leu Ala Cys
35 40 45

Val Ser Trp Met Pro Cys Gly Phe Ser Pro Ser Pro Val Ala His His
 50 55 60

Leu Val Pro Gly Pro Pro Asp Thr Pro Ala Gln Gln Leu Arg Cys Gly
 65 70 75 80

Trp Thr Val Gly Gly Trp Leu Leu Ser Leu Val Arg Gly Arg Lys Pro
 85 90 95

Ser Gly Asp Phe Glu Trp Arg Gln Gly Trp Arg Gly Pro Gly Glu Glu
 100 105 110

Asp Trp Pro Glu Ser Pro Ser Pro Lys Val Leu Met Asp Ser Ala Gly
 115 120 125

Gly Leu Leu Pro Cys Leu Pro Pro Gly Ala Arg Thr Ala Glu Gly Pro
 130 135 140

Ile Met Val Leu Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser
 145 150 155 160

Leu Thr Leu Leu Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser
 165 170 175

Glu Pro Ser Ser Glu Glu Gln Gln Leu Cys Ala Leu Ser Lys His Pro Thr
 180 185 190

Val Ala Phe Glu Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro
 195 200 205

Gly Ala Arg Asp Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln
 210 215 220

Leu Ile Val Gly Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn
 225 230 235 240

Val Ser Leu Leu Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg
 245 250 255

Arg Ser Cys Gln Ser Lys Gly Lys Thr Glu Glu Glu Cys Gln Asn Tyr
 260 265 270

Val Arg Val Leu Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr
 275 280 285

Asn Ala Phe Ser Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser
 290 295 300

Arg Thr Thr Glu Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro
 305 310 315 320

Arg His Asn Ser Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala
 325 330 335

Ala Thr Val Ile Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser
 340 345 350

Leu Gly Ser Gly Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp
 355 360 365

Leu Asn Glu Pro Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala
 370 375 380

Tyr Phe Phe Leu Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr
 385 390 395 400

Val Tyr Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg
 405 410 415

Phe Leu Leu Glu Asp Thr Trp Thr Phe Met Lys Ala Arg Leu Asn
 420 425 430

Cys Ser Arg Pro Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser
 435 440 445

Ala Phe His Leu Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr
 450 455 460

Asn Val Asn Ser Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser
 465 470 475 480

Ala Ile Ser Gln Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro
 485 490 495

Arg Ala Ala Trp Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys
 500 505 510

Gly Thr Leu Pro Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser
 515 520 525

Leu Gln Asp Ala Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro
 530 535 540

Val Thr Pro Glu Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His
 545 550 555 560

Leu Val Val Asp Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu
 565 570 575

Tyr Ile Gly Thr Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala
 580 585 590

Ser Arg Ser Leu His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro
 595 600 605

Pro Gly Arg Arg Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala
 610 615 620

Arg Ala Leu Phe Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu
 625 630 635 640

Glu Arg Cys Ala Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg
 645 650 655

Asp Pro Tyr Cys Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu
 660 665 670

Glu Asp Ser Ser Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys
 675 680 685

Pro Val Arg Asn Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro

690	695	700
Trp Gln Pro Cys Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu		
705	710	715
720		
Cys Arg Ala Arg Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu		
725	730	735
Asp Cys Leu Gly Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly		
740	745	750
Gly Arg Gly Pro Arg Gly Ala Ser Trp Ala Ala Val Gln Ala Arg Pro		
755	760	765
Val Ala Ser Gly Phe Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala		
770	775	780
Pro Arg His Gly Gly Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg		
785	790	795
800		
Phe Cys Asn Glu Asn Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser		
805	810	815
Trp Gly Ser Trp Ser Lys Cys Ser Ser Asn Cys Gly Gly Met Gln		
820	825	830
Ser Arg Arg Arg Ala Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly		
835	840	845
Val Glu Phe Lys Thr Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg		
850	855	860
Asn Thr Pro Trp Thr Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly		
865	870	875
880		
Ala Arg Gln Glu Gln Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala		
885	890	895
Asp Pro His Gly Leu Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr		
900	905	910
Cys Pro Ala Asp Gly Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu		
915	920	925
Val Leu Leu Arg Ser Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly		
930	935	940
Trp Ala Ala Trp Gly Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu		
945	950	955
960		
Gly Phe Arg Val Arg Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn		
965	970	975
Gly Gly Leu Pro Cys Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn		
980	985	990
Pro Gln Ala Cys Pro Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp		
995	1000	1005
Ser Pro Cys Ser Ala Ser Cys Gly Gly Gly His Tyr Gln Arg Thr		
1010	1015	1020

Arg Ser Cys Thr Ser Pro Ala Pro Ser Pro Gly Glu Asp Ile Cys
 1025 1030 1035
 Leu Gly Leu His Thr Glu Glu Ala Leu Cys Ala Thr Gln Ala Cys
 1040 1045 1050
 Pro Glu Gly Trp Ser Pro Trp Ser Glu Trp Ser Lys Cys Thr Asp
 1055 1060 1065
 Asp Gly Ala Gln Ser Arg Ser Arg His Cys Glu Glu Leu Leu Pro
 1070 1075 1080
 Gly Ser Ser Ala Cys Ala Gly Asn Ser Ser Gln Ser Arg Pro Cys
 1085 1090 1095
 Pro Tyr Ser Glu Ile Arg Val Ile Leu Pro Ala Ser Ser Met Glu
 1100 1105 1110
 Glu Ala Thr Asp Cys Ala Gly Phe Asn Leu Ile His Leu Val Ala
 1115 1120 1125
 Thr Gly Ile Ser Cys Phe Leu Gly Ser Gly Leu Leu Thr Leu Ala
 1130 1135 1140
 Val Tyr Leu Ser Cys Gln His Cys Gln Arg Gln Ser Gln Glu Ser
 1145 1150 1155
 Thr Leu Val His Pro Ala Thr Pro Asn His Leu His Tyr Lys Gly
 1160 1165 1170
 Gly Gly Thr Pro Lys Asn Glu Lys Tyr Thr Pro Met Glu Phe Lys
 1175 1180 1185
 Thr Leu Asn Lys Asn Asn Leu Ile Pro Asp Asp Arg Ala Asn Phe
 1190 1195 1200
 Tyr Pro Leu Gln Gln Thr Asn Val Tyr Thr Thr Thr Tyr Tyr Pro
 1205 1210 1215
 Ser Pro Leu Asn Lys His Ser Phe Arg Pro Glu Ala Ser Pro Gly
 1220 1225 1230
 Gln Arg Cys Phe Pro Asn Ser
 1235 1240

<210> 14
 <211> 4567
 <212> DNA
 <213> Homo sapiens

<400> 14
 gcggccgccc cattccccaga ccggccgcca gccccatctgg ttagctcccg ccgcgtccg 60
 cccgccccggga gtcgggagcc gcggggaaacc gggcacctgc acccgccctct gggagtgagt 120
 ggttccagct ggtgcctggc ctgtgtctct tggatgccct gtggcttcag tccgtctccct 180
 gttggccacc acctcggtccc tggggccgcct gataccccag cccaacagct aaggtgtgga 240
 tggacagtag ggggctggct tctctcaactg gtcaggggtc ttctccctgt tctgcctccc 300
 ggagcttagga ctgcagaggg gccttatcatg gtgcttgcag gccccctggc tgtctcgctg 360
 ttgtctggcca gcctcacact gctgggtgtcc cacctctcca gctcccagga tgtctccaggt 420
 gagcccaagca gtgagcagca gctgtgcgcc ctttagcaagc acccccaccgt ggcctttgaa 480

gacctgcagc	cgtgggtctc	taacttcacc	taccctggag	cccgaggattt	ctcccaagctg	540
gctttggacc	cctccggaa	ccagctcatc	gtgggagcca	ggaactacct	cttcagactc	600
agccctgcca	atgtctct	tcttcaggcc	acagagtggg	cctccagtga	ggacacgcgc	660
cgctccgtcc	aaagcaaagg	gaagacttag	gaggagtgtc	agaactacgt	gcgagtcctg	720
atcgtcgccc	gccgaaagg	gttcatgtgt	ggaaccatg	cctttcccc	catgtgcacc	780
agcagacagg	tgggaaacct	cagccggact	actgagaaga	tcaatggtgt	ggcccgtgc	840
ccctatgacc	cacgcacaaa	ctccacacgt	gtcatctcct	cccaggggga	gctctatgca	900
gccacggtca	tcgacttctc	aggtcgggac	cctgccatct	accgcagcct	gggcagtggg	960
ccaccgccttc	gcactgccc	ataataactcc	aagtggctta	atgagccaaa	cttcgtggca	1020
gcctatgata	ttgggtgtt	tgcataactc	ttcctgcggg	agaacgcagt	ggagcacgac	1080
tgtggacgca	ccgtgtactc	tcgcgtggcc	cgcgtgtgca	agaatgacgt	ggggggccga	1140
ttcctgctgg	aggacacatg	gaccacattc	atgaaggccc	ggctcaactg	ctccgcggcc	1200
ggcgaggtcc	ccttctacta	taacgagctg	cagagtgcct	tccacttgcc	agagcaggac	1260
ctcatctatg	gagtttcac	aaccaacgta	aacagcatcg	cggttctgc	tgtctgcgcc	1320
ttcaacctca	gtgctatctc	ccagggttc	aatggccat	ttcgctacca	ggagaacccc	1380
agggctgcct	ggctcccat	agccaacccc	atccccattt	tccagtgtgg	caccctgcct	1440
gagaccggtc	ccaacgagaa	cctgacggag	cgcagcctgc	aggacgcgca	gccccttc	1500
ctgatgagcg	aggccgtgca	gccggtgaca	cccgagccct	gtgtcaccca	ggacagcgtg	1560
cgcttctcac	acctcgtgg	ggacctggg	caggctaaag	acacgctcta	ccatgtactc	1620
tacattggca	ccgagtcggg	caccatctg	aaggcgctgt	ccacggcgag	ccgcagcctc	1680
cacggctgt	acctggagga	gctgcacgt	ctgcccccc	ggccgcgcga	gcccctgcgc	1740
agcctgcga	tcctgcacag	cgcccgcgcg	ctcttcgtgg	ggctgagaga	cgccgtcctg	1800
cgggtcccac	tggagaggt	cgccgcctac	cgcagccagg	gggcatgcct	ggggggccgg	1860
gaccctgact	gtggctggg	cgggaagcag	caacgttgc	gcacactcga	ggacagctcc	1920
aacatgagcc	tctggaccca	gaacatcacc	gcctgtctg	tgcggaatgt	gacacggat	1980
gggggcttcg	gcccattggc	accatggcaa	ccatgtgagc	acttggatgg	ggacaactca	2040
ggcttgcct	tgtgtcgagc	tcgatctgt	gattccctc	gaccccgctg	tggggccctt	2100
gactgcctgg	ggccagccat	ccacatcgcc	aactgttca	ggaatggggc	gtggaccccg	2160
tgttcatctgt	gggcgtgt	cagcacgtcc	tgtggcatcg	gtttccagg	ccgcagcga	2220
agttgcagca	accctgctcc	ccgcccacgg	ggccgcattc	gcgtgggca	gagccgggag	2280
gaacggttt	gtaatgagaa	cacgccttgc	ccggtgccca	tcttctggc	ttcctggggc	2340
tcctggagca	agtgcagcag	caactgttga	gggggcatgc	agtgcgcggc	tcgggcctgc	2400
gagaacggca	actcctgcct	gggctgcgc	gtggagttca	agacgtgca	ccccgaggc	2460
tgccccgaag	tgcggcgca	cacccctgg	acgcgtggc	tgcggcgaa	cgtgacgcag	2520
ggcggggcac	ggcaggagca	gcgggtccgc	ttcacctgcc	gcccgcct	tgcagacccg	2580
cacggcctgc	agttcggcag	gagaaggacc	gagacgagga	cctgtcccc	ggacggctcc	2640
ggctcctgcg	acaccgacgc	cctgggtggag	gtcctcctgc	gcagcgggag	cacccccc	2700
cacacggtga	gcggggctg	gccgcctgg	ggcccggt	cgtcctgc	ccggactgc	2760
gagctgggt	tccgcgtcc	caagagaacg	tgcactaacc	cggagccccc	caacggggc	2820
ctgcccctgc	tggggatgc	tgccgagttac	caggactgca	accccccaggc	ttgcccagtt	2880
cggggtgct	gttcctgc	gacctcatgg	tctccatgct	cagttccctg	tgggtgggg	2940
cactatcaac	gcacccgttc	ctgcaccaggc	ccgcacccct	ccccagggt	ggacatctgt	3000
ctcgggctgc	acacggagga	gfcactatgt	gccacacagg	cctgcccaga	aggctggc	3060
ccctggctgt	agtggagtaa	gtgcactgac	gacggagccc	agagccga	ccggcactgt	3120
gaggagctcc	tcccagggtc	cagcgcmtgt	gctggaaaca	gcagccagag	ccgcoccctgc	3180
ccctacagcg	agattcscgt	catcctgcca	gcctccagca	tggaggaggc	caccgactgt	3240
gcaggggttca	atctcatcca	cttgggtggcc	acgggcattc	cctgcttctt	gggctctggg	3300
ctccctgaccc	tagcaagtta	cctgtctgc	cagcaactg	agcgtcagtc	ccaggagtcc	3360
acactggtcc	atccctccac	ccccaaat	ttgcactaca	agggcggagg	caccccgaa	3420
aatgaaaagt	acacacccat	gaaattcaag	accctgaaca	agaataactt	gatccctgtat	3480
gacagagcca	acttctaccc	attgcagcag	accaatgtgt	acacgactac	ttactacca	3540
agccccctga	acaaacacag	cttccggccc	gaggcctac	ctggacaacg	gtgcttcccc	3600
aacagctgtat	accgcgtcc	tggggacttg	ggcttctgc	cttcataagg	cacagagcag	3660
atggagatgg	gacagtggag	ccagtttgt	tttccctc	tgcactaggg	caagaacttg	3720
ctgccttgc	tgtgggggt	cccatccggc	ttcagagagc	tctggctggc	attgaccatg	3780
ggggaaagg	ctgggttcag	gctgacatata	ggccgcagg	ccagttcagc	ccaggtctmt	3840
catggttatc	ttccaaccca	ctgtcacgt	gacactatgc	tgccatgcct	gggcgtgtgg	3900
cctactgggc	atttggagaa	ytggagaatg	gagatggca	gagggcaggc	tttaagtt	3960
gggttggaga	caacttcctg	tggccccac	aagctgagtc	tggccttctc	cagctggccc	4020
aaaaaaaggc	ctttgttaca	tcctgattat	ctctgaaagt	aatcaatcaa	gtggctccag	4080
tagctctgga	ttttctgcca	gggctggccc	attgtggtgc	tgccccagta	tgacatggga	4140

ccaaaggccag	cgcaggttat	ccacctctgc	ctggaaagtct	atactctacc	cagggcatcc	4200
ctctggtcag	aggcagtgag	tactggaaac	tggaggctga	cctgtgctta	gaagtccttt	4260
aatctggct	ggtacaggcc	tcagccttc	cctcaatgca	cggaaagggtgg	cccaggagag	4320
agatcaatg	ccataggagg	cagaagtctg	gcctctgtgc	ctctatggag	actatcttcc	4380
agttgtctgt	caacagagtt	gttggcttag	acctgcttgg	gagtctctgc	tggcccttca	4440
tctgttcagg	aacacacaca	cacacacact	cacacacgca	cacacaatca	caatttgcta	4500
cagcaacaaa	aaagacattt	ggctgtggca	ttattaatta	aagatgatat	ccagtcaaaaa	4560
						4567

<210> 15
<211> 453
<212> DNA
<213> Homo sapiens

<400> 15						
agtaatcagc	tcggtaccgg	catgtgctgt	agccagcgca	ggttatccac	ctctgcctgg	60
aagtctatac	tctaccagg	gcatccctct	ggtcagaggc	agttagtact	gggaactgga	120
ggctgacctg	tgcttagaag	tcctttaatc	tgggctggta	caggcctcag	ccttgccttc	180
aatgcacgaa	aggtggccca	ggagagagga	tcaatgccat	aggaggcaga	agtctggcct	240
ctgtgcctct	atggagacta	tcttccagg	gctgctcaac	agagttgttg	gctgagacct	300
gcttgggagt	ctctgctggc	ccttcatctg	ttcaggaaca	cacacacaca	cacactcaca	360
cacgcacaca	caatcacaat	ttgctacagc	aacaaaaaaag	acattgggct	gtggcattat	420
taattaaaga	tgatatccag	tcaaaaaaaaa	act			453

<210> 16
<211> 4675
<212> DNA
<213> Homo sapiens

<400> 16						
gccccccccc	cattcccaga	ccggccgcca	gcccacatctgg	ttagctcccg	ccgctccgcg	60
ccgccccggg	gtcgggagcc	gcggggaaacc	gggcacac	acccgcctct	gggagtgagt	120
ggttccagct	ggtgctggc	ctgtgtctct	tggatgcct	gtggcttcag	tccgtctcct	180
gttgccacc	acctcgtccc	tggggccgcct	gatacccccag	cccaacagct	aagggtgtgga	240
tggacagtag	ggggctggct	tctctcactg	gtcaggggca	ggaagccaag	tggagacttt	300
gaatggaggc	aaggatggag	gggacctgg	gaagaggact	ggcctgaatc	acctccccca	360
aagggtcctca	tggactgagc	tggaggtctt	ctcccctgtc	tgcctcccg	agctaggact	420
gcagaggggc	ctatcatgg	gcttgcagc	cccctggctg	tctcgctgtt	gctgccagc	480
ctcacactgc	tggtgtccca	cctctccagc	tcccaggatg	tctccagtg	gcccagcagt	540
gagcagcagc	tgtgcgcct	tagcaagcac	cccaccgtgg	ccttgaaga	cctgcagccg	600
tgggtctcta	acttcaccta	ccctggagcc	cgggatttct	cccagctggc	tttggacccc	660
tcgggaaacc	agctcatgt	gggagccagg	aactacctct	tcagactcag	ccttgccaaat	720
gtctctcttc	ttcaggccac	agagtggccc	tccagtgagg	acacgcgcgc	ctcctgccaa	780
agcaaaggga	agactgagga	ggagtgtcag	aactacgtc	gagtctgtat	cgtgcggcgc	840
cggaaagggt	tcatgtgtgg	aaccaatgcc	ttttccccca	tgtgcaccag	cagacaggtg	900
gggaacctca	gccggactac	tgagaagatc	aatgggtgg	cccgctgccc	ctatgaccca	960
cggccacaact	ccacagctgt	catctccccc	cagggggagc	tctatgcagc	cacggtcatc	1020
gacttctca	gtcgggaccc	tgccatctac	cgcagcctgg	gcagtggggcc	accgcttcgc	1080
actgccccat	ataactccaa	gtggcttaat	gagccaaact	tcgtggcagc	ctatgatatt	1140
gggctgtttt	catacttctt	cctgcgggag	aacgcagtg	agcacgactg	tggacgcacc	1200
gtgtactctc	gcgtggcccg	cgtgtcaag	aatgcagtg	ggggccgatt	cctgctggag	1260
gacacatgga	ccacattcat	gaaggccccg	ctcaactgt	cccgccccgg	cgaggtcccc	1320
ttctactata	acgagctgca	gagtgccttc	cacttgccag	agcaggacct	catctatgga	1380
gttttcacaa	ccaacgtaaa	cagcatcg	gcttctgt	tctgcgcctt	caacctcagt	1440
gctatctccc	aggcttcaa	tggccctatt	cgctaccagg	agaaccccccag	ggctgcctgg	1500
ctccccatag	ccaacccat	ccccaaatc	cagtggtggc	ccctgcctga	gaccggcccc	1560
aacgagaacc	tgacggagcg	cagcctgcag	gacgcgcagc	gccttctct	gatgagcgag	1620
gccgtgcagc	cggtgacacc	cgagccctgt	gtcaccagg	acagcgtgcg	cttctcacac	1680
ctcgtggtgg	acctggtgca	ggctaaagac	acgctctacc	atgtactcta	cattggcacc	1740

gagtcgggc	ccatcctgaa	ggcgctgtcc	acggcgagcc	gcagcctcca	cggctgctac	1800
ctggaggagc	tgcacagtgc	cccccccggg	cgccgcgagc	ccctgcgcag	cctgcgcata	1860
ctgcacagcg	cccgccgcgt	cttcgtgggg	ctgagagacg	gcgtcctgcg	ggtcccactg	1920
gagaggtgcg	ccgcctaccg	cagccagggg	gcatgcctgg	gggcccggga	cccgtaactgt	1980
ggctgggacg	ggaagcagca	acgttgccgc	acactcgagg	acagctccaa	catgagccctc	2040
tgaccccaga	acatcaccgc	ctgtcctgtg	cggaatgtga	cacgggatgg	gggcttcggc	2100
ccatggtcac	catggcaacc	atgtgagcac	ttggatgggg	acaactcaagg	ctctgcctg	2160
tgtcgagctc	gatcctgtga	ttccccctcga	ccccgcgtg	ggggccttga	ctgcctgggg	2220
ccagccatcc	acatgccaa	ctgctccagg	aatggggcgt	ggaccccgtg	gtcatcgtag	2280
gcgcgtgtca	gcacgtcctg	ttggatcgcc	ttccaggtcc	gccagcgaag	ttgcagcaac	2340
cctgctcccc	gccacggggg	ccgcatctgc	gtgggcaaga	gccgggagga	acggttctgt	2400
aatgagaaca	cgcctgccc	ggtgcccattc	ttctgggctt	cctggggctc	ctggagcaag	2460
tgcagcagca	actgtggagg	gggcatgcag	tcgcggcg	gggcctgcga	gaacggcaac	2520
tctgcctgg	gctgcggcgt	ggagttcaag	acgtgcacacc	ccgagggctg	ccccgaagtg	2580
cggcgaaca	ccccctggac	gccgtggctg	cccgtaacg	tgacgcagg	cggggcacgg	2640
caggagcagc	ggttccgcctt	cacctgcgc	gcgcgccttg	cagacccgca	cggcctgcag	2700
ttcggcagga	gaaggaccga	gacgaggacc	tgtccgcgg	acggctccgg	ctcctgcgac	2760
accgacgccc	ttgtggaggt	cctcctgcgc	agcgggagca	cctcccccga	cacggtgagc	2820
gggggctggg	ccgcctgggg	cccggtgtc	tcctgcctcc	gggactgcga	gctgggcttc	2880
cgcgtccgc	agagaacgtg	cactaaccgg	gagcccccga	acgggggct	gccctgcgtg	2940
ggcgatgctg	ccgagatcca	gactgcacac	ccccaggctt	gcccaagtcc	gggtgcttgg	3000
tctgcgtgg	cctcatggc	tccatgccta	gcttcctgtg	gtgggggtca	ctataaacgc	3060
accgcgttcc	gcaccagccc	cgcacccctcc	ccagggtgagg	acatctgtct	cgggctgcac	3120
acggaggagg	cactatgtgc	cacacaggcc	tgcccagaag	gctggcgcc	ctggctcgag	3180
tggagtaagt	geactgacga	gggagccag	agccgaagcc	ggcactgtga	ggaggtcctc	3240
ccagggtcca	gcmcmtgtc	tggaaacagc	agccagagcc	gcccctgccc	ctacagcgag	3300
attcscgtca	tcctgccagc	ctccagcatg	gaggaggcca	ccgactgtgc	agggttcaat	3360
ctcatccact	tggtggccac	gggcatactcc	tgcttcttgg	gtctgggtc	cctgacccta	3420
gcagtgtacc	tgtctgcac	gcactgccc	cgtcagtccc	aggagtccac	actgtccat	3480
cctgccaccc	ccaaccattt	gcactacaag	ggcgaggca	ccccgaagaa	tgaaaagtac	3540
acacccatgg	aattcaagac	cctgaacaag	aataactga	tccctgatga	cagagccaa	3600
ttctacccat	tgcaggcagac	caatgtgtac	acgactactt	actacccaa	ccccctgaac	3660
aaacacagct	tccggccga	gcctcacct	ggacaacggt	gttcccaa	cagctgatac	3720
cgcgcgtcctg	gggacttggg	cttcttgcct	tcataaggca	cagagcagat	ggagatggga	3780
cagtggagcc	agtttggttt	tccctctctg	cactaggcca	agaacttgc	gcctgcctg	3840
tgggggggtcc	catccggctt	cagagagctc	tggctggcat	tgaccatggg	ggaaaggggct	3900
ggtttcaggc	tgacatatgg	ccgcagggtcc	agttcagccc	aggctmtca	tggttatctt	3960
ccaaacccact	gtcacgcgt	cactatgtcg	ccatgcctgg	gctgtggacc	tactgggcat	4020
ttgaggaayt	ggagaatgg	gatggcaaga	gggcaggctt	ttaagtttgg	gttggagaca	4080
acttccctgt	gccccccacaa	gctgagtcgt	gccttctca	gctggcccca	aaaaaggccct	4140
ttgctacatc	ctgattatct	ctgaaagtaa	tcaatcaagt	ggctccagta	gctctggatt	4200
ttctgccagg	gctggccat	tgtgggtctg	ccccagatgt	acatgggacc	aaggccagcg	4260
cagggttatcc	acctctgcct	gaaagtctat	actctaccca	ggcataccct	ctggtcagag	4320
gcagtgagta	ctggaaactg	gagggtgacc	tgtgtttaga	agtcccttaa	tctggctgg	4380
tacaggcctc	agcctgcccc	tcaatgcacg	aaagggtggcc	caggagagag	gatcaatgcc	4440
ataggaggca	gaagtctggc	ctctgtgcct	ctatggagac	tatcttccag	ttgtgtctca	4500
acagagttgt	tggctgagac	ctgcttggg	gtctctgcgt	gcccttcata	tgttcaggaa	4560
cacacacaca	cacacactca	cacacgcaca	cacaatcaca	atttgctaca	gcaacaaaaaa	4620
agacatttggg	ctgtggcatt	attaattaaa	gatgatatcc	agtcaaaaaaa	aaact	4675

<210> 17
<211> 4731
<212> DNA
<213> Homo sapiens

<400> 17						
attggagatg	ctcgaaaaa	ggctggcccg	tttgttgcctg	cttttctgcg	gccagacccaa	60
gccgtctgga	gctgtggtc	aggttttctt	gctgacccca	cctgaccaca	gtggcctggg	120
tggactctac	aggaaatgt	tgttttctc	ctggagcag	tagcagcagt	cctggctccc	180
ctggactgag	aactccatc	cagcccccagg	aagcccgac	ccccttcag	ggatctggaa	240

ccgggtgtgcc	tgtggcccca	ggtctgctcc	caggcgtggg	ctgaagtct	gacttctgtc	300
gctgggggca	aggagtggga	gagcccaqct	gctgcctggg	ctttggcaga	cagcaggctg	360
atgggtctgg	cttccccgag	actgcttctc	ctgcctgctg	tctgattttc	ctgcatggtg	420
cccgcagctg	agctgctacg	ggtcttctc	cctgtctgcc	tcccggagct	aggactgcag	480
aggggcctat	catggtgctt	gcaggcccc	tggctgtctc	gctgttgctg	cccaagcctca	540
cactgcttgt	gtccccacctc	tccagctccc	aggatgtctc	cagtgagccc	agcagtgagc	600
agcagctgtg	cggcccttagc	aagcacccca	ccgtggcctt	tgaagacactg	cagccgtggg	660
tctctaactt	cacctaccct	ggagcccggg	atttctccca	gctggctttt	gaccctccg	720
ggaaccagct	catcggtgg	gccaggaact	acctcttcag	actcagcctt	gccaatgtct	780
ctcttcttca	ggccacagag	ttggcctcca	gtgaggacac	gcccgcgtcc	tgccaaagca	840
aagggaagac	tgaggaggag	tgtcagaact	acgtgcgagt	cctgatgtc	gccggccgga	900
aggtgttcat	gtgtggaaacc	aatgccttt	cccccatgtg	caccagcaga	caggtgggg	960
acctcagccg	gactactgag	aagatcaatg	gtgtggccc	ctgcccctat	gaccacgccc	1020
acaactccac	agctgtcattc	tcctcccagg	gggagctcta	tgcaagccacg	gtcatcgact	1080
tctcaggtcg	ggaccctgccc	atctaccgca	gcctggcag	ttggccaccg	cttcgcactg	1140
cccaataataa	ctccaaagtgg	cttaatgagc	caaacttcgt	ggcagcctat	gatattggc	1200
tgtttgcata	cttcttcctg	cgggagaacg	cagtggagca	cgactgtgga	cgcaccgtgt	1260
actctcgcgt	ggccgcgtg	tgcaagaatg	acgtgggggg	ccgattcc	ctggaggaca	1320
catggaccac	attcatgaag	gcccggctca	actgtcccg	cccggcgag	gtcccttct	1380
actataaacg	gctcagactg	gccttccact	tgccagagca	ggacccatc	tatggagtt	1440
tcacaaccaa	cgtaaacagc	atcgggctt	ctgctgtctg	cccttcaac	ctcagtgcata	1500
tctcccaggc	tttcaatggc	ccatttcgct	accaggagaa	ccccagggct	gcctggctcc	1560
ccatagccaa	ccccatcccc	aatttccagt	gtggcaccct	gcctgagacc	ggtcccaacg	1620
agaacactgac	ggagcgcagc	ctgcaggacg	cgcagcgcct	cttccctgatg	agcaggccg	1680
tgcagccgt	gacacccgag	ccctgtgtca	cccaggacag	cgtgcgttc	tcacacctcg	1740
tggtggacct	ggtgcaggct	aaagacacgc	tctaccatgt	actctacatt	ggcaccgagt	1800
cgggcacccat	cctgaaggcg	ctgtccacgg	cgagccgcag	cctccacggc	tgctacctgg	1860
agagactgca	cgtctgccc	cccgggcgcc	gcgagccct	gcccgcgtc	cgcatcctgc	1920
acagcgcccg	cgcgccttcc	gtggggctga	gagacggcgt	cctgcggg	ccactggaga	1980
ggtgcgcgc	ctaccgcagc	cagggggcat	gcctggggc	ccgggacccg	tactgtggct	2040
gggacgggaa	gcagcaacgt	tgcaagcacac	tcgaggacag	ctccaacatg	agcctctgga	2100
cccagaacat	caccgcctgt	cctgtgcgca	atgtgacacg	ggatggggc	ttcggccat	2160
ggtcaccatg	gcaaccatgt	gagcacttgg	atggggacaa	ctcaggctt	tgcctgtgtc	2220
gagctcgatc	ctgtgattcc	cctcgacc	gctgtgggg	ccttgactgc	ctggggccag	2280
ccatccacat	cgccaaactgc	tccaggaatg	ggcgctggac	cccgtggta	tcgtgggcgc	2340
tgtgcagcac	gtccctgtggc	atcggcttcc	aggtccgcca	gcaagttgc	agcaaccctg	2400
ctccccgcca	cggggccgc	atctgcgtgg	gcaagagccg	ggaggaacgg	ttctgtatg	2460
agaacacgc	ttgcccgggt	cccatcttct	gggcttc	gggcttc	agcaagtgc	2520
gcagcaactg	tggagggggc	atgcagtgc	ggcgtcgggc	ctgca	ggcaactcct	2580
gcctgggctg	ccgcgtggag	ttcaagacgt	gcaaccccg	gggctgcccc	gaatgcggc	2640
gcaacacccc	ctggacgcgc	tggctgccc	tgaacgtac	gcagggcgg	gcacggcagg	2700
agcagcggtt	ccgcttcacc	tccgcgcgc	cccttgc	cccgcacggc	ctgcagttcg	2760
gcaggagaag	gaccgagacg	aggacctgc	ccgcggacgg	ctccggctcc	tgcgacaccg	2820
acgcctgggt	ggaggtcctc	ctgcgcagcg	ggagcac	cccgcacacg	gtgagcgggg	2880
gctggggccgc	ctggggcccg	ttgtcgctt	gctccgg	ctgcgagctg	ggctccgc	2940
tccgcagag	aacgtgcact	aaccggagc	ccgcacacg	gggcctgccc	tgctggggc	3000
atgtctccg	gtaccaggac	tgcaacccccc	aggcttgc	agttcg	gtctggctt	3060
gctggaccc	atggtctcca	tgctcagctt	cctgtgg	gggtca	caacgcaccc	3120
gttcctgcac	cagccccgca	ccctccca	gtgaggacat	ctgtctc	ctgcacacgg	3180
aggaggca	atgtgccaca	caggcctgc	cagaaggctg	gtgc	tctgagtg	3240
gtaagtgcac	tgacgacgg	gcccgagagc	gaagccgg	ctgt	gaggag	3300
ggtcgcgc	mtgtgtgg	aacagcagcc	agagccccc	ctgc	ccacttcc	3360
scgtcatcc	gccagctcc	agcatggagg	aggccacca	ctgt	gcagg	3420
tccacttgg	ggccacgggc	atctcctgt	tcttgg	ggc	accctagc	3480
tgtacctgtc	ttgcccggac	tgccagcgtc	agtccc	gtcc	acactg	3540
ccacccca	ccatttgac	tacaaggcg	gaggcac	gtcc	catcct	3600
ccatggaa	caagaccctg	aacaagaata	acttgat	gtc	gatgc	3660
acccattgc	gcagaccaat	gtgtacacg	ctacttacta	ccca	agcccc	3720
acagcttccg	gcccggaggcc	tcacctggac	aacgtgtt	ccca	acacgc	3780
gtcctgggg	cttggggctt	ttgccttcat	aaggcacaga	gcagatgg	tgataccg	3840
ggagccagtt	tggtttctc	cctctgcact	aggccaagaa	cttgctgc	tgcctgtgg	3900

gggtcccata cggcttcaga gagctctggc tggcattgac catggggaa aggctggtt	3960
tcaaggctgac atatgccgc aggtccagtt cagcccagg ctmtcatggt tatcttccaa	4020
cccaactgtca cgctgacact atgctgccat gcctgggctg tggacctact gggcatttga	4080
ggaaytggag aatggagatg gcaagagggc aggctttaa gtttgggttg gagacaactt	4140
cctgtggccc ccacaagctg agtctggcct tctccagctg gccccaaaaa aggccttgc	4200
tacatectga ttatctctga aagtaatcaa tcaagtggct ccagtagetc tggatttct	4260
gccaggcgtg ggccattgtg gtgctgcccc agtatgacat gggaccaagg ccagcgcagg	4320
ttatccacct ctgcctggaa gtctatactc taccaggc atccctctgg tcagaggcag	4380
tgagtaactgg gaactggagg ctgacctgtg cttagaagtc cttaatctg ggctggtaca	4440
ggcctcagcc ttgcctcaa tgcacgaaag gtggcccagg agagaggatc aatccatag	4500
gagggcagaag tctggcctct gtgcctctat ggagactatc ttccagttgc tgctcaacag	4560
agttgttggc tgagacctgc ttggagttc ctgctggccc ttcatctgtt caggaacaca	4620
cacacacaca cactcacaca cgcacacaca atcacaattt gctacagcaa caaaaaagac	4680
attgggctgt ggcattatta attaaagatg atatccagtc aaaaaaaaaac t	4731

<210> 18
<211> 4703
<212> DNA
<213> Homo sapiens

<400> 18	
goggccgccc cattcccaga cggccgcca gcccacatgg ttagctcccgg ccgcctccgc	60
ccgccccggg gtcgggagcc gcggggaaacc gggcacctgc acccgccctct gggagccagc	120
ttgggtccgg gttgcaactgg gccctgcccag ggctgtggc ggcgcacatcg ggctgcagcg	180
gcatggggc cccgggaccc aggccctggag aaggagacgg acgagtgggg ctgagggacg	240
gagggacaga gtgagtggtt ccagctgggt cctggcctgt gtcttctgg tgcctgtgg	300
cttcagtcgg tctccctgtt cccaccaccc cgtccctggg ccgcctgata ccccaagccca	360
acagctaagg tgtggatgga cagtaggggg ctggcttctc tcaactggtca ggggtcttct	420
cccccgtctg cctcccgag cttagactgc agaggggcct atcatggtgc ttgcaggccc	480
cetggctgtc tgcgttgtc tgcccagctc cacactgctg gtgtcccacc tctccagctc	540
ccaggatgtc tccagtgagc ccagcagtg a cagcagctg tgcgcctta gcaagcaccc	600
caccgtggcc tttgaagacc tgcagccgt ggtctctaacc ttcacctacc ctggagcccg	660
ggatttctcc cagctggctt tggacccttc cgggaaccag ctcacgtggc gagccaggaa	720
ctaccttcc agactcagcc ttgccaatgt ctcttctt caggccacag agtgggcctc	780
cagtgaggac acgcgcgct cctgccaatgg caaagggaag actgaggagg agtgcagaa	840
ctacgtgcga gtcctgatcg tgcgcggccg gaagggttca atgtgtggaa ccaatgcctt	900
ttccccatg tgcaccagca gacaggtgg gaacccatcg cggactactg agaagatcaa	960
tgggtggcc cgctggccct atgacccacg ccacaactcc acagctgtca tctccctccca	1020
gggggagctc tatgcagcca cggcatcgat ctttcaggt cgggaccctg ccatctaccg	1080
cagcctggc agtggccac cgcttcgcac tgccaaatat aactccaatg ggcttaatga	1140
gccaacttc gtggcagct atgatattgg gctgtttgc tacttcttcc tgcgggagaa	1200
cgcagtggag cacgactgtg gacgcaccgt gtactctcgc tggcccgccg tgcagaa	1260
tgacgtgggg ggccgattcc tgctggagga cacaatggacc acattcatga aggcccggt	1320
caactgctcc cggccggcg aggtccccctt ctactataac gagctgcaga gtgccttcca	1380
cttgccagag caggacactca tctatggagt ttccacaacc aacgtaaaca gcatcgccgc	1440
ttctgtgtc tgcgccttca acctcagtc tatctccag gcttcaatg gcccatttcg	1500
ctaccaggag aacccaggc ctgcctggc ccccatagcc aacccatcc ccaatttcca	1560
gtgtggcacc ctgcctgaga cgggtcccaa cggaaacctg acggagcgcgc gcctgcagga	1620
cgcgcagcgc ctcttcgtc tgagcggagc cgtgcagccg gtacaccctg agccctgtgt	1680
cacccaggac agcgtgcgtc totcacaccc cgtgtggac ctggcgcagg ctaaaagacac	1740
gctctaccat gtacttaca ttggcaccga gtcgggcacc atcctgaagg cgctgtccac	1800
ggcgagccgc agcctccacg gctgtactct ggaggagctg cacgtgtgc ccccccggcg	1860
ccgcgcagccc ctgcgcagcc tgcgcacatcc gcacagcgc cgcgcgtct tcgtgggct	1920
gagagacggc gtcctcgcccc tcccaactgga gaggtgcgc cgcattccca gccaggggc	1980
atgcctgggg gccccgggacc cgtactgtgg ctggacggg aagcagcaac gttgcagcac	2040
actcgaggac agctccaaca tgagcctctg gaccagaac atcaccgcct tgcctgtgc	2100
gaatgtgaca cggatgggg gttcggccc atggcacca tggcaaccat gtgagcactt	2160
ggatggggac aactcaggct cttgcctgtg tcgagctcgat ccctgtgatt ccctcgacc	2220
ccgcgtgtgg ggccttgact gcctggggcc agccatccac atcgcctact gctccaggaa	2280
tggggcgtgg accccgtgtt ctcgtggc gctgtgcagc acgtcctgtg gcatcgccct	2340

ccaggtccgc cagcgaagtt gcagcaaccc tgctccccgc cacgggggcc gcatacgctg	2400
ggccaagagc cgggaggaac gttctgtaa tgagaacacg cttgcggcc tgccatctt	2460
ctgggttcgc tgggtctcct ggagcaagt cagcagcaac tgtggagggg gcatgcagtc	2520
gcggcgctgg gcctgcaga acggcaactc ctgcctggc tgcggcgtgg agttcaagac	2580
gtgcaacccc gagggctgcc ccaaagtgcg ggcacacacc ccctggacgc cgtggctgcc	2640
cgtgaacgtg acgcaggcgg gggcacggca ggagcagcgg ttccgcttca cctggcgcc	2700
gccccttgc gacccacg gcctgcagg cggcaggaga aggaccgaga cgaggacctg	2760
tcccgcggac ggctccggct cctgcacac cgacgcctg gtggaggtcc tcctgcgcag	2820
cgggagcacc tccccgcaca cggtgagcgg gggctggcc gcctggggcc cgtgtcgtc	2880
ctgctcccg gactgcgagc tgggtctccg cgtccgcaag agaacgtgca ctaacccgga	2940
gccccgcaac gggggctgc cctgcgtgg cgatgctgcc gaggattcagg actgcaaccc	3000
ccaggcttgc ccagttcggg gtgcttggc ctgctggacc tcatggtctc catgtcagc	3060
ttccctgtggt ggggtcaact atcaacgcac cggttccctc accagccccg caccctcccc	3120
agtgaggac atctgtctcg ggctgcacac ggaggaggca ctatgtgcca cacaggctg	3180
cccaagaaggc tggtcgcct ggtctgagg gagaatgtc actgacgacg gagccagag	3240
ccgaagccgg cactgtgagg agtcctccc agggtccagc gcmtgtctg gaaacagcag	3300
ccagagccgc ccctgcctt acagcgagat tcscgtcatc ctgcccgc ccagcatgga	3360
ggaggccacc gactgtgcag gttcaatct catccactt gttggccacgg gcatctccgt	3420
cttcttggc tctggctcc tgacccttagc agtgtacctg tcttgcgc gactgcccagc	3480
tcagtcctcag gagtcacac tggtccatcc tgccacccccc aaccatttgc actacaagg	3540
cgaggccacc ccgaagaatg aaaagtacac acccatggaa tcaagaccc tgaacaagaa	3600
taacttgatc cctgtatgaca gagccaactt ctacccattt cagcagacca atgtgtacac	3660
gactacttac taccaagcc ccctgaacaa acacagctt cggcccgagg cttcacctgg	3720
acaacgggtgc ttcccaaca gctgataccg ccgtcttgg gacttggct tcttgccttc	3780
ataaggcaca gagcagatgg agatggaca gtggagccag tttggtttc tccctctgca	3840
ctaggccaa aacttgcgtc ctgcctgtg ggggtccca tccggcttca gagagctctg	3900
gctggcattt accatgggg aaaggcgtgg tttcaggctg acatatggcc gcaggtccag	3960
ttcagcccag gtctmtcatg gttatcttcc aaccactgt cacgctgaca ctatgtgcc	4020
atgcctggc tgggaccta ctgggcattt gaggaaaytgg agaatggaga tggcaagagg	4080
gcaggcttt aagttgggt tggagacaac ttccctgtggc ccccacaagc tgagtctggc	4140
cttctccagg tggcccaaaa aaaggcctt gctacatctt gattatctt gaaagtaatc	4200
aatcaagtgg ctccagtagc tctggatttt ctgcaggc tggccatgg tgggtctgcc	4260
ccagtatgac atggaccaa gccagcga gttatccac ctctgcctt aagtctatac	4320
tctacccttgc gcatccctt gtcagagggc agttagtact gggacttgg gctgaccc	4380
tgcttagaag tccttaatc tggcttggta caggcctcag cttgccttc aatgcacgaa	4440
aggtggccca ggagagagga tcaatgcac agggcaga agtctggct ctgtgcctt	4500
atggagacta tcttcagg tctgcgtcaac agagttgtt gctgagaccc gcttggag	4560
ctctgctggc cttcatctg ttcaggaaca cacacacaca cacactcaca cacgcacaca	4620
caatcacaat ttgctacagc aaaaaaaag acattggct gtggcattat taattaaaga	4680
tgatatccag taaaaaaaaa act	4703

<210> 19
<211> 4405
<212> DNA
<213> Homo sapiens

<400> 19

gcggccgccc cattcccaga ccggccgcca gcccattctgg ttagctcccg ccgctccgc	60
ccggccggga gtcgggagcc gcggggaaacc gggcacctgc acccgccctt gggagggttt	120
ctccccctgtc tgcctcccg agcttagact gcagaggggc ctatcatgtt gcttgcaggc	180
ccccctggctg ttcgcgtt gctgcccagc ctcacactgc tgggttccca ccttcctc	240
tcccaggatg tctccaggta gcccagcagt gagcagcgc tgcggccct tagcaagcac	300
cccacccgtgg ctttgaaga cttgcagccg tgggtctcta acttcaccta ccctggagcc	360
cgggattttcc cccagctggc tttggacccc tccggaaacc agtcatctgt gggaggccagg	420
aactacctt tcagactcag cttgcacat gtctctttc ttcaaggccac agatggggcc	480
tccaggatgg acacgcgcgc cttctgcacaa agcaaggaa agactgagga ggagtgtcag	540
aactacgtgc gagtcctgtat ctgcggccgc cggaaagggtt tcatgtgtgg aaccaatgcc	600
ttttccccc tttgtgcaccag cagacaggtt gggaaacctca gcccactac tgagaagatc	660
aatgggtgtgg cccgctgccc ctatgacccca cggcacaact ccacagctgt catctctcc	720
cagggggagc tctatgcacg caccgtcatc gacttctcag gtcgggaccc tgccatctac	780

cgcagcctgg	gcagtgggcc	accgcttcgc	actgccccaa	ataactccaa	gtggcttaat	840
gagccaaact	tcgtggcagc	ctatgatatt	gggctgtttt	catacttott	cctgcgggag	900
aacgcagtgg	agcacgactg	tggacgcacc	gtgtactctc	gcgtggcccg	cgtgtgcaag	960
aatgacgtgg	ggggccgatt	cctgctggag	gacacatgga	ccacattcat	gaaggcccgg	1020
ctcaactgct	cccgccccgg	cgaggtcccc	ttctactata	acgagctgca	gagtgcctc	1080
cacttgccag	agcagagact	catctatgga	gtttcaca	ccaacgtaaa	cagcatcgcg	1140
gcttctgctg	tctgcgcctt	caacctcagt	gctatctccc	aggcttcaa	tggcccat	1200
cgctaccagg	agaaccccag	gctgcctgg	ctcccccata	ccaacccat	ccccaaatttc	1260
cagtgtggca	ccctgcctga	gaccggtccc	aacgagaacc	tgacggagcg	cagcctgcag	1320
gacgcgcagc	gcctcttcct	gatgagcag	gccgtgcagc	cggtgacacc	cgagccctgt	1380
gtcacccagg	acagcgtgcg	cttctcacac	ctcgtggtgg	acctggtgca	ggctaaagac	1440
acgctctacc	atgtactcta	cattggcacc	gagtcgggca	ccatcctgaa	ggcgtgtcc	1500
acggcgagcc	gcagcctcca	cggtgcgtac	ctggaggagc	tgcacgtgct	gccccccggg	1560
cgccgcgagc	ccctgcgcag	cctgcgcata	ctgcacagc	cccgcgcgct	cttcgtggg	1620
ctgagagacg	gcgtcctgcg	gttcccactg	gagaggtgcg	ccgcctaccg	cagccagggg	1680
gcatgcctgg	gggccccggg	cccgtactgt	ggctgggacg	ggaagcagca	acgttgca	1740
acactcgagg	acagctccaa	catgagcctc	tggacccaga	acatcacccg	ctgtccctgt	1800
cggaaatgtga	cacggatgg	gggcttcggc	ccatggtcac	catggcaacc	atgtgagcac	1860
ttggatgggg	acaactcagg	ctttgcctg	tgtcgagctc	gatccctgt	ttccctcga	1920
ccccgctgtg	ggggccttga	ctgcctgggg	ccagccatcc	acatgcctaa	ctgtccagg	1980
aatggggcgt	ggaccccgt	gtcatcggt	gctgtgtca	gcacgtctg	tggcatggc	2040
ttccaggtcc	gccagcgaag	ttgcagcaac	cctgtcccc	gccacggggg	ccgcatactgc	2100
gtgggcaaga	gcccggagga	acggttctgt	aatgagaaca	cgccttgc	gttgcctac	2160
ttctgggctt	cctggggctc	ctggagcaag	tgcagcagca	actgtggagg	ggcatgtcag	2220
tcgcggcg	gggcctgcga	gaacggcaac	tcctgcctg	gctgcgggt	ggagttcaag	2280
acgtgcAAC	ccgagggctg	ccccgaatgt	cgcgcaaca	ccccctggac	gccgtggctg	2340
cccgtgaac	tgacgcagg	ccccggaccc	caggagcagc	gttccgc	cacctgccc	2400
gcccccttg	cagacccgca	ccgcctgcag	ttcggcagga	gaaggaccga	gacgaggacc	2460
tgtccgcgg	acggctccgg	tcctgcgac	accgacgccc	tggtgaggt	cctctgcgc	2520
agcgggagca	cctcccgca	cacgggtgagc	gggggctggg	ccgcctgggg	ccgcgttgtc	2580
tcctgtctcc	gggactgcga	gctgggcttc	cgcgatcgca	agagaacgt	actaacc	2640
gagccccgca	acggggcc	gccctgcgt	ggcgatgt	ccgagatcca	ggactgcaac	2700
ccccaggctt	gcccagttcg	gggtgcttgg	tcctgttga	cctcatggc	tccatgtca	2760
gcttcctgtg	gtgggggtca	ctatcaacgc	accgttcct	gcaccagccc	cgcaccctcc	2820
ccaggtgagg	acatctgtct	ccccgtgcac	acggaggagg	cactatgtc	cacacaggcc	2880
tgcccagaag	gctggtcg	ctggtctgag	tggagtaatg	gcactgac	cgagccccag	2940
agccgaagcc	ggcactgtga	ggagctcc	ccaggggtca	gcgcmtgtc	tggaaacacg	3000
agccagagcc	gcccctgccc	ctacagcgag	attcscgtc	tcctgc	ctccagcat	3060
gaggaggcca	ccgactgtgc	agggttcaat	ctcatccact	tggtgccac	ggcatctcc	3120
tgttcttgg	gctctgggt	cctgaccata	gcagtgtacc	tgtcttgc	gcactgccc	3180
cgtcagtccc	aggagtccac	actggtccat	cctgccaccc	ccaaccattt	gcactacaag	3240
ggcggaggca	ccccgaagaa	taaaaagttac	acaccatgg	aattcaagac	cctgaacaag	3300
aataacttga	tccctgatga	cagacccaa	ttctacccat	tgcagcagac	aatgtgtac	3360
acgactactt	actacccaa	ccccctgaa	aaacacagct	tccggccca	ggcctcacct	3420
ggacaacgg	gcttccccaa	cagctgatac	cgccgtcctg	gggacttggg	cttcttgc	3480
tcataaggca	cagacgat	ggagatggg	cagtggagcc	agtttgggtt	tctccctctg	3540
caactaggcca	agaacttgc	gccttgcctg	tgggggtcc	catccggctt	cagagagctc	3600
tggctggcat	tgaccatggg	ggaaagggt	ggttcaggc	tgacatatgg	ccgcagggtcc	3660
agttcagccc	aggtctmtca	tgttatctt	ccaaacct	gtcacgtca	cactatgt	3720
ccatgcctgg	gctgtggacc	tactggcat	ttgaggaat	ggagaatgga	gatggcaaga	3780
ggcaggcgtt	ttaagttgg	gttggagaca	acttctgt	gccccacaa	gctgagtct	3840
gccttctcca	gctggcccca	aaaaaggct	ttgtatc	ctgattatct	ctgaaaagtaa	3900
tcaatcaagt	ggctccagta	gctctggatt	ttctgc	gctggccat	tgtggct	3960
ccccagtagt	acatgggacc	aaggccagcg	cagttatcc	acctctgcct	ggaagtctat	4020
actctaccca	gggcatacc	ctgggtcagag	gcagtgt	ctgggaactg	gaggctgacc	4080
tgtgcttaga	agtcctttaa	tctggctgg	tacaggc	agccttgc	tcaatgcac	4140
aaaggtggcc	caggagagag	gatcaatg	ataggaggca	gaagtctgg	ctctgtgc	4200
ctatggagac	tatcttccag	ttgctgtca	acagagttgt	tggctgagac	ctgttggga	4260
gtctctgt	gcccttcate	tgttcagggaa	cacacacaca	cacacactca	cacacgcaca	4320
cacaatcaca	atttgctaca	gcaacaaaaaa	agacattggg	ctgtggcatt	attaattaaa	4380
gatgatatcc	agtcaaaaaaa	aaact				4405

<210> 20
<211> 3938
<212> DNA
<213> Homo sapiens

<400> 20

gcggccgccc	cattcccaga	ccggccgcca	gcccatctgg	ttagctcccg	ccgctccgca	60
ccgccccggg	gtcgggagcc	gcggggaaacc	gggcacctgc	acccgcctct	gggagtgagt	120
ggttccagct	ggtgctcggc	ctgtgtctct	tggatccct	gtggcttcag	tccgtctcct	180
gttgcccacc	acctcgccc	ttggccgcct	gataccccag	cccaacagct	aagggtgtgga	240
tggacagtag	ggggctggct	tctctcaactg	gtcaggggtc	ttctccctcg	tctgcctccc	300
ggagctagga	ctgcagaggg	gcctatcatg	gtgcttgcag	gccccctggc	tgttcgcgt	360
ttgtctccca	gcctcacact	gctggtgtcc	cacctctcca	gctcccagga	tgttccagt	420
gagcccagca	gtgagcagca	gctgtgcgcc	cttagcaagc	accccacccgt	ggcccttgaa	480
gacctgcagc	cgtgggtctc	taacttcacc	taccctggag	cccggttattt	ctcccgactg	540
gctttggacc	cctccggaa	ccagctcatc	gtgggagcca	ggaactaccc	cttcagactc	600
agccttgcca	atgtctctct	tcttcaggcc	acagagtggg	cctccagtg	ggacacgcgc	660
cgctccctgcc	aaagcaaagg	gaagactgag	gaggagtgtc	agaactacgt	gcgagtccctg	720
atcgtcgccc	gcccggaggt	gttcatgtgt	ggaaccatg	cctttcccc	catgtgcacc	780
agcagacagg	tggggAACCT	cagccggact	actgagaaga	tcaatgggt	ggcccgctgc	840
ccctatgacc	cacgcacaaa	ctccacagct	gtcatctcct	cccaggggga	gctctatgca	900
gccacggtca	tcgacttctc	aggtcgggac	cctgcatct	accgcagcc	ggcagtgccc	960
ccaccgcttc	gcactgccc	atataactcc	aagtggctt	atgagccaaa	tttgcgtggca	1020
gcctatgata	ttgggtgtt	tgcatacttc	ttcctgcggg	agaacgcagt	ggagcacgac	1080
tgtggacgca	ccgtgtactc	tcgcgtggcc	cgcgtgtgca	agaatgacgt	ggggggccga	1140
ttcctgtctgg	aggacacatg	gaccacattc	atgaaggccc	ggctcaactg	ctccggcccg	1200
ggcgaggtcc	ccttctacta	taacgagctg	cagagtgcct	tccacttgcc	agagcaggac	1260
ctcatctatg	gagtttcac	aaccaacgt	aacagcatg	cggcttctgc	tgtctgcgcc	1320
ttcaaacctca	gtgctatctc	ccaggcttcc	aatggccat	ttcgctacca	ggagaacccc	1380
agggctgcct	ggctccccat	agccaacccc	atccccattt	tccagtgtgg	caccctgcct	1440
gagaccgggtc	ccaacgagaa	cctgacggag	cgcagcctgc	aggacgcgca	gccccttcc	1500
ctgatgagcg	aggccgtgca	gccgggtgaca	cccggccct	gtgtcaccca	ggacagcgtg	1560
cgttctcac	acctcggtgt	ggacctgggt	caggctaaag	acacgctcta	ccatgtactc	1620
tacattggca	ccgagtcggg	caccatctg	aaggcgctgt	ccacggcgag	ccgcagccct	1680
cacggctgt	acctggagga	gctgcacgt	ctgcccccc	ggccgcgcga	gcccctgcgc	1740
agccctgcga	tcctgcacag	cgccccgcgc	ctcttcgtgg	ggctgagaga	cggcgtccctg	1800
cgggtcccac	tggagaggtg	cgccgcctac	cgcagccagg	gggcatgcct	ggggggccgg	1860
gaccgggtact	gtggctggga	cgggaaagcag	caacgttgca	gcacactcga	ggacagctcc	1920
aacatgagcc	tctggaccca	gaacatcacc	gcctgtctg	tgcggaatgt	gacacggat	1980
gggggcttgc	gcccattggc	accatggcaa	ccatgtgagc	acttggatgg	ggacaactca	2040
ggctcttgcc	tgtgtcgagc	tcgatctgt	gattccctc	gaccccgctg	tggggcctt	2100
gactgcctgg	ggccagccat	ccacatcgcc	aactgttcca	ggaatggggc	gtggaccccg	2160
tggtcatctgt	gggcgtgt	cagcacgtcc	tgtggcatcg	gcttccaggt	ccgcacgcga	2220
attgtcagca	accctgtctc	ccgcccacgg	ggccgcacatc	cgctggggcaa	gagccgggag	2280
gaacggttot	gtaatgagaa	cacgccttgc	ccggtgccca	tcttctgggc	ttctctgggc	2340
tcctggagca	agtgcagcag	caactgtg	gggggcattgc	agtgcggcg	tcgggcctgc	2400
gagaacggca	actcctgcct	gggctgcgc	gtggagttca	agacgtgca	ccccgggggc	2460
tgccccgaag	tgcggcgca	cacccctgg	acgcgtggc	tgccctgtaa	cgtgacgcag	2520
ggcggggcac	ggcaggagca	gcgggtccgc	ttcacctg	gcccgcctt	tgcagaccccg	2580
cacggcctgc	agttcggtcag	gagaaggacc	gagacgagga	cctgtccccc	ggacggctcc	2640
ggctctgcg	acaccgacgc	cctgggtggag	gtcctcctgc	gcagcggggag	cacccccc	2700
cacacggtga	gcggggctg	ggccgcctgg	ggcccggtgt	cgtccctgc	ccgggactgc	2760
gagctgggt	tccgcgtccg	caagagaacg	tgcactaacc	cgagcccc	caacgggggc	2820
ctgcccgc	tgggcgtatc	tgccgagtc	caggactgca	accccccaggc	ttgcccagtt	2880
cggggtgctt	gttcctgt	gacctcatgg	tctccatgt	cagttccctg	tgggtgggggt	2940
cactatcaac	gcacccgttc	ctgcaccagc	cccgcaccc	ccccaggtga	ggacatctgt	3000
ctcgggctgc	acacggagga	ggcactatgt	gccacacagg	cctgcccaga	aggctggtgc	3060
ccctggtctg	agtggagtaa	gtgcactgac	gacggagccc	agagccgaag	ccggcactgt	3120
gaggagctcc	tcccagggtc	cagcgcmtgt	gctgaaaca	gcagccagag	ccgccccctgc	3180

ccctacagcg	agattcscgt	catcctgcca	gcctccagca	tggaggaggc	caccgactgt	3240
gcagggttca	atctcatcca	cttggtggcc	acgggcacatct	cctgcttctt	gggctctggg	3300
ctcctgaccc	tagcagtgt	cctgtcttgc	cagcactgccc	agcgtcagtc	ccaggagttcc	3360
acaactggtcc	atcctgccac	ccccaaaccat	ttgcactaca	agggcggagg	caccccgaa	3420
aatgaaaagt	acacacccat	ggaattcaag	accctgaaca	agaataactt	gatccctgtat	3480
gacagagcca	acttctaccc	attgcagcag	accaatgcca	gogcaggtta	tccacctctg	3540
cctggaaagtc	tatactctac	ccagggcatc	cctctggtca	gaggcagtga	gtactggaa	3600
ctggaggctg	acctgtgctt	agaagtccctt	taatctgggc	tggtacaggc	ctcagcccttg	3660
ccctcaatgc	acgaaagggtg	gcccaggaga	gaggatcaat	gccataggag	gcagaagtct	3720
ggcctctgtg	cctctatgga	gactatotc	cagttgtctgc	tcaacagagt	tgttggctga	3780
gacctgctt	ggagtctctg	ctggcccttc	atctgttca	gaacacacac	acacacacac	3840
tcacacacgc	acacacaatc	acaatttgct	acagcaacaa	aaaagacatt	gggctgtggc	3900
attattaatt	aaagatgata	tccagtcaaa	aaaaaact			3938

<210> 21
<211> 1095
<212> PRT
<213> *Homo sapiens*

<400> 21
Met Val Leu Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser Leu
1 5 10 15

Thr Leu Leu Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser Glu
20 25 30

Pro	Ser	Ser	Glu	Gln	Gln	Leu	Cys	Ala	Leu	Ser	Lys	His	Pro	Thr	Val
35						40						45			

Ala Phe Glu Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly
50 55 60

Ala Arg Asp Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu
65 70 75 80

Ile Val Gly Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val
85 90 95

Ser Leu Leu Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg
100 105 110

Ser Cys Gln Ser Lys Gly Lys Thr Glu Glu Glu Cys Gln Asn Tyr Val
115 120 125

Arg Val Leu Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr Asn
130 135 140

Ala	Phe	Ser	Pro	Met	Cys	Thr	Ser	Arg	Gln	Val	Gly	Asn	Leu	Ser	Arg
145					150					155					160

Thr Thr Glu Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg
165 170 175

His	Asn	Ser	Thr	Ala	Val	Ile	Ser	Ser	Gln	Gly	Glu	Leu	Tyr	Ala	Ala
				180				185					190		

Thr Val Ile Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu
195 200 205

Gly Ser Gly Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu

210	215	220
Asn Glu Pro Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr		
225	230	235 240
Phe Phe Leu Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr Val		
245	250	255
Tyr Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly Arg Phe		
260	265	270
Leu Leu Glu Asp Thr Trp Thr Phe Met Lys Ala Arg Leu Asn Cys		
275	280	285
Ser Arg Pro Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala		
290	295	300
Phe His Leu Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn		
305	310	315 320
Val Asn Ser Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser Ala		
325	330	335
Ile Ser Gln Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg		
340	345	350
Ala Ala Trp Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly		
355	360	365
Thr Leu Pro Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu		
370	375	380
Gln Asp Ala Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro Val		
385	390	395 400
Thr Pro Glu Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His Leu		
405	410	415
Val Val Asp Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu Tyr		
420	425	430
Ile Gly Thr Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser		
435	440	445
Arg Ser Leu His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro Pro		
450	455	460
Gly Arg Arg Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala Arg		
465	470	475 480
Ala Leu Phe Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu Glu		
485	490	495
Arg Cys Ala Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp		
500	505	510
Pro Tyr Cys Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu		
515	520	525
Asp Ser Ser Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro		
530	535	540

Val Arg Asn Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp
 545 550 555 560
 Gln Pro Cys Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys
 565 570 575
 Arg Ala Arg Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp
 580 585 590
 Cys Leu Gly Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly Gly
 595 600 605
 Arg Gly Pro Arg Gly Ala Ser Trp Ala Ala Val Gln Ala Arg Pro Val
 610 615 620
 Ala Ser Gly Phe Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro
 625 630 635 640
 Arg His Gly Gly Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe
 645 650 655
 Cys Asn Glu Asn Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp
 660 665 670
 Gly Ser Trp Ser Lys Cys Ser Ser Asn Cys Gly Gly Met Gln Ser
 675 680 685
 Arg Arg Arg Ala Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly Val
 690 695 700
 Glu Phe Lys Thr Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg Asn
 705 710 715 720
 Thr Pro Trp Thr Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly Ala
 725 730 735
 Arg Gln Glu Gln Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala Asp
 740 745 750
 Pro His Gly Leu Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr Cys
 755 760 765
 Pro Ala Asp Gly Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu Val
 770 775 780
 Leu Leu Arg Ser Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly Trp
 785 790 795 800
 Ala Ala Trp Gly Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu Gly
 805 810 815
 Phe Arg Val Arg Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn Gly
 820 825 830
 Gly Leu Pro Cys Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn Pro
 835 840 845
 Gln Ala Cys Pro Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp Ser
 850 855 860

Pro Cys Ser Ala Ser Cys Gly Gly Gly His Tyr Gln Arg Thr Arg Ser
 865 870 875 880
 Cys Thr Ser Pro Ala Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu
 885 890 895
 His Thr Glu Glu Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp
 900 905 910
 Ser Pro Trp Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser
 915 920 925
 Arg Ser Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala
 930 935 940
 Gly Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val
 945 950 955 960
 Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly Phe
 965 970 975
 Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu Gly Ser
 980 985 990
 Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His Cys Gln Arg
 995 1000 1005
 Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr Pro Asn His
 1010 1015 1020
 Leu His Tyr Lys Gly Gly Thr Pro Lys Asn Glu Lys Tyr Thr
 1025 1030 1035
 Pro Met Glu Phe Lys Thr Leu Asn Lys Asn Asn Leu Ile Pro Asp
 1040 1045 1050
 Asp Arg Ala Asn Phe Tyr Pro Leu Gln Gln Thr Asn Val Tyr Thr
 1055 1060 1065
 Thr Thr Tyr Tyr Pro Ser Pro Leu Asn Lys His Ser Phe Arg Pro
 1070 1075 1080
 Glu Ala Ser Pro Gly Gln Arg Cys Phe Pro Asn Ser
 1085 1090 1095

<210> 22
 <211> 1248
 <212> PRT
 <213> Homo sapiens

<400> 22
 Arg Pro Pro His Ser Gln Thr Gly Arg Gln Pro Ile Trp Leu Ala Pro
 1 5 10 15
 Ala Ala Pro Arg Arg Pro Gly Val Gly Ser Arg Gly Glu Pro Gly Thr
 20 25 30
 Cys Thr Arg Leu Trp Glu Pro Ala Trp Val Arg Val Ala Leu Gly Pro
 35 40 45

Ala Arg Ala Val Val Gly Ala Ser Gly Leu Gln Arg Arg Trp Gly Pro
 50 55 60

Gly Thr Gln Ala Trp Arg Arg Arg Arg Thr Ser Glu Ala Glu Gly Arg
 65 70 75 80

Arg Asp Arg Val Ser Gly Ser Ser Trp Cys Leu Ala Cys Val Ser Trp
 85 90 95

Met Pro Cys Gly Phe Ser Pro Ser Pro Val Ala His His Leu Val Pro
 100 105 110

Gly Pro Pro Asp Thr Pro Ala Gln Gln Leu Arg Cys Gly Trp Thr Val
 115 120 125

Gly Gly Trp Leu Leu Ser Leu Val Arg Gly Leu Leu Pro Cys Leu Pro
 130 135 140

Pro Gly Ala Arg Thr Ala Glu Gly Pro Ile Met Val Leu Ala Gly Pro
 145 150 155 160

Leu Ala Val Ser Leu Leu Pro Ser Leu Thr Leu Leu Val Ser His
 165 170 175

Leu Ser Ser Ser Gln Asp Val Ser Ser Glu Pro Ser Ser Glu Gln Gln
 180 185 190

Leu Cys Ala Leu Ser Lys His Pro Thr Val Ala Phe Glu Asp Leu Gln
 195 200 205

Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp Phe Ser Gln
 210 215 220

Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu Ile Val Gly Ala Arg Asn
 225 230 235 240

Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val Ser Leu Leu Gln Ala Thr
 245 250 255

Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln Ser Lys Gly
 260 265 270

Lys Thr Glu Glu Glu Cys Gln Asn Tyr Val Arg Val Leu Ile Val Ala
 275 280 285

Gly Arg Lys Val Phe Met Cys Gly Thr Asn Ala Phe Ser Pro Met Cys
 290 295 300

Thr Ser Arg Gln Val Gly Asn Leu Ser Arg Thr Thr Glu Lys Ile Asn
 305 310 315 320

Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg His Asn Ser Thr Ala Val
 325 330 335

Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile Asp Phe Ser
 340 345 350

Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly Pro Pro Leu
 355 360 365

Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro Asn Phe Val

370	375	380
Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu Arg Glu Asn 385 390 395 400		
Ala Val Glu His Asp Cys Gly Arg Thr Val Tyr Ser Arg Val Ala Arg 405 410 415		
Val Cys Lys Asn Asp Val Gly Gly Arg Phe Leu Leu Glu Asp Thr Trp 420 425 430		
Thr Thr Phe Met Lys Ala Arg Leu Asn Cys Ser Arg Pro Gly Glu Val 435 440 445		
Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala Phe His Leu Pro Glu Gln 450 455 460		
Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn Val Asn Ser Ile Ala Ala 465 470 475 480		
Ser Ala Val Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln Ala Phe Asn 485 490 495		
Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp Leu Pro Ile 500 505 510		
Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro Glu Thr Gly 515 520 525		
Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala Gln Arg Leu 530 535 540		
Phe Leu Met Ser Glu Ala Val Gln Pro Val Thr Pro Glu Pro Cys Val 545 550 555 560		
Thr Gln Asp Ser Val Arg Phe Ser His Leu Val Val Asp Leu Val Gln 565 570 575		
Ala Lys Asp Thr Leu Tyr His Val Leu Tyr Ile Gly Thr Glu Ser Gly 580 585 590		
Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu His Gly Cys 595 600 605		
Tyr Leu Glu Glu Leu His Val Leu Pro Pro Gly Arg Arg Glu Pro Leu 610 615 620		
Arg Ser Leu Arg Ile Leu His Ser Ala Arg Ala Leu Phe Val Gly Leu 625 630 635 640		
Arg Asp Gly Val Leu Arg Val Pro Leu Glu Arg Cys Ala Ala Tyr Arg 645 650 655		
Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys Gly Trp Asp 660 665 670		
Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser Asn Met Ser 675 680 685		
Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro Val Arg Asn Val Thr Arg 690 695 700		

Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys Glu His Leu
 705 710 715 720

Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg Ser Cys Asp
 725 730 735

Ser Pro Arg Pro Arg Cys Gly Leu Asp Cys Leu Gly Pro Ala Ile
 740 745 750

His Ile Ala Asn Cys Ser Arg Asn Gly Ala Val Asp Pro Val Val Ile
 755 760 765

Val Gly Arg Cys Ala Ala Thr Ser Cys Gly Ile Gly Phe Gln Val Arg
 770 775 780

Gln Arg Ser Cys Ser Asn Pro Ala Pro Arg His Gly Gly Arg Ile Cys
 785 790 795 800

Val Gly Lys Ser Arg Glu Glu Arg Phe Cys Asn Glu Asn Thr Pro Cys
 805 810 815

Pro Val Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser Lys Cys Ser
 820 825 830

Ser Asn Cys Gly Gly Met Gln Ser Arg Arg Arg Ala Cys Glu Asn
 835 840 845

Gly Asn Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr Cys Asn Pro
 850 855 860

Glu Gly Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr Pro Trp Leu
 865 870 875 880

Pro Val Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln Arg Phe Arg
 885 890 895

Phe Thr Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu Gln Phe Gly
 900 905 910

Arg Arg Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly Ser Gly Ser
 915 920 925

Cys Asp Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser Gly Ser Thr
 930 935 940

Ser Pro His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly Pro Trp Ser
 945 950 955 960

Ser Cys Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg Lys Arg Thr
 965 970 975

Cys Thr Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys Val Gly Asp
 980 985 990

Ala Ala Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro Val Arg Gly
 995 1000 1005

Ala Trp Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala Ser Cys
 1010 1015 1020

Gly Gly Gly His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro Ala
 1025 1030 1035

Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu
 1040 1045 1050

Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp
 1055 1060 1065

Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser Arg Ser
 1070 1075 1080

Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala Gly
 1085 1090 1095

Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val
 1100 1105 1110

Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly
 1115 1120 1125

Phe Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu
 1130 1135 1140

Gly Ser Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His
 1145 1150 1155

Cys Gln Arg Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr
 1160 1165 1170

Pro Asn His Leu His Tyr Lys Gly Gly Gly Thr Pro Lys Asn Glu
 1175 1180 1185

Lys Tyr Thr Pro Met Glu Phe Lys Thr Leu Asn Lys Asn Asn Leu
 1190 1195 1200

Ile Pro Asp Asp Arg Ala Asn Phe Tyr Pro Leu Gln Gln Thr Asn
 1205 1210 1215

Val Tyr Thr Thr Tyr Tyr Pro Ser Pro Leu Asn Lys His Ser
 1220 1225 1230

Phe Arg Pro Glu Ala Ser Pro Gly Gln Arg Cys Phe Pro Asn Ser
 1235 1240 1245

<210> 23
<211> 1150
<212> PRT
<213> Homo sapiens

<400> 23
Ala Ala Ala Pro Phe Pro Asp Arg Pro Pro Ala His Leu Val Ser Ser
1 5 10 15

Arg Arg Ser Ala Pro Pro Gly Ser Arg Glu Pro Arg Gly Thr Gly His
20 25 30

Leu His Pro Pro Leu Gly Gly Leu Leu Pro Cys Leu Pro Pro Gly Ala
35 40 45

Arg Thr Ala Glu Gly Pro Ile Met Val Leu Ala Gly Pro Leu Ala Val
 50 55 60

Ser Leu Leu Leu Pro Ser Leu Thr Leu Leu Val Ser His Leu Ser Ser
 65 70 75 80

Ser Gln Asp Val Ser Ser Glu Pro Ser Ser Glu Gln Gln Leu Cys Ala
 85 90 95

Leu Ser Lys His Pro Thr Val Ala Phe Glu Asp Leu Gln Pro Trp Val
 100 105 110

Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp Phe Ser Gln Leu Ala Leu
 115 120 125

Asp Pro Ser Gly Asn Gln Leu Ile Val Gly Ala Arg Asn Tyr Leu Phe
 130 135 140

Arg Leu Ser Leu Ala Asn Val Ser Leu Leu Gln Ala Thr Glu Trp Ala
 145 150 155 160

Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln Ser Lys Gly Lys Thr Glu
 165 170 175

Glu Glu Cys Gln Asn Tyr Val Arg Val Leu Ile Val Ala Gly Arg Lys
 180 185 190

Val Phe Met Cys Gly Thr Asn Ala Phe Ser Pro Met Cys Thr Ser Arg
 195 200 205

Gln Val Gly Asn Leu Ser Arg Thr Thr Glu Lys Ile Asn Gly Val Ala
 210 215 220

Arg Cys Pro Tyr Asp Pro Arg His Asn Ser Thr Ala Val Ile Ser Ser
 225 230 235 240

Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile Asp Phe Ser Gly Arg Asp
 245 250 255

Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly Pro Pro Leu Arg Thr Ala
 260 265 270

Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro Asn Phe Val Ala Ala Tyr
 275 280 285

Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu Arg Glu Asn Ala Val Glu
 290 295 300

His Asp Cys Gly Arg Thr Val Tyr Ser Arg Val Ala Arg Val Cys Lys
 305 310 315 320

Asn Asp Val Gly Gly Arg Phe Leu Leu Glu Asp Thr Trp Thr Thr Phe
 325 330 335

Met Lys Ala Arg Leu Asn Cys Ser Arg Pro Gly Glu Val Pro Phe Tyr
 340 345 350

Tyr Asn Glu Leu Gln Ser Ala Phe His Leu Pro Glu Gln Asp Leu Ile
 355 360 365

Tyr Gly Val Phe Thr Thr Asn Val Asn Ser Ile Ala Ala Ser Ala Val
 370 375 380

 Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln Ala Phe Asn Gly Pro Phe
 385 390 395 400

 Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp Leu Pro Ile Ala Asn Pro
 405 410 415

 Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro Glu Thr Gly Pro Asn Glu
 420 425 430

 Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala Gln Arg Leu Phe Leu Met
 435 440 445

 Ser Glu Ala Val Gln Pro Val Thr Pro Glu Pro Cys Val Thr Gln Asp
 450 455 460

 Ser Val Arg Phe Ser His Leu Val Val Asp Leu Val Gln Ala Lys Asp
 465 470 475 480

 Thr Leu Tyr His Val Leu Tyr Ile Gly Thr Glu Ser Gly Thr Ile Leu
 485 490 495

 Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu His Gly Cys Tyr Leu Glu
 500 505 510

 Glu Leu His Val Leu Pro Pro Gly Arg Arg Glu Pro Leu Arg Ser Leu
 515 520 525

 Arg Ile Leu His Ser Ala Arg Ala Leu Phe Val Gly Leu Arg Asp Gly
 530 535 540

 Val Leu Arg Val Pro Leu Glu Arg Cys Ala Ala Tyr Arg Ser Gln Gly
 545 550 555 560

 Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys Gly Trp Asp Gly Lys Gln
 565 570 575

 Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser Asn Met Ser Leu Trp Thr
 580 585 590

 Gln Asn Ile Thr Ala Cys Pro Val Arg Asn Val Thr Arg Asp Gly Gly
 595 600 605

 Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys Glu His Leu Asp Gly Asp
 610 615 620

 Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg Ser Cys Asp Ser Pro Arg
 625 630 635 640

 Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly Pro Ala Ile His Ile Ala
 645 650 655

 Asn Cys Ser Arg Asn Gly Ala Val Asp Pro Val Val His Arg Gly Pro
 660 665 670

 Leu Cys Ser His Val Leu Trp His Ala Ala Ser Arg Ser Ala Ser Glu
 675 680 685

 Val Ala Ala Thr Leu Leu Pro Ala Thr Gly Ala Ala Ser Ala Trp Ala

690	695	700
Arg Ala Trp Glu Glu Arg Phe Cys Asn Glu Asn Thr Pro Cys Pro Val		
705	710	715
720		
Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser Lys Cys Ser Ser Asn		
725	730	735
Cys Gly Gly Gly Met Gln Ser Arg Arg Arg Ala Cys Glu Asn Gly Asn		
740	745	750
Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr Cys Asn Pro Glu Gly		
755	760	765
Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr Pro Trp Leu Pro Val		
770	775	780
Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln Arg Phe Arg Phe Thr		
785	790	795
800		
Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu Gln Phe Gly Arg Arg		
805	810	815
Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly Ser Gly Ser Cys Asp		
820	825	830
Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser Gly Ser Thr Ser Pro		
835	840	845
His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly Pro Trp Ser Ser Cys		
850	855	860
865		
Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg Lys Arg Thr Cys Thr		
870	875	880
Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys Val Gly Asp Ala Ala		
885	890	895
Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro Val Arg Gly Ala Trp		
900	905	910
Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala Ser Cys Gly Gly Gly		
915	920	925
His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro Ala Pro Ser Pro Gly		
930	935	940
945		
Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu Ala Leu Cys Ala Thr		
950	955	960
965		
Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp Ser Glu Trp Ser Lys Cys		
970	975	
980		
Thr Asp Asp Gly Ala Gln Ser Arg Ser Arg His Cys Glu Glu Leu Leu		
985	990	
995		
Pro Gly Ser Ser Ala Cys Ala Gly Asn Ser Ser Gln Ser Arg Pro Cys		
1000	1005	
1010		
Pro Tyr Ser Glu Ile Arg Val Ile Leu Pro Ala Ser Ser Met Glu		
1015	1020	

Glu Ala Thr Asp Cys Ala Gly Phe Asn Leu Ile His Leu Val Ala
 1025 1030 1035
 Thr Gly Ile Ser Cys Phe Leu Gly Ser Gly Leu Leu Thr Leu Ala
 1040 1045 1050
 Val Tyr Leu Ser Cys Gln His Cys Gln Arg Gln Ser Gln Glu Ser
 1055 1060 1065
 Thr Leu Val His Pro Ala Thr Pro Asn His Leu His Tyr Lys Gly
 1070 1075 1080
 Gly Gly Thr Pro Lys Asn Glu Lys Tyr Thr Pro Met Glu Phe Lys
 1085 1090 1095
 Thr Leu Asn Lys Asn Asn Leu Ile Pro Asp Asp Arg Ala Asn Phe
 1100 1105 1110
 Tyr Pro Leu Gln Gln Thr Asn Val Tyr Thr Thr Thr Tyr Tyr Pro
 1115 1120 1125
 Ser Pro Leu Asn Lys His Ser Phe Arg Pro Glu Ala Ser Pro Gly
 1130 1135 1140
 Gln Arg Cys Phe Pro Asn Ser
 1145 1150

<210> 24
 <211> 1211
 <212> PRT
 <213> Homo sapiens

<400> 24
 Ala Ala Ala Pro Phe Pro Asp Arg Pro Pro Ala His Leu Val Ser Ser
 1 5 10 15
 Arg Arg Ser Ala Pro Pro Gly Ser Arg Glu Pro Arg Gly Thr Gly His
 20 25 30
 Leu His Pro Pro Leu Gly Val Ser Gly Ser Ser Trp Cys Leu Ala Cys
 35 40 45
 Val Ser Trp Met Pro Cys Gly Phe Ser Pro Ser Pro Val Ala His His
 50 55 60
 Leu Val Pro Gly Pro Pro Asp Thr Pro Ala Gln Gln Leu Arg Cys Gly
 65 70 75 80
 Trp Thr Val Gly Gly Trp Leu Leu Ser Leu Val Arg Gly Leu Leu Pro
 85 90 95
 Cys Leu Pro Pro Gly Ala Arg Thr Ala Glu Gly Pro Ile Met Val Leu
 100 105 110
 Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser Leu Thr Leu Leu
 115 120 125
 Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser Glu Pro Ser Ser
 130 135 140

Glu Gln Gln Leu Cys Ala Leu Ser Lys His Pro Thr Val Ala Phe Glu
 145 150 155 160
 Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp
 165 170 175
 Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu Ile Val Gly
 180 185 190
 Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val Ser Leu Leu
 195 200 205
 Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln
 210 215 220
 Ser Lys Gly Lys Thr Glu Glu Cys Gln Asn Tyr Val Arg Val Leu
 225 230 235 240
 Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr Asn Ala Phe Ser
 245 250 255
 Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser Arg Thr Thr Glu
 260 265 270
 Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg His Asn Ser
 275 280 285
 Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile
 290 295 300
 Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly
 305 310 315 320
 Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro
 325 330 335
 Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu
 340 345 350
 Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr Val Tyr Ser Arg
 355 360 365
 Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg Phe Leu Leu Glu
 370 375 380
 Asp Thr Trp Thr Thr Phe Met Lys Ala Arg Leu Asn Cys Ser Arg Pro
 385 390 395 400
 Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala Phe His Leu
 405 410 415
 Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn Val Asn Ser
 420 425 430
 Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln
 435 440 445
 Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp
 450 455 460

Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro
 465 470 475 480
 Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala
 485 490 495
 Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro Val Thr Pro Glu
 500 505 510
 Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His Leu Val Val Asp
 515 520 525
 Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu Tyr Ile Gly Thr
 530 535 540
 Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu
 545 550 555 560
 His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro Pro Gly Arg Arg
 565 570 575
 Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala Arg Ala Leu Phe
 580 585 590
 Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu Glu Arg Cys Ala
 595 600 605
 Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys
 610 615 620
 Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser
 625 630 635 640
 Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro Val Arg Asn
 645 650 655
 Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys
 660 665 670
 Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg
 675 680 685
 Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly
 690 695 700
 Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly Ala Val Asp Pro
 705 710 715 720
 Val Val Ile Val Gly Arg Cys Ala Ala Thr Ser Cys Gly Ile Gly Phe
 725 730 735
 Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro Arg His Gly Gly
 740 745 750
 Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe Cys Asn Glu Asn
 755 760 765
 Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser
 770 775 780
 Lys Cys Ser Ser Asn Cys Gly Gly Met Gln Ser Arg Arg Arg Ala

785	790	795	800												
Cys	Glu	Asn	Gly	Asn	Ser	Cys	Leu	Gly	Cys	Gly	Val	Glu	Phe	Lys	Thr
				805					810					815	
Cys	Asn	Pro	Glu	Gly	Cys	Pro	Glu	Val	Arg	Arg	Asn	Thr	Pro	Trp	Thr
								820		825				830	
Pro	Trp	Leu	Pro	Val	Asn	Val	Thr	Gln	Gly	Gly	Ala	Arg	Gln	Glu	Gln
					835			840			845				
Arg	Phe	Arg	Phe	Thr	Cys	Arg	Ala	Pro	Leu	Ala	Asp	Pro	His	Gly	Leu
					850			855			860				
Gln	Phe	Gly	Arg	Arg	Arg	Thr	Glu	Thr	Arg	Thr	Cys	Pro	Ala	Asp	Gly
					865		870			875				880	
Ser	Gly	Ser	Cys	Asp	Thr	Asp	Ala	Leu	Val	Glu	Val	Leu	Leu	Arg	Ser
					885			890			895				
Gly	Ser	Thr	Ser	Pro	His	Thr	Val	Ser	Gly	Gly	Trp	Ala	Ala	Trp	Gly
					900			905			910				
Pro	Trp	Ser	Ser	Cys	Ser	Arg	Asp	Cys	Glu	Leu	Gly	Phe	Arg	Val	Arg
					915		920			925					
Lys	Arg	Thr	Cys	Thr	Asn	Pro	Glu	Pro	Arg	Asn	Gly	Gly	Leu	Pro	Cys
					930		935			940					
Val	Gly	Asp	Ala	Ala	Glu	Tyr	Gln	Asp	Cys	Asn	Pro	Gln	Ala	Cys	Pro
					945		950			955				960	
Val	Arg	Gly	Ala	Trp	Ser	Cys	Trp	Thr	Ser	Trp	Ser	Pro	Cys	Ser	Ala
					965			970			975				
Ser	Cys	Gly	Gly	His	Tyr	Gln	Arg	Thr	Arg	Ser	Cys	Thr	Ser	Pro	
					980		985			990					
Ala	Pro	Ser	Pro	Gly	Glu	Asp	Ile	Cys	Leu	Gly	Leu	His	Thr	Glu	Glu
					995			1000			1005				
Ala	Leu	Cys	Ala	Thr	Gln	Ala	Cys	Pro	Glu	Gly	Trp	Ser	Pro	Trp	
					1010		1015			1020					
Ser	Glu	Trp	Ser	Lys	Cys	Thr	Asp	Asp	Gly	Ala	Gln	Ser	Arg	Ser	
					1025		1030			1035					
Arg	His	Cys	Glu	Glu	Leu	Leu	Pro	Gly	Ser	Ser	Ala	Cys	Ala	Gly	
					1040		1045			1050					
Asn	Ser	Ser	Gln	Ser	Arg	Pro	Cys	Pro	Tyr	Ser	Glu	Ile	Arg	Val	
					1055		1060			1065					
Ile	Leu	Pro	Ala	Ser	Ser	Met	Glu	Glu	Ala	Thr	Asp	Cys	Ala	Gly	
					1070		1075			1080					
Phe	Asn	Leu	Ile	His	Leu	Val	Ala	Thr	Gly	Ile	Ser	Cys	Phe	Leu	
					1085		1090			1095					
Gly	Ser	Gly	Leu	Leu	Thr	Leu	Ala	Val	Tyr	Leu	Ser	Cys	Gln	His	
					1100		1105			1110					

Cys Gln Arg Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr
 1115 1120 1125

Pro Asn His Leu His Tyr Lys Gly Gly Gly Thr Pro Lys Asn Glu
 1130 1135 1140

Lys Tyr Thr Pro Met Glu Phe Lys Thr Leu Asn Lys Asn Asn Leu
 1145 1150 1155

Ile Pro Asp Asp Arg Ala Asn Phe Tyr Pro Leu Gln Gln Thr Asn
 1160 1165 1170

Ala Ser Ala Gly Tyr Pro Pro Leu Pro Gly Ser Leu Tyr Ser Thr
 1175 1180 1185

Gln Gly Ile Pro Leu Val Arg Gly Ser Glu Tyr Trp Glu Leu Glu
 1190 1195 1200

Ala Asp Leu Cys Leu Glu Val Leu
 1205 1210

<210> 25

<211> 1203

<212> PRT

<213> Homo sapiens

<400> 25

Ala Ala Ala Pro Phe Pro Asp Arg Pro Pro Ala His Leu Val Ser Ser
 1 5 10 15

Arg Arg Ser Ala Pro Pro Gly Ser Arg Glu Pro Arg Gly Thr Gly His
 20 25 30

Leu His Pro Pro Leu Gly Val Ser Gly Ser Ser Trp Cys Leu Ala Cys
 35 40 45

Val Ser Trp Met Pro Cys Gly Phe Ser Pro Ser Pro Val Ala His His
 50 55 60

Leu Val Pro Gly Pro Pro Asp Thr Pro Ala Gln Gln Leu Arg Cys Gly
 65 70 75 80

Trp Thr Val Gly Gly Trp Leu Leu Ser Leu Val Arg Gly Leu Leu Pro
 85 90 95

Cys Leu Pro Pro Gly Ala Arg Thr Ala Glu Gly Pro Ile Met Val Leu
 100 105 110

Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser Leu Thr Leu Leu
 115 120 125

Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser Glu Pro Ser Ser
 130 135 140

Glu Gln Gln Leu Cys Ala Leu Ser Lys His Pro Thr Val Ala Phe Glu
 145 150 155 160

Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp

	165	170	175
Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu Ile Val Gly			
180	185	190	
Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val Ser Leu Leu			
195	200	205	
Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln			
210	215	220	
Ser Lys Gly Lys Thr Glu Glu Cys Gln Asn Tyr Val Arg Val Leu			
225	230	235	240
Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr Asn Ala Phe Ser			
245	250	255	
Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser Arg Thr Thr Glu			
260	265	270	
Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg His Asn Ser			
275	280	285	
Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile			
290	295	300	
Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly			
305	310	315	320
Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro			
325	330	335	
Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu			
340	345	350	
Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr Val Tyr Ser Arg			
355	360	365	
Val, Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg Phe Leu Leu Glu			
370	375	380	
Asp Thr Trp Thr Thr Phe Met Lys Ala Arg Leu Asn Cys Ser Arg Pro			
385	390	395	400
Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala Phe His Leu			
405	410	415	
Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn Val Asn Ser			
420	425	430	
Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln			
435	440	445	
Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp			
450	455	460	
Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro			
465	470	475	480
Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala			
485	490	495	

Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro Val Thr Pro Glu
 500 505 510
 Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His Leu Val Val Asp
 515 520 525
 Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu Tyr Ile Gly Thr
 530 535 540
 Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu
 545 550 555 560
 His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro Pro Gly Arg Arg
 565 570 575
 Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala Arg Ala Leu Phe
 580 585 590
 Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu Glu Arg Cys Ala
 595 600 605
 Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys
 610 615 620
 Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser
 625 630 635 640
 Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro Val Arg Asn
 645 650 655
 Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys
 660 665 670
 Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg
 675 680 685
 Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly
 690 695 700
 Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly Ala Val Asp Pro
 705 710 715 720
 Val Val Ile Val Gly Arg Cys Ala Ala Thr Ser Cys Gly Ile Gly Phe
 725 730 735
 Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro Arg His Gly Gly
 740 745 750
 Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe Cys Asn Glu Asn
 755 760 765
 Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser
 770 775 780
 Lys Cys Ser Ser Asn Cys Gly Gly Met Gln Ser Arg Arg Arg Ala
 785 790 795 800
 Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr
 805 810 815

Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr
 820 825 830

Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln
 835 840 845

Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu
 850 855 860

Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly
 865 870 875 880

Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser
 885 890 895

Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly
 900 905 910

Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg
 915 920 925

Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys
 930 935 940

Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro
 945 950 955 960

Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala
 965 970 975

Ser Cys Gly Gly His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro
 980 985 990

Ala Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu
 995 1000 1005

Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp
 1010 1015 1020

Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser Arg Ser
 1025 1030 1035

Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala Gly
 1040 1045 1050

Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val
 1055 1060 1065

Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly
 1070 1075 1080

Phe Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu
 1085 1090 1095

Gly Ser Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His
 1100 1105 1110

Cys Gln Arg Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr
 1115 1120 1125

Pro Asn His Leu His Tyr Lys Gly Gly Gly Thr Pro Lys Asn Glu

1130	1135	1140													
Lys	Tyr	Thr	Pro	Met	Glu	Phe	Lys	Thr	Leu	Asn	Lys	Asn	Asn	Leu	
1145						1150					1155				
Ile	Pro	Asp	Asp	Arg	Ala	Asn	Phe	Tyr	Pro	Leu	Gln	Gln	Thr	Asn	
1160						1165					1170				
Val	Tyr	Thr	Thr	Thr	Tyr	Tyr	Pro	Ser	Pro	Leu	Asn	Lys	His	Ser	
1175						1180					1185				
Phe	Arg	Pro	Glu	Ala	Ser	Pro	Gly	Gln	Arg	Cys	Phe	Pro	Asn	Ser	
1190						1195					1200				
<210> 26															
<211> 1240															
<212> PRT															
<213> Homo sapiens															
<400> 26															
Ala	Ala	Ala	Pro	Phe	Pro	Asp	Arg	Pro	Pro	Ala	His	Leu	Val	Ser	Ser
1				5						10			15		
Arg	Arg	Ser	Ala	Pro	Pro	Gly	Ser	Arg	Glu	Pro	Arg	Gly	Thr	Gly	His
						20			25			30			
Leu	His	Pro	Pro	Leu	Gly	Val	Ser	Gly	Ser	Ser	Trp	Cys	Leu	Ala	Cys
						35			40			45			
Val	Ser	Trp	Met	Pro	Cys	Gly	Phe	Ser	Pro	Ser	Pro	Val	Ala	His	His
						50			55			60			
Leu	Val	Pro	Gly	Pro	Pro	Asp	Thr	Pro	Ala	Gln	Gln	Leu	Arg	Cys	Gly
						65			70			75			80
Trp	Thr	Val	Gly	Gly	Trp	Leu	Leu	Ser	Leu	Val	Arg	Gly	Arg	Lys	Pro
						85			90			95			
Ser	Gly	Asp	Phe	Glu	Trp	Arg	Gln	Gly	Trp	Arg	Gly	Pro	Gly	Glu	Glu
						100			105			110			
Asp	Trp	Pro	Glu	Ser	Pro	Ser	Pro	Lys	Val	Leu	Met	Asp	Ser	Ala	Gly
						115			120			125			
Gly	Leu	Leu	Pro	Cys	Leu	Pro	Pro	Gly	Ala	Arg	Thr	Ala	Glu	Gly	Pro
						130			135			140			
Ile	Met	Val	Leu	Ala	Gly	Pro	Leu	Ala	Val	Ser	Leu	Leu	Leu	Pro	Ser
						145			150			155			160
Leu	Thr	Leu	Leu	Val	Ser	His	Leu	Ser	Ser	Ser	Gln	Asp	Val	Ser	Ser
						165			170			175			
Glu	Pro	Ser	Ser	Glu	Gln	Gln	Leu	Cys	Ala	Leu	Ser	Lys	His	Pro	Thr
						180			185			190			
Val	Ala	Phe	Glu	Asp	Leu	Gln	Pro	Trp	Val	Ser	Asn	Phe	Thr	Tyr	Pro
						195			200			205			
Gly	Ala	Arg	Asp	Phe	Ser	Gln	Leu	Ala	Leu	Asp	Pro	Ser	Gly	Asn	Gln

210	215	220
Leu Ile Val Gly Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn		
225	230	235
240		
Val Ser Leu Leu Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg		
245	250	255
Arg Ser Cys Gln Ser Lys Gly Lys Thr Glu Glu Glu Cys Gln Asn Tyr		
260	265	270
Val Arg Val Leu Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr		
275	280	285
Asn Ala Phe Ser Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser		
290	295	300
Arg Thr Thr Glu Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro		
305	310	315
320		
Arg His Asn Ser Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala		
325	330	335
Ala Thr Val Ile Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser		
340	345	350
Leu Gly Ser Gly Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp		
355	360	365
Leu Asn Glu Pro Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala		
370	375	380
Tyr Phe Phe Leu Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr		
385	390	395
400		
Val Tyr Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg		
405	410	415
Phe Leu Leu Glu Asp Thr Trp Thr Thr Phe Met Lys Ala Arg Leu Asn		
420	425	430
Cys Ser Arg Pro Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser		
435	440	445
Ala Phe His Leu Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr		
450	455	460
Asn Val Asn Ser Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser		
465	470	475
480		
Ala Ile Ser Gln Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro		
485	490	495
Arg Ala Ala Trp Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys		
500	505	510
Gly Thr Leu Pro Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser		
515	520	525
Leu Gln Asp Ala Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro		
530	535	540

Val Thr Pro Glu Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His
 545 550 555 560
 Leu Val Val Asp Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu
 565 570 575
 Tyr Ile Gly Thr Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala
 580 585 590
 Ser Arg Ser Leu His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro
 595 600 605
 Pro Gly Arg Arg Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala
 610 615 620
 Arg Ala Leu Phe Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu
 625 630 635 640
 Glu Arg Cys Ala Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg
 645 650 655
 Asp Pro Tyr Cys Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu
 660 665 670
 Glu Asp Ser Ser Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys
 675 680 685
 Pro Val Arg Asn Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro
 690 695 700
 Trp Gln Pro Cys Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu
 705 710 715 720
 Cys Arg Ala Arg Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu
 725 730 735
 Asp Cys Leu Gly Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly
 740 745 750
 Gly Arg Gly Pro Arg Gly Ala Ser Trp Ala Ala Val Gln Ala Arg Pro
 755 760 765
 Val Ala Ser Gly Phe Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala
 770 775 780
 Pro Arg His Gly Gly Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg
 785 790 795 800
 Phe Cys Asn Glu Asn Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser
 805 810 815
 Trp Gly Ser Trp Ser Lys Cys Ser Ser Asn Cys Gly Gly Met Gln
 820 825 830
 Ser Arg Arg Arg Ala Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly
 835 840 845
 Val Glu Phe Lys Thr Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg
 850 855 860

Asn Thr Pro Trp Thr Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly
 865 870 875 880

Ala Arg Gln Glu Gln Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala
 885 890 895

Asp Pro His Gly Leu Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr
 900 905 910

Cys Pro Ala Asp Gly Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu
 915 920 925

Val Leu Leu Arg Ser Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly
 930 935 940

Trp Ala Ala Trp Gly Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu
 945 950 955 960

Gly Phe Arg Val Arg Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn
 965 970 975

Gly Gly Leu Pro Cys Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn
 980 985 990

Pro Gln Ala Cys Pro Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp
 995 1000 1005

Ser Pro Cys Ser Ala Ser Cys Gly Gly Gly His Tyr Gln Arg Thr
 1010 1015 1020

Arg Ser Cys Thr Ser Pro Ala Pro Ser Pro Gly Glu Asp Ile Cys
 1025 1030 1035

Leu Gly Leu His Thr Glu Glu Ala Leu Cys Ala Thr Gln Ala Cys
 1040 1045 1050

Pro Glu Gly Trp Ser Pro Trp Ser Glu Trp Ser Lys Cys Thr Asp
 1055 1060 1065

Asp Gly Ala Gln Ser Arg Ser Arg His Cys Glu Glu Leu Leu Pro
 1070 1075 1080

Gly Ser Ser Ala Cys Ala Gly Asn Ser Ser Gln Ser Arg Pro Cys
 1085 1090 1095

Pro Tyr Ser Glu Ile Arg Val Ile Leu Pro Ala Ser Ser Met Glu
 1100 1105 1110

Glu Ala Thr Asp Cys Ala Gly Phe Asn Leu Ile His Leu Val Ala
 1115 1120 1125

Thr Gly Ile Ser Cys Phe Leu Gly Ser Gly Leu Leu Thr Leu Ala
 1130 1135 1140

Val Tyr Leu Ser Cys Gln His Cys Gln Arg Gln Ser Gln Glu Ser
 1145 1150 1155

Thr Leu Val His Pro Ala Thr Pro Asn His Leu His Tyr Lys Gly
 1160 1165 1170

Gly Gly Thr Pro Lys Asn Glu Lys Tyr Thr Pro Met Glu Phe Lys

1175	1180	1185
Thr Leu Asn Lys Asn Asn	Leu Ile Pro Asp Asp Arg	Ala Asn Phe
1190	1195	1200
Tyr Pro Leu Gln Gln Thr Asn	Val Tyr Thr Thr Tyr Tyr Pro	
1205	1210	1215
Ser Pro Leu Asn Lys His Ser	Phe Arg Pro Glu Ala Ser Pro Gly	
1220	1225	1230
Gln Arg Cys Phe Pro Asn Ser		
1235	1240	

<210> 27
<211> 4567
<212> DNA
<213> Homo sapiens

<400> 27

cgggccgccc cattcccaga ccggccgcca gcccacatctgg ttagctcccc	ccgctccgcg	60
ccgccccggga gtcggggagcc gcggggaaacc gggcacctgc acccgccctct	gggagttagt	120
gttccagct ggtgcctggc ctgtgtctct tggatgccct gtggcttcag tccgtctcc		180
ttggcccacc acctcgtccc tggggccgct gatacccccag cccaacagct aagggtgtgga		240
tggacagtag ggggctggct tctctcaactg gtcaggggtc ttctccctgt tctgcctccc		300
ggagcttagga ctgcagaggg gcctatcatg gtgcttgcag gccccctggc tgcgtcgctg		360
ttgctgcccgc gcctcacact gtttgttgcac cacctctcca gctcccagga tgcgtccagt		420
gagcccgaca gtgagcagca gctgtgcgcc cttagcaagc acccccacccgt ggcccttgaa		480
gacctgcagc cgtgggtctc taacttcacc taccctggag cccgggattt ctcccagctg		540
gtttggacc cctccggaa ccagctcatc gtgggagcca ggaactacct cttcagactc		600
agccttgcca atgtctctct tcttcaggcc acagagtggg cctccagtgaa ggacacgcgc		660
cgctcctgccc aaagcaaagg gaagactgag gaggagtgtc agaactacgt gcgagtccgt		720
atcgctcgccg gccggaaagggt gttcatgtgt ggaaccaatg ctttttcccc catgtgcacc		780
agcagacagg tggggAACCT cagccggact actgagaaga tcaatgggtgt ggcccgctgc		840
cccttatgacc cacggccacaa ctccacagct gtcacatctct cccaggggaa gctctatgca		900
gccacggta tcgacttctc aggtcgggac cctgccatct accgcagccct gggcagtggg		960
ccaccgcttc gcactgccc atataactcc aagtggctta atgagccaaa cttcgtggca		1020
gccttatgata ttggctgtt tgcatacttc ttccctgggg agaacgcagt ggagcacgac		1080
tgtggacgca ccgttactc tcgcgtggcc cgctgtgca agaatgacgt gggggccgaa		1140
ttccctgtgg aggacacatg gaccacattt atgaaggccc ggctcaactg ctcccggcc		1200
ggcgagggtcc ctttctacta taacgagctg cagagtgcct tccacttgcc agagcaggac		1260
ctcatctatg gagtttcac aaccaacgta aacagcatcg cggcttctgc tgtctgcgc		1320
ttcaacctca gtgctatctc ccaggcttcc aatggcccat ttgcgtacca ggagaacccc		1380
aggggctgcct ggctcccat agccaacccc atcccaatt tccagtggtt caccctgcct		1440
gagaccggtc ccaacgagaa cctgacggag cgcaacgcgc aggacgcgc ggcctcttc		1500
ctgatgagcg aggccgtgca gcccgtgaca cccgagccct gtgtcacca ggacagcgtg		1560
cgcttctcac acctcgtggt ggacctgggt caggctaaag acacgctta ccatgtactc		1620
tacattggca ccgagtcggg caccatctt aaggcgctgt ccacggcggag ccgcagccctc		1680
cacggctgtt acctggagga gtcacatctg ctgcctcccg ggccgcgcgaa gcccctgcgc		1740
agcctgcgca tcctgcacag cggccgcgcg ctcttcgtgg ggctgagaga cggcgtccgt		1800
cgggctccac tggagaggtg cggccctac cgcaaggccagg gggcatgcct gggggccgg		1860
gaccctgtact gtggctggga cgggaaggcag caacgttgc gcacactcga ggacagctcc		1920
aacatgagcc tctggaccca gaacatcacc gcctgtcttg tgcggaaatgt gacacggat		1980
gggggcttcg gcccattggc accatggcaa ccatgtgagc acttggatgg ggacaactca		2040
ggctcttggc tggatgtggc tcgatctgt gattcccttc gaccccgctg tggggccctt		2100
gactgcctgg ggccagccat ccacatcgcc aactgttca ggaatggggc gtggaccccg		2160
tggatgttca gggcgctgtg cagcacgtcc tgcgttgcgt gcttccaggt ccgcagcga		2220
agttgcagca accctgttcc cggccacggg ggccgcacatc gctgtggccaa gagccggag		2280
gaacgggttct gtaatgagaa cacgccttgc cgggtgccc tcttctggcc ttccctggggc		2340
tcctggagca agtgcagcag caactgtgga ggggcacatgc agtcgcgcg tcggccgtgc		2400

gagaacggca	actcctgcct	gggctgcggc	gtggagttca	agacgtgcaa	ccccgaggc	2460
tgccccgaag	tgcggcgcaa	cacccctgg	acgcgcgtgc	tgcccgtgaa	cgtgacgcag	2520
ggcggggcac	ggcaggagca	gcgggttccgc	ttcacctgcc	gcgcgcct	tgcagaccccg	2580
cacggcctgc	agttcggcag	gagaaggacc	gagacgagga	cctgtcccg	ggacggctcc	2640
ggctcctgcg	acaccgacgc	cctggtggag	gtcctcctgc	gcagcggag	caccccccgg	2700
cacacggta	gcgggggctg	ggccgcctgg	ggcccggtgt	cgtcctgctc	ccgggactgc	2760
gagctgggct	tccgcgtccg	caagagaacg	tgcactaacc	cggagccccg	caacggggc	2820
ctgcctgcg	tgggcgatgc	tgccgagttac	caggactgca	accccccaggc	ttgcccagtt	2880
cgggggtgtt	ggtcctgctg	gacctcatgg	tctccatgtc	cagcttcctg	tggtgggggt	2940
cactatcaac	gcacccgttc	ctgcaccaggc	cccgacccct	ccccaggtga	ggacatctgt	3000
ctcgggctgc	acacggagga	ggcactatgt	gccacacagg	cctgcccaga	aggctggctcg	3060
ccctggtctg	agtggagtaa	gtgcactgac	gacggagccc	agagccgaag	ccggcactgt	3120
gaggagctcc	tcccagggtc	cagcgcmtgt	gctgaaaaca	gcagccagag	ccggccctgc	3180
ccctacagcg	agattcscgt	catcctgcca	gcctccagca	tggaggaggc	caccgactgt	3240
gcagggttca	atctcatcca	cttggtggcc	acggcatct	cctgcttctt	gggctctggg	3300
ctcctgaccc	tagcagtgt	cctgtcttgc	cagcaactgca	agcgtcagtc	ccaggagttc	3360
acactggtcc	atcctgcccac	ccccaaaccat	ttgcactaca	agggcggagg	caccccgaaag	3420
aatgaaaagt	acacacccat	ggaattcaag	accctgaaca	agaataactt	gatccctgtat	3480
gacagagcca	acttctaccc	attgcagcag	accatgtgt	acacgactac	ttactaccca	3540
agccccctga	acaaacacag	cttccggccc	gaggcctcac	ctggacaacg	gtgctttccc	3600
aacagctgat	accggcggtcc	tggggacttg	ggcttcttgc	cttcataagg	cacagagcg	3660
atggagatgg	gacagtggag	ccagtttgg	tttctccctc	tgcaactaggc	caagaacttg	3720
ctgccttgcc	tgtgggggt	cccatccggc	ttcagagagc	tctggctggc	attgaccatg	3780
ggggaaagg	ctgggtttag	gctgacat	ggccgcagg	ccagttcagc	ccaggtctmt	3840
catggttatc	ttccaaaccca	ctgtcacgt	gacactatgc	tgccatgcct	gggctgtgga	3900
cctactgggc	atttgagaa	ytggagaatg	gagatggcaa	gagggcaggc	ttttaagtt	3960
gggttggaga	caacttcctg	tggcccccac	aagctgagtc	tggccttctc	cagctggccc	4020
aaaaaaaggc	ctttgtaca	tcctgattat	ctctgaaagt	aatcaatcaa	gtggctccag	4080
tagctctgga	ttttctgcca	gggctggcc	attgtggtgc	tgcccagta	tgacatggga	4140
ccaaggccag	cgcagggttat	ccacccctgc	ctggaaagtct	atactctacc	cagggcatcc	4200
ctctggtcag	aggcagttag	tactgggaac	tggaggctga	cctgtgccta	gaagtccttt	4260
aatctgggt	ggtacaggcc	tcagccttgc	cctcaatgca	cgaaagggtgg	cccaggagag	4320
aggatcaatg	ccataggagg	cagaagtctg	gcctctgtgc	ctctatggag	actatcttcc	4380
agttgctgt	caacagagtt	gttggcttag	acctgcttgg	gagtctctgc	tggcccttca	4440
tctgttcagg	aacacacaca	cacacacact	cacacacgc	cacacaatca	caatttgcta	4500
cagcaacaaa	aaagacattg	ggctgtggca	ttattaatta	aagatgat	ccagtcaaaa	4560
aaaaact						4567

<210> 28
<211> 453
<212> DNA
<213> Homo sapiens

<400> 28

agtaatcagc	tcgggttccgg	catgtgctgt	agccagcgca	ggttatccac	ctctgcctgg	60
aagtctatac	tctacccagg	gcatccctct	ggtcagaggc	agttagtact	gggaacttgg	120
ggctgacctg	tgcttagaag	tcctttaatc	tgggtctggta	caggcctcag	ccttgcctc	180
aatgcacgaa	agggtggccca	ggagagagga	tcaatgccat	aggaggcaga	agtctggcct	240
ctgtgcctct	atggagacta	tcttccagg	gctgtcaac	agagttgtt	gctgagacct	300
gcttgggagt	ctctgctggc	ccttcatctg	ttcaggaaca	cacacacaca	cacactcaca	360
cacgcacaca	caatcacaat	ttgctacagc	aacaaaaaaag	acattggct	gtggcattat	420
taattaaaga	tgtatccag	tcaaaaaaaaa	act			453

<210> 29
<211> 4675
<212> DNA
<213> Homo sapiens

<400> 29

gcggccgccc cattcccaga ccggccgcca gcccacatctgg ttagctccccg ccgtcccgcg	60
ccgccccggga gtcggggagcc gcggggaaacc gggcacctgc acccgccctct gggagtgagt	120
gttccagct ggtgcctggc ctgtgtctct tggatgccct gtggcttcag tccgtctccct	180
ttggccacc acctcgccc tggggccgcct gatacccccag cccaacagct aagggtgtgga	240
tggacagtag ggggtggct tctctcaactg gtcaggggca ggaagccaag tggagacttt	300
aatgggaggc aaggatggag gggacactggg gaagaggact ggcctgaatc accttccca	360
aagggtctca tggactgagc tggaggttctt ctcccctgtc tgccctcccg agctaggact	420
gcagaggggc ctatcatggt gttgcagggc cccctggctg tctcgctgtt gctgcccagc	480
ctcacactgc ttgtgtccca cctctccaa ccccaggatg tctccagtgta gcccagcagt	540
gagcagcagc tgtgcgcctt tagcaagcac cccaccgtgg cctttaaga cctgcagccg	600
tgggtctcta acttacacta ccctggagcc cgggatttct cccagctggc tttggacccc	660
tccgggaacc agctcatcg gggagccagg aactacctct tcagactcag ccttgccaaat	720
gtctctttc ttcaaggccac agagtggggc tccagtgagg acacgcggcg ctctgccaa	780
agcaaaggga agactgagga ggagtgtcag aactacgtgc gagtcctgtat cgtgcggcgc	840
cggaaagggtgt tcatgtgtgg aaccaatgcc tttttccca tttgtcaccagg cagacagggt	900
gggaaacctca gccggactac tgagaagatc aatgtgtgg cccgctgccc ctatgaccca	960
cgcacacaact ccacagctgt catctccctt cagggggagc tctatgcagc cacggtcac	1020
gacttcttag gtcgggaccc tgccatctac cgccgcctgg gcaagtggcc accgccttcgc	1080
actgccccat ataactccaa gtggcttaat gagccaaact tcgtggcagc ctatgatatt	1140
gggctgtttt catacttctt cctgcgggag aacgcagtgg agcacgactg tggacgcacc	1200
gtgtactctc gcgtggccc cgtgtgcaag aatgacgtgg gggggccgatt cctgctggag	1260
gacacatgga ccacattcat gaaggccccc ctcaactgct cccgccccggg cgaggtcccc	1320
ttctactata acgagctgca gagtgccctt cactgcccag agcaggacact catctatgga	1380
gttttcacaaa ccaacgtaaa cagcatcg cgttctgtg tctgcgcctt caacctcagt	1440
gctatctccc aggcttcaa tggcccatatt cgctaccagg agaaccggc ggctgcctgg	1500
ctccccatag ccaacccat ccccaatttc cagtggtggca ccctgcctga gaccggccc	1560
aacgagaacc tgacggagcg cagcctgcaag gacgcgcagc gccttcttct gatgagcag	1620
gccgtgcagc cggtgacacc cggccctgt gtcacccagg acagcgtgcg cttdtcacac	1680
ctcggtgtgg acctgggtgca ggctaaagac acgctctacc atgtactcta cattggcacc	1740
gagtcgggca ccatccgtaa ggccgtgtcc acggcgagcc gcagcctcca cggctgctac	1800
ctggaggagc tgcacacgt gccccccggg cggccgcagc ccctgcgcag cctgcgcate	1860
ctgcacagcg cccgcgcgct cttcggtgg ctgagagacg gcgtcctgcg ggtcccactg	1920
gagaggtgcg ccgccttaccg cagccagggg gcatgcctgg gggcccccggg cccgtactgt	1980
ggctgggacg ggaagcagca acgttgcagc acactcgagg acagctccaa catgagcctc	2040
tggacccaga acatcaccgc ctgtcctgtg cggaatgtga cacggatgg gggcttcggc	2100
ccatggtcac catggcaacc atgtgagcac ttggatgggg acaactcagg ctctgcctg	2160
tgtcgagctc gatccgtgtt tccccctcga cccccgtgtg ggggccttga ctgcctgggg	2220
ccagccatcc acatcccaa ctgctccagg aatggggcgt ggaccggctg gtcatcggt	2280
gcgctgtgca gcacgtcctg tggcatggc ttccagggtcc gccagcgaag ttgcagcaac	2340
cctgctcccc gccacggggg ccgcacatctgc gtgggcaaga gcccggagga acggttctgt	2400
aatgagaaca cgccttggcc ggtgcccattc ttctgggttt cctggggctc ctggagcaag	2460
tgcagcagca actgtggagg gggcatgcag tcgcggcgtc gggcctgcga gAACGGCAAC	2520
tcctgcctgg gctgcggcgt ggagttcaag acgtgcaacc cggagggtgt cccggaaatg	2580
ccggcgaaca cccctggac gccgtggctg cccgtgaacg tgacgcaggg cggggcacgg	2640
caggagcagc gttccgtt cacctgcgcg gcgccttgc cagacccca cggctgcag	2700
ttcggcagga gaaggaccga gacgaggacc tggcccgccg acggctccgg ctctgcgac	2760
accgacgccc tggtgaggt cttctgcgc agcgggagca cttcccccga caccggtgac	2820
gggggctggg ccgcctgggg cccgtggctg tccctgccttcc gggactgcga gctgggcttc	2880
cgcgccgca agagaacgtg cactaaccgc gagccccgc acgggggctt gcctgcgtg	2940
ggcgatgctg ccgagatcca ggactgcaac ccccaggctt gcccagttcg ggggtctgg	3000
tcctgcgtga cctcatggc tccatgcctca gcttcctgtg gtgggggtca ctatcaacgc	3060
acccgttctt gcaccagccc cgcaccctcc ccaggtgagg acatctgtct cggctgcac	3120
acggaggagg cactatgtgc cacacaggcc tggccagaag gctggtcgc cttgtctgag	3180
tggagtaatg gcactgacga cggagccagg agccgaagcc ggcactgtga ggagctcctc	3240
ccagggtcca ggcgcmtgtgc tggaaacagc agccagagcc gcccctgccc ctacagcag	3300
attcscgtca tcctgccagc ctccagcatg gaggaggcca cgcactgtgc agggttcaat	3360
ctcatccact ttgtggccac gggcatctcc tgcttcttgg gctctggct cctgacccta	3420
gcagtgtacc tggcttgcca gcaactgccc cgtcaagtccc aggagtccac actggtccat	3480
cctgccaccc ccaaccattt gcactacaag ggcggaggca ccccgaaagaa tgaaaagtac	3540
acacccatgg aattcaagac cctgaacaag aataacttga tccctgtatga cagagccaaac	3600
ttctacccat tgcagcagac caatgtgtac acgactactt actacccaag cccctgaac	3660

aaacacagct	tccggccccga	ggcctcacct	ggacaacggt	gcttcccaa	cagtgatac	3720
cgcgtcctg	gggacttggg	tttctgcct	tcataaggca	cagagcagat	ggagatggga	3780
cagtggagcc	agtttggtt	tctccctctg	cactaggca	agaacttgc	gcctgcctg	3840
tggggggctc	catccggctt	cagagagctc	tggctggcat	tgaccatggg	ggaaagggct	3900
gttttcaggc	tgacatatgg	ccgcagggtcc	agttcagccc	aggctmtca	tggttatctt	3960
ccaacccact	gtcacgctga	cactatgcgt	ccatgcctgg	gctgtggacc	tactgggcat	4020
ttgaggaayt	ggagaatggg	gatggcaaga	gggcaggctt	ttaagtttg	gttggagaca	4080
acttcctgtg	gcccccacaa	gctgagtcgt	gcctctcca	gctggccca	aaaaaggcct	4140
ttgctacatc	ctgattatct	ctgaaagtaa	tcaatcaagt	ggctccagta	gctctggatt	4200
ttctgccagg	gctggccat	tgtggtgcgt	ccccagtagt	acatgggacc	aaggccagcg	4260
caggttatcc	acctctgcct	ggaagtctat	actctaccca	gggcattcct	ctggtcagag	4320
gcagtgagta	ctgggaactg	gaggctgacc	tgtgcttaga	agtcctttaa	tctgggctgg	4380
tacaggcctc	agcctgccc	tcaatgcacg	aaaggtggcc	caggagagag	gatcaatgcc	4440
ataggaggca	gaagtctggc	ctctgtgcct	ctatggagac	tatcttcag	ttgctgctca	4500
acagagttgt	tggctgagac	ctgctggga	gtctctgcgt	gcccttcatac	tgttcaggaa	4560
cacacacaca	cacacactca	cacacgcaca	cacaatcaca	atttgctaca	gcaacaaaaaa	4620
agacattggg	ctgtggcatt	attaattaaa	gatgatatcc	agtcaaaaaaa	aaact	4675

<210> 30
<211> 4731
<212> DNA
<213> Homo sapiens

<400> 30						
attggagatg	ctcgggggca	ggctgcccg	tttgtgcctg	cttttctgcg	gccagaccaa	60
gccgtctgga	gctgtggc	aggtttctt	gctgaccta	cctgaccaca	gtggcctggg	120
tggactctac	agggaaatgt	tgtttctcc	ctggagcag	tagcagcagt	cctggctccc	180
ctggactgag	aactcctcat	cagccccagg	aagccggac	ccccttccag	ggatctggaa	240
ccggtgtgcc	tgtggccca	ggtctgcctc	caggcgtggg	ctgaagtctt	gacttctgtc	300
gctggggca	aggagtggg	gagcccagct	gctgcctggg	cttggcaga	cagcaggctg	360
atgggtgtgg	cttccccgag	actgcttctc	ctgcctgcgt	tctgatttcc	ctgcatggtg	420
cccgcagctg	agctgctacg	ggtcttctcc	cctgtctgcc	tcccggagct	aggactgcag	480
aggggcctat	catggtgctt	gcaggcccc	tggctgtctc	gctgttgcgt	cccagcctca	540
cactgcttgt	gtcccacctc	tccagctccc	aggatgtctc	cagtgagccc	agcagtgagc	600
agcagctgtg	cgcccttagc	aagcacccca	ccgtggcctt	tgaagacctg	cagccgtggg	660
tctctaactt	cacctaccct	ggagcccg	atttctccca	gctggcttt	gaccctccg	720
gaaaccagct	catgtggg	gccaggaact	acctcttcag	actcagcctt	gccaatgtct	780
ctcttcttca	ggccacacag	tggcctcca	gtgaggacac	gcgcgcgtcc	tgc当地agca	840
aagggaagac	tgaggaggag	tgtcagaact	acgtgcgat	cctgatgc	gcggccgg	900
aggtgttcat	gtgtggaaacc	aatgcctttt	ccccatgtg	caccagcaga	cagtgggg	960
acctcagccg	gactactgag	aagatcaatg	gtgtggcccg	ctgcccatt	gaccacgccc	1020
acaactccac	agctgtcatc	tcctcccagg	gggagctcta	tgcagccacg	gtcatcgact	1080
tctcaggctg	ggaccctgccc	atctaccgca	gcctggcag	tggccaccg	cttcgcactg	1140
cccaatataa	ctccaaagtgg	cttaatgagc	caaacttcgt	ggcagccat	gatattgggc	1200
tgtttgcata	cttcttcctg	cgggagaacg	cagtgagca	cgactgtgg	cgccaccgtgt	1260
actctcgctg	ggcccgctg	tgcaagaatg	acgtgggggg	ccgattctg	ctggaggaca	1320
catggaccac	attcatgaag	gcccggctca	actgctcccg	cccgccgg	gtccccttct	1380
actataacga	gctgcagagt	gcctccact	tgccagagca	ggacctatc	tatggagttt	1440
tcacaaccaa	cgtaaacagc	atcgccgctt	ctgcgtctg	cgccttcaac	ctcagtgc	1500
tctcccaggc	tttcaatggc	ccatttcgt	accaggagaa	ccccagggt	gcctggctcc	1560
ccatagccaa	ccccatcccc	aatttccagt	gtggcaccct	gcctgagacc	ggtcccaacg	1620
agaacctgac	ggagcgcagc	ctgcaggacg	cgcagcgcct	cttccctgat	agcgaggccg	1680
tgcagccggt	gacacccgag	ccctgtgtca	cccaggacag	cgtgcgc	tcacacctcg	1740
tggtgaccc	ggtgcaggct	aaagacacgc	tctaccatgt	actctacatt	ggcaccgagt	1800
cgggcaccat	cctgaaggcg	ctgtccacgg	cgagccgcag	cctccacggc	tgctacactgg	1860
aggagctgca	cgtgcgtccc	cccggccg	gcgagccct	gcccgcgt	cgcacatcctgc	1920
acagcgc	cgcgccttc	gtgggctga	gagacggcgt	cctgcggc	ccactggaga	1980
ggtgcgcgc	ctaccgcagc	cagggggcat	gcctggggc	ccgggacccg	tactgtggct	2040
gggacgggaa	gcagcaacgt	tgcagcacac	tcgaggacag	ctccaacatg	agcctctgg	2100
cccagaacat	caccgcctgt	cctgtgcgga	atgtgacacg	gatggggc	ttcggccat	2160

ggtcaccatg	gcaaccatgt	gagcacttgg	atggggacaa	ctcaggctct	tgcctgtgtc	2220
gagctcgatc	ctgtgattcc	cctcgacc	gctgtgggg	ccttgactgc	ctggggccag	2280
ccatccacat	cgc	ccatgc	tccaggaatg	ggcg	ttcc	2340
tgtcagcac	gtc	ctgtggc	atcggcttcc	agg	cc	2400
ctccccgcca	cgg	ggcc	atctgcgtgg	gca	aa	2460
agaacacgccc	ttg	cccg	gttcttct	ggg	ctc	2520
gcagcaactg	tgg	gggg	atgcagtgc	ggc	ctgg	2580
gcctgggctg	ccg	cg	ttcaagacgt	gca	ac	2640
gcaacacccc	ctgg	ac	ttgg	gg	gg	2700
agcagcggtt	ccg	ttc	cc	cc	cc	2760
gcaggagaag	gac	cc	agg	cc	cc	2820
acgccttgtt	ggagg	tc	tc	gg	cc	2880
gctggggccgc	ctgg	gg	ttgg	cc	cc	2940
tccgcaagag	aac	gt	gt	cc	cc	3000
atgctgccga	gt	acc	agg	cc	cc	3060
gctggacctc	atgg	gt	ctc	ag	ct	3120
gttcctgcac	cag	ccc	cc	cc	cc	3180
aggaggca	atgt	gcc	ca	cc	cc	3240
gtaagtgcac	tgac	gac	gg	cc	cc	3300
ggtccagcgc	mtgt	gt	gg	cc	cc	3360
scgtcatcct	gcc	ag	gg	cc	cc	3420
tccacttgg	ggcc	ac	gg	cc	cc	3480
tgtacctgtc	ttgc	cag	tc	cc	cc	3540
ccaccccaa	ccatt	tg	ca	gg	cc	3600
ccatggaatt	caag	acc	tt	gg	cc	3660
acccattgca	gc	ag	tt	gg	cc	3720
acagcttccg	gccc	gagg	cc	ac	cc	3780
gtcctggg	cttgg	gtt	cc	tt	cc	3840
ggagccagtt	tg	ttt	ct	tc	cc	3900
gggtcccatc	cg	gtt	cc	tc	cc	3960
tcaggctgac	at	at	gg	cc	cc	4020
cccactgtca	cg	ct	gt	cc	cc	4080
ggaaytggag	aat	gg	gg	cc	cc	4140
cctgtggccc	cc	aca	ag	cc	cc	4200
tacatcctga	tt	at	tc	tt	cc	4260
gccagggctg	gg	cc	at	tt	cc	4320
ttatccacct	ct	gc	ct	cc	cc	4380
tgtagtactgg	ga	act	gg	cc	cc	4440
gcctcagcc	tt	gc	cct	cc	cc	4500
gaggcagaag	tct	gg	cct	cc	cc	4560
agttgttggc	tg	ag	ac	cc	cc	4620
cacacacaca	cac	tc	ca	cc	cc	4680
attgggtgt	gg	catt	tt	cc	cc	4731
ataaagatg	at	tt	cc	cc	cc	
aaaaaaaac	aa	aa	aa	aa	aa	
t						

<210> 31
<211> 4703
<212> DNA
<213> Homo sapiens

<400> 31						
gcggccgccc	cattccaga	ccggccgcca	gcccatctgg	ttagctcccg	ccgctccgcg	60
ccgcccgg	gtcgggagcc	gccccggaa	ggcacctgc	accgcctct	gggagccagc	120
ttgggtccgg	gttgactgg	ccctgccc	ggctgtggc	ggcgcatctg	ggctgcagcg	180
gcgatggg	cccg	gg	agg	gg	gg	240
gagggacaga	gtg	gg	cc	gg	cc	300
cttcagtcg	tct	c	cc	cc	cc	360
acagctaagg	tgt	gg	tt	cc	cc	420
cccctgtctg	cct	cc	gg	cc	cc	480
cctggctgtc	tcg	ctt	gg	cc	cc	540
ccaggatgtc	tcc	cc	gg	cc	cc	600

caccgtggcc	tttgaagacc	tgcagccgtg	ggtctctaac	ttcacctacc	ctggagcccg	660
ggatttctcc	cagctggctt	tggaccctc	cggsaaccag	ctcatcggtt	gagccaggaa	720
ctacctcttc	agactcagcc	ttgccaatgt	ctctttctt	caggccacag	agtgggcctc	780
cagtgaggac	acgcgccgct	cctgccaaag	caaagggaag	actgaggagg	agtgtcagaa	840
ctacgtgcga	gtcctgatcg	tcgcccggcg	gaaggtgttc	atgtgtgaa	ccaatgcctt	900
ttccccatg	tgcaccagca	gacaggtggg	gaacctcagc	cgfactactg	agaagatcaa	960
tggtgtggcc	cgctgcccct	atgaccacag	ccacaactcc	acagctgtca	tctcctccca	1020
gggggagctc	tatgcagcca	cggtcatcga	cttctcaggt	cgggaccctg	ccatctaccg	1080
cagcctgggc	agtggccac	cgcttcgac	tgcccaatata	aactccaagt	ggcttaatga	1140
gccaaacttc	gtggcagcct	atgatattgg	gctgttgca	tacttcttc	tgccggagaa	1200
cgcagtggag	cacgactgtg	gacgcaccgt	gtactctcgc	gtggcccgcg	tgtgcaagaa	1260
tgacgtgggg	ggccgattcc	tgctggagga	cacatggacc	acattcatga	aggcccggt	1320
caactgctcc	cgcggggcg	aggtccccctt	ctactataac	gagctgcaga	gtgccttcca	1380
tttgcagag	caggacctca	tctatggagt	tttcacaacc	aacgtaaaca	gcatcgccgc	1440
ttctgctgtc	tgcccttca	acctcagtc	tatctccag	gctttcaatg	gcccatttcg	1500
ctaccaggag	aaccccaggg	ctgcctggt	ccccatagcc	aaccccattcc	ccaatttcca	1560
gtgtggcacc	ctgcctgaga	ccgggtcccaa	cgagaacactg	acggagcga	gcctgcagga	1620
cgcgcagcgc	ctcttctga	tgagcgaggc	cgtgcagccg	tgacaccccg	agccctgtgt	1680
caccaggagc	agcgtgcgt	tctcacac	cgtgtggac	ctggtgcagg	ctaaagacac	1740
gctctaccat	gtactctaca	ttggcaccga	gtcgggcacc	atcctgaagg	cgctgtccac	1800
ggcgagccgc	agcctccacg	gctgtacact	ggaggagctg	cacgtgtgc	ccccggggcg	1860
ccgcgagccc	ctgcgcagcc	tgcgcatct	gcacagcgcc	cgcgcgctct	tcgtggggct	1920
gagagacggc	gtcctgcggg	tcccactgga	gaggtgcgccc	gcctaccgca	gccagggggc	1980
atgcctgggg	gcccgggacc	cgtaactgtgg	ctggacggg	aagcagcaac	gttgagcac	2040
actcgaggac	agctccaaca	tgaggctctg	gaccagaac	atcaccgcct	gtcctgtcg	2100
gaatgtgaca	cgggatgggg	gcttcggccc	atggtcacca	tggcaaccat	gtgagcactt	2160
ggatggggac	aactcaggct	tttgctgtg	tcgagctcga	tcctgtgatt	cccttcgacc	2220
ccgctgtggg	ggccttgact	gcctggggcc	agccatccac	atcgccaact	gtcccaaggaa	2280
tggggcgtgg	acccctgtgt	catcggtggc	gctgtgcagc	acgtcctgtg	gcatcggtt	2340
ccaggtccgc	cagcgaagtt	gcagcaaccc	tgctcccccgc	cacgggggcc	gcatctgcgt	2400
gggcaagagc	cgggaggaac	ggttctgtaa	tgagaacacg	ccttgcggcg	tgcccatctt	2460
ctgggcttcc	tgggcttcc	ggagcaagtg	cagcagcaac	tgtggagggg	gcatgcagtc	2520
gcggcgtcgg	gcctgcgaga	acggcaactc	ctgcctggc	tgccggcgtgg	agttcaagac	2580
gtgcaacccc	gagggctgcc	ccgaagtgcg	gcaacaccc	ccctggacgc	cgtggctgccc	2640
cgtgaacgtg	acgcaggcgc	gggcacggca	ggagcagcgg	ttccgcttca	cctgcccgc	2700
gcccctttca	gacccgcacg	gcctgcagtt	cgccaggaga	aggaccgaga	cgaggacctg	2760
tcccgccggc	ggctccggct	cctgcgacac	cgacccctg	gtggaggtcc	tcctgcgcag	2820
cgggagcacc	tcccccaca	cggtgagogg	gggctggggcc	gcctggggcc	cgtggctgtc	2880
ctgctccccc	gactgcgagc	tgggcttccg	cgtccgcaag	agaacgtgca	ctaaccggaa	2940
gccccggcaac	gggggcctgc	cctgcgtggg	cgatgtgc	gagtaccagg	actgcaaccc	3000
ccaggcttc	ccagttcggg	gtgcttggc	ctgctggacc	tcatgttctc	catgctcagc	3060
tccctgtgtt	gggggtcaact	atcaacgcac	ccgttccctgc	accagcccc	caccctcccc	3120
aggtgaggac	atctgtctcg	ggctgcacac	ggaggaggca	ctatgtgca	cacaggcctg	3180
cccagaaggc	tggtccttcc	ggtctgagtg	gagtaagtgc	actgacgacg	gagcccaagag	3240
ccgaagccgg	cactgtgagg	agctctccc	agggtccagc	gcmtgtgtc	gaaacagcag	3300
ccagagccgc	ccctggccct	acagcgagat	tcscgtcatc	ctgcccagct	ccagcatgga	3360
ggaggccacc	gactgtgcag	ggttcaatct	catccacttg	gtggccacgg	gcatctctg	3420
cttcttggc	tctggctcc	tgacccttagc	agtgtacctg	tcttgc	actgccagcg	3480
tcagtccttc	gagttccacac	tggtccatcc	tgccacccccc	aaccatttc	actacaagg	3540
cgaggccacc	ccgaagaatg	aaaagtacac	accatggaa	ttcaagaccc	tgaacaagaa	3600
taacttgatc	cctgtatgaca	gagccaaactt	ctaccatttgc	cagcagacca	atgtgtacac	3660
gactacttac	tacccaagcc	ccctgaacaa	acacagcttgc	cgccccgagg	cctcacctgg	3720
acaacgggtc	ttccccaaaca	gctgataccg	ccgtcctggg	gacttggct	tcttgccttc	3780
ataaggcaca	gagcagatgg	agatgggaca	gtggagccag	tttggtttc	tccctctgca	3840
ctaggccaag	aacttgctgc	cttgcctgtg	gggggtccca	tccggcttca	gagagctctg	3900
gctggcatgg	accatgggggg	aaagggtctgg	tttcaggctg	acatatggcc	gcaggtccag	3960
ttcagcccaag	gtctmtcatg	gttatcttc	aaccactgt	cacgctgaca	ctatgtgtc	4020
atgcctgggc	tgtggaccta	ctggcattt	gaggaaytgg	agaatggaga	tggcaagagg	4080
gcaggcttt	aagttgggt	tggagacaac	ttcctgtggc	ccccacaagc	tgagtctggc	4140
cttctccagc	tggccccc	aaaggcctt	gctacatct	gattatctt	gaaagtaatc	4200
aatcaagtgg	ctccagtagc	tctggatttt	ctgcccaggc	tggccatttgc	tggcgtgcc	4260

ccagtatgac	atgggaccaa	ggccagcgca	ggttatccac	ctctgcctgg	aagtctatac	4320
tctaccagg	gcatcccctct	ggtcagaggc	agttagtact	gggaactgga	ggctgacctg	4380
tgcttagaa	tcctttaatc	tggtctggta	caggcctcag	ccttgcctc	aatgcacgaa	4440
aggtggcca	ggagagagga	tcaatgccat	aggaggcaga	agtctggct	ctgtgcctct	4500
atggagacta	tcttcagtt	gctgctcaac	agagttgtt	gctgagacct	gcttgggagt	4560
ctctgctggc	ccttcatctg	ttcaggaaca	cacacacaca	cacactcaca	cacgcacaca	4620
caatcacaat	ttgctacagc	aacaaaaaaag	acattgggct	gtggcattat	taattaaaga	4680
tgatatccag	tcaaaaaaaaa	act				4703

<210> 32
<211> 4405
<212> DNA
<213> Homo sapiens

<400> 32						
gccccccgccc	cattcccaga	ccggccgcca	gcccacatctgg	ttagctcccg	ccgctccgcg	60
ccgccccggga	gtcgggagcc	gcggggaaacc	gggcacctgc	acccgcctct	gggaggtctt	120
ctccccctgtc	tgccctcccg	agcttagact	gcagaggggc	ctatcatgtt	gcttgcaggc	180
cccctggctg	tctcgctgtt	gctgcccagc	ctcacactgc	tggtgtccca	cctctccagc	240
tcccaggatg	tctccagtg	gcccagcagt	gagcagcagc	tgtgcgcct	tagaagcac	300
cccaccgtgg	cctttaaga	cctgcagccg	tgggtctcta	acttcaccta	ccctggagcc	360
cgggattttct	cccagctggc	tttggacccc	tccgggaacc	agctcatgt	gggagccagg	420
aactacctt	tcaagactcag	ccttgccaaat	gtctctttc	ttcaggccac	agagtgggcc	480
tccagtgagg	acacgcggc	ctcctgccaa	agcaaaaggga	agactgagga	ggagtgtcag	540
aactacgtgc	gagtccgtat	cgtcgcggc	cggaagggtgt	tcatgtgtt	aaccaatgcc	600
ttttccccca	tgtgcaccag	cagacaggtg	gggaacctca	gccggactac	tgagaagatc	660
aatggtgtgg	cccgctgccc	ctatgaccca	cgccacaact	ccacagctgt	catctcctcc	720
cagggggagc	tctatgcagc	cacggtcatac	gacttctcg	gtcgggaccc	tgccatctac	780
cgcagctgg	gcagtggcc	accgcttcgc	actgcccatt	ataactccaa	gtggcttaat	840
gagccaaact	tcgtggcagc	ctatgatatt	gggctgttt	catacttctt	cctgcgggag	900
aacgcagtgg	agcaacgactg	tggacgcacc	gtgtacttc	gcgtggcccg	cgtgtcaag	960
aatgacgtgg	ggggccgatt	ctctgtggag	gacacatgga	ccacattcat	gaaggcccg	1020
ctcaactgct	cccgccccggg	cgagggtcccc	ttctactata	acgagctgca	gagtgccttc	1080
cacttgcag	agcaggacct	catctatgga	gtttcacaa	ccaacgtaaa	cagcatcgcg	1140
gcttctgctg	tctgcgcctt	caacctca	gctatctccc	aggcttcaa	tggccattt	1200
cgctaccagg	agaaccccag	ggctgcctgg	ctccccatag	ccaacccat	ccccatttc	1260
cagtgtggca	ccctgcctga	gaccggctcc	aacgagaacc	tgacggagcg	cagcctgcag	1320
gacgcgcagc	gcctcttcc	gatgagcag	gccgtgcagc	cggtgacacc	cgagccctgt	1380
gtcaccagg	acagcgtgc	cttctcacac	ctcgtggtg	acctggtca	ggctaaagac	1440
acgctctacc	atgtactcta	cattggcacc	gagtcggca	ccatcctgaa	ggcgtgtcc	1500
acggcgagcc	gcagcctcca	cggctgctac	ctggaggagc	tgcacgtgt	gccccccggg	1560
cggccgcagc	ccctgcgcag	cctgcgcatac	ctgcacagcg	ccgcgcgcgt	cttcgtgggg	1620
ctgagagacg	gcgtcctgc	ggtcccactg	gagaggtgc	ccgcctaccg	cagccagggg	1680
gcatgcctgg	ggggccggga	cccgactgt	ggctgggacg	ggaagcagca	acgttgcagc	1740
acactcgagg	acagctccaa	catgagcctc	tggacccaga	acatcacccg	ctgtcctgt	1800
cggaatgtga	cacggatgg	gggcttcggc	ccatggtcac	catggcaacc	atgtgagcac	1860
ttggatgggg	acaactcagg	cttgcctg	tgtcgagtc	gatcctgt	ttcccctcga	1920
cccccgctgt	ggggccttga	ctgcctgggg	ccagccatcc	acatgccaa	ctgtccagg	1980
aatggggcgt	ggaccccg	gtcatcg	gctgtgt	gcacgtcct	tggcatcg	2040
ttccaggtcc	gccagcgaag	ttgcagcaac	cctgtcccc	gccacgggg	ccgcacatctgc	2100
gtgggcaaga	gcccggagga	acggtctgt	aatgagaaca	ccgccttgc	ggtgcctatc	2160
ttctgggctt	cctggggctc	ctggagcaag	tgcagcagca	actgtggagg	ggcgtgcag	2220
tcgcggcgtc	gggcctgc	gaacggcaac	tcctgcctgg	gctgcggcg	ggagttcaag	2280
acgtgcaacc	ccgaggggctg	ccccgaagt	cgccgcaaca	ccccctgac	ggcggtgg	2340
cccgtaacg	tgacgcagg	cggggcacgg	caggagcagc	ggttccgc	cacctgccc	2400
gcggcccttg	cagacccgca	cggcctgcag	ttcggcagga	gaaggaccga	gacgaggacc	2460
tgtcccgccgg	acggctccgg	ctcctgcgac	accgacccc	tggtgaggt	cctctgcgc	2520
agcggggagca	cctccccgca	cacggtg	ggggctgggg	ccgcctgggg	cccggtgtcg	2580
tcctgctccc	gggactgcga	gctgggctt	cgcgtccgca	agagaacgt	cactaacc	2640
gagccccc	acggggcc	gccctgcgt	ggcgatgct	ccgagatcca	ggactgcaac	2700

ccccaggctt	gcccagttcg	gggtgcttgg	tcctgctgga	cctcatggtc	tccatgctca	2760
gcttcctgtg	gtgggggtca	ctatcaacgc	acccgttccct	gcaccagcccc	cgcaccctcc	2820
ccaggtgagg	acatctgtct	cgggctgcac	acggaggagg	cactatgtgc	cacacaggcc	2880
tgcccagaag	gctggtcgcc	ctggctctgag	tggagtaagt	gcactgacga	cggagccag	2940
agccgaagcc	ggcactgtga	ggagctccctc	ccagggtcca	gkgcmtgtgc	tggaaacagc	3000
agccagagcc	gcccctgccc	ctacagcgag	attcscgtca	tcctgcccagc	ctccagcatg	3060
gaggaggcca	ccgactgtgc	agggttcaat	ctcatccact	tggtgccac	gggcacatctcc	3120
tgcttcttgg	gctctggct	cctgacccta	gcagtgtacc	tgtcttggca	gcactgcccag	3180
cgtcagtccc	aggagttcac	actggtccat	cctgccaccc	ccaaccattt	gcactacaag	3240
ggcggaggca	ccccgaagaa	tgaaaaagtac	acaccatgg	aattcaagac	cctgaacaag	3300
aataacttga	tccctgatga	cagagccaaac	ttcttacccat	tgccagcagac	aatgtgtac	3360
acgactact	actacccaag	ccccctgaac	aaacacagct	tccggcccca	ggcctcacct	3420
ggacaacggt	gcttccccaa	cagctgatac	cgccgtcctg	gggacttggg	cttcttgccct	3480
tcataaggca	cagagcagat	ggagatggga	cagtggagcc	agtttgggtt	tctccctctg	3540
cactaggcca	agaacttgct	gccttgcctg	tgggggtcc	catccggctt	cagagagctc	3600
tggctggcat	tgaccatggg	gaaaaggct	ggttcaggc	tgacatatgg	ccgcaggctcc	3660
agttcagccc	aggtctmtca	tggttatctt	ccaaacccact	gtcacgctga	cactatgtgc	3720
ccatgcctgg	gctgtggacc	tactggcat	ttgaggaayt	ggagaatgg	gatggcaaga	3780
gggcaggctt	ttaagtttgg	gttggagaca	acttctgtg	gccccccacaa	gctgagtcgt	3840
gccttctcca	gctggcccca	aaaaaggcct	ttgctacatc	ctgattatct	ctgaaagtaa	3900
tcaatcaagt	ggctccagta	gctctggatt	ttctgcccagg	gctggccat	tgtggtgctg	3960
ccccagtagt	acatgggacc	aaggccagcg	cagttatcc	acctctgcct	ggaagtctat	4020
actctaccca	gggcacccct	ctggtcagag	gcagttagta	ctgggaactg	gaggctgacc	4080
tgtgcttaga	agtcccttaa	tctgggctgg	tacaggcctc	agccttggcc	tcaatgcacg	4140
aaaggtggcc	caggagagag	gatcaatgcc	ataggaggca	gaagtctggc	ctctgtgcct	4200
ctatggagac	tatcttccag	ttgctgctca	acagagttgt	tggctgagac	ctgcttggga	4260
gtctctgctg	gcccttcatc	tgttcaggaa	cacacacaca	cacacactca	cacacgcaca	4320
cacaatcaca	atttgcatac	gaaacaaaaaa	agacattggg	ctgtggcatt	attaattaaa	4380
gatgatatcc	agtcaaaaaaa	aaact				4405

<210> 33
<211> 3938
<212> DNA
<213> Homo sapiens

<400> 33						
gcggccgc	cattccaga	ccggccgcca	gcccacatctgg	ttagctcccg	ccgctccgcg	60
ccgcccgg	gtcgggagcc	gcggggaaacc	gggcacactgc	acccgcctct	gggagtgtagt	120
gttccagct	gtgcctggc	ctgtgtctct	tggatgcctt	gtggcttcag	tccgtctccct	180
gttcccacc	acctcgtccc	tggggccct	gataacccag	ccaaacagct	aagggtgtgga	240
tggacagtag	ggggctggct	tctctcactg	gtcaggggtc	ttctccctgt	tctgcctccc	300
ggagcttaga	ctgcagaggg	gcctatcatg	gtgcttgcag	gccccctggc	tgtctcgctg	360
ttgctgcca	gcctcacact	gctgggttcc	cacctctcca	gctcccagga	tgtctccagt	420
gagcccaga	gtgagcagca	gctgtgcgcc	cttagcaagc	accccacccgt	ggcctttgaa	480
gacctgcagc	cgtgggtctc	taacttcacc	taccctggag	cccgggattt	ctcccagctg	540
gctttggacc	cctccggaa	ccagctcatc	gtgggagcca	ggaactaacct	cttcagactc	600
agccttgcca	atgtctct	tcttcaggcc	acagagtggg	cctccagtg	ggacacgcgc	660
cgctcctgcc	aaagcaaagg	gaagactgag	gaggagtgtc	agaactacgt	gcaagtctgc	720
atcgctgc	gcccggaaaggt	gttcatgtgt	ggaaccaatg	ccttttcccc	catgtgcacc	780
agcagacagg	tggggaacct	cagccggact	actgagaaga	tcaatgggt	ggcccgtgc	840
ccctatgacc	caccccacaa	ctccacagct	gtcatctcc	cccaggggaa	gctctatgca	900
gccacggta	tcgacttctc	aggtcgggac	cctgccatct	accgcagcct	ggcagtgccc	960
ccaccgctc	gcactgccc	atataactcc	aagtggctta	atgagccaa	ttcgtggca	1020
gcctatgata	ttgggctgtt	tgcataacttc	ttcctgcccgg	agaacgcagt	ggagcacgac	1080
tgtggacgca	ccgtgtactc	tcgcgtggcc	cgcgtgtgca	agaatgcacgt	ggggggccg	1140
ttcctgtcttgg	aggacacatg	gaccacattc	atgaaggccc	ggctcaactg	ctcccggccc	1200
ggcgagggtcc	ccttctacta	taacgagctg	cagagtgcct	tccacttgcc	agagcaggac	1260
ctcatctatg	gagttttcac	aaccaacgta	aacagcatcg	cggcttctgc	tgtctgcgc	1320
ttcaacaccta	gtgctatctc	ccaggcttc	aatggccat	ttcgtctacca	ggagaacccc	1380
agggctgcct	ggctcccat	agccaacccc	atcccaatt	tccagtgtgg	caccctgcct	1440

gagaccggtc ccaacgagaa cctgacggag cgacgcgc aggacgcga gcgccttc 1500
 ctgatgagcg aggccgtgca gccggtaca cccgagccct gtgtcacca ggacagcgtg 1560
 cgcttctcac acctcgttgt ggacctggg caggtaaag acacgctcta ccatgtactc 1620
 tacattggca ccgagtggg caccatctg aaggcgctgt ccacggcgag ccgcagcctc 1680
 cacggctgct acctggagga gtcgcacgtg ctgcggccgg ggcgccgca gcccctgcgc 1740
 agcctgcgca tcctgcacag cgccgcgcg ctctcgtgg ggctgagaga cggcgtcctg 1800
 cgggtcccac tggagaggtg cgccgcctac cgacgcccagg gggcatgcct gggggcccg 1860
 gaccctgtact gtggctggg cgggaagcag caacgttgca gcacactcga ggacagctcc 1920
 aacatgagcc tctggaccca gaacatcacc gcctgtcctg tgccgaatgt gacacggat 1980
 gggggcttcg gccccatggtc accatggcaa ccatgtgagc acttggatgg ggacaactca 2040
 ggctcttgcc tgtgtcggc tcgatcctgt gattccctc gaccccgctg tggggccctt 2100
 gactgcctgg ggccagccat ccacatcgcc aactgctcca ggaatgggc gtggaccccg 2160
 tggtcatcgt gggcgctgtg cagcacgtcc tgcgcatecg gcttccaggt cggccagcga 2220
 agttgcagca accctgctcc cgccacggg ggccgcattc gcgtgggcaa gagccggag 2280
 gaacggttct gtaatgagaa cacgccttgc ccggtgccca tcttctggc ttcctgggc 2340
 tcctggagca agtgcagcag caactgtgca gggggcatgc agtgcgcggc tcgggcctgc 2400
 gagaacggca actcctgcct gggctgcggc gtggagttca agacgtgcaaa ccccgaggc 2460
 tgccccgaag tgcggcgca caccggctgg acgcgcgtggc tgcccgatgg cgtacgcag 2520
 ggcggggcac ggcaggagca gcggttccgc ttcacctgccc gcgcgcctt tgcagaccccg 2580
 cacggcctgc agttcggcag gagaaggacc gagacgagga cctgtcccgc ggacggctcc 2640
 ggctcctgcg acaccgcacgc cctgggtggag gtcctcctgc gcagcggag caccccccgg 2700
 cacacggtga gcgggggctg ggccgcctgg ggcccgatgg cgtcctgc cccggactgc 2760
 gagctgggtc tccgcgtccg caagagaacg tgcactaacc cggagccccc caacggggc 2820
 ctgcctgcg tggcgatgc tgccgagttac caggactgca accccaggc ttggccagtt 2880
 cgggggtgtt ggtctgctg gacctcatgg tctccatgtc cagttctgt tggtgggggt 2940
 cactatcaac gcacccgttc ctgcaccacgc cccgcaccct ccccaggtga ggacatctgt 3000
 ctcgggctgc acacggagga ggcactatgt gccacacagg cctgcccaga aggctggc 3060
 ccctggtctg agtggagtaa gtgcactgac gacggagccc agagccaa cccggactgt 3120
 gaggagctcc tcccgaggc cagcgcmtgt gctgaaaaca gcagccagag ccccccgtc 3180
 ccctacagcg agattcscgt catcctgcca gcctccagca tggaggaggg caccgactgt 3240
 gcagggttca atctcatcca cttggtgcc acggcatct cctgcttctt gggctctggg 3300
 ctccctgaccc tagcagtgtc cctgtcttc cagcaactgca agcgtcaagtc ccaggagtc 3360
 acactggtcc atcctgcccac ccccaaccat ttgcactaca agggcggagg caccggaaag 3420
 aataaaaagt acacacccat ggaattcaag accctgaaca agaataactt gatccctgt 3480
 gacagagcca acttctaccc attgcagcag accaatgcca ggcgcaggta tccaccttg 3540
 cctgaaagtc tataactctac ccagggcattc cctctggtca gaggcagtga gtactggaa 3600
 ctggaggctg acctgtgtt agaagtcctt taatctggc tggtagggc ctcagccttg 3660
 ccctcaatgc acgaaagggtg gcccaggaga gaggatcaat gccataggag gcagaagtct 3720
 ggcctctgtg cctctatggc gactatcttc cagttgtc tcaacagagt tggctgtga 3780
 gacctgcttg ggagtctctg ctggcccttc atctgttcag gaacacacac acacacacac 3840
 tcacacacgc acacacacatc acaatttgct acagcaacaa aaaagacatt gggctgtggc 3900
 attattaatt aaagatgata tccagtcaaa aaaaaact 3938

<210> 34
 <211> 1095
 <212> PRT
 <213> Homo sapiens

<400> 34
 Met Val Leu Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser Leu
 1 5 10 15

Thr Leu Leu Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser Glu
 20 25 30

Pro Ser Ser Glu Gln Gln Leu Cys Ala Leu Ser Lys His Pro Thr Val
 35 40 45

Ala Phe Glu Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly
 50 55 60

Ala Arg Asp Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu
 65 70 75 80

Ile Val Gly Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val
 85 90 95

Ser Leu Leu Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg
 100 105 110

Ser Cys Gln Ser Lys Gly Lys Thr Glu Glu Glu Cys Gln Asn Tyr Val
 115 120 125

Arg Val Leu Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr Asn
 130 135 140

Ala Phe Ser Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser Arg
 145 150 155 160

Thr Thr Glu Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg
 165 170 175

His Asn Ser Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala
 180 185 190

Thr Val Ile Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu
 195 200 205

Gly Ser Gly Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu
 210 215 220

Asn Glu Pro Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr
 225 230 235 240

Phe Phe Leu Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr Val
 245 250 255

Tyr Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg Phe
 260 265 270

Leu Leu Glu Asp Thr Trp Thr Phe Met Lys Ala Arg Leu Asn Cys
 275 280 285

Ser Arg Pro Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala
 290 295 300

Phe His Leu Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn
 305 310 315 320

Val Asn Ser Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser Ala
 325 330 335

Ile Ser Gln Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg
 340 345 350

Ala Ala Trp Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly
 355 360 365

Thr Leu Pro Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu
 370 375 380

Gln Asp Ala Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro Val
 385 390 395 400
 Thr Pro Glu Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His Leu
 405 410 415
 Val Val Asp Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu Tyr
 420 425 430
 Ile Gly Thr Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser
 435 440 445
 Arg Ser Leu His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro Pro
 450 455 460
 Gly Arg Arg Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala Arg
 465 470 475 480
 Ala Leu Phe Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu Glu
 485 490 495
 Arg Cys Ala Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp
 500 505 510
 Pro Tyr Cys Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu
 515 520 525
 Asp Ser Ser Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro
 530 535 540
 Val Arg Asn Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp
 545 550 555 560
 Gln Pro Cys Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys
 565 570 575
 Arg Ala Arg Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp
 580 585 590
 Cys Leu Gly Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly Gly
 595 600 605
 Arg Gly Pro Arg Gly Ala Ser Trp Ala Ala Val Gln Ala Arg Pro Val
 610 615 620
 Ala Ser Gly Phe Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro
 625 630 635 640
 Arg His Gly Gly Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe
 645 650 655
 Cys Asn Glu Asn Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp
 660 665 670
 Gly Ser Trp Ser Lys Cys Ser Ser Asn Cys Gly Gly Met Gln Ser
 675 680 685
 Arg Arg Arg Ala Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly Val
 690 695 700
 Glu Phe Lys Thr Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg Asn

705	710	715	720
Thr Pro Trp Thr Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly Ala			
725		730	735
Arg Gln Glu Gln Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala Asp			
740		745	750
Pro His Gly Leu Gln Phe Gly Arg Arg Thr Glu Thr Arg Thr Cys			
755		760	765
Pro Ala Asp Gly Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu Val			
770		775	780
Leu Leu Arg Ser Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly Trp			
785	790	795	800
Ala Ala Trp Gly Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu Gly			
805		810	815
Phe Arg Val Arg Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn Gly			
820		825	830
Gly Leu Pro Cys Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn Pro			
835		840	845
Gln Ala Cys Pro Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp Ser			
850	855	860	
Pro Cys Ser Ala Ser Cys Gly Gly His Tyr Gln Arg Thr Arg Ser			
865	870	875	880
Cys Thr Ser Pro Ala Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu			
885		890	895
His Thr Glu Glu Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp			
900		905	910
Ser Pro Trp Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser			
915		920	925
Arg Ser Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala			
930		935	940
Gly Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val			
945		950	960
Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly Phe			
965		970	975
Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu Gly Ser			
980		985	990
Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His Cys Gln Arg			
995		1000	1005
Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr Pro Asn His			
1010		1015	1020
Leu His Tyr Lys Gly Gly Thr Pro Lys Asn Glu Lys Tyr Thr			
1025		1030	1035

Pro Met Glu Phe Lys Thr Leu Asn Lys Asn Asn Leu Ile Pro Asp
 1040 1045 1050

Asp Arg Ala Asn Phe Tyr Pro Leu Gln Gln Thr Asn Val Tyr Thr
 1055 1060 1065

Thr Thr Tyr Tyr Pro Ser Pro Leu Asn Lys His Ser Phe Arg Pro
 1070 1075 1080

Glu Ala Ser Pro Gly Gln Arg Cys Phe Pro Asn Ser
 1085 1090 1095

<210> 35

<211> 1248

<212> PRT

<213> Homo sapiens

<400> 35

Arg Pro Pro His Ser Gln Thr Gly Arg Gln Pro Ile Trp Leu Ala Pro
 1 5 10 15

Ala Ala Pro Arg Arg Pro Gly Val Gly Ser Arg Gly Glu Pro Gly Thr
 20 25 30

Cys Thr Arg Leu Trp Glu Pro Ala Trp Val Arg Val Ala Leu Gly Pro
 35 40 45

Ala Arg Ala Val Val Gly Ala Ser Gly Leu Gln Arg Arg Trp Gly Pro
 50 55 60

Gly Thr Gln Ala Trp Arg Arg Arg Arg Thr Ser Glu Ala Glu Gly Arg
 65 70 75 80

Arg Asp Arg Val Ser Gly Ser Ser Trp Cys Leu Ala Cys Val Ser Trp
 85 90 95

Met Pro Cys Gly Phe Ser Pro Ser Pro Val Ala His His Leu Val Pro
 100 105 110

Gly Pro Pro Asp Thr Pro Ala Gln Gln Leu Arg Cys Gly Trp Thr Val
 115 120 125

Gly Gly Trp Leu Leu Ser Leu Val Arg Gly Leu Leu Pro Cys Leu Pro
 130 135 140

Pro Gly Ala Arg Thr Ala Glu Gly Pro Ile Met Val Leu Ala Gly Pro
 145 150 155 160

Leu Ala Val Ser Leu Leu Pro Ser Leu Thr Leu Leu Val Ser His
 165 170 175

Leu Ser Ser Ser Gln Asp Val Ser Ser Glu Pro Ser Ser Glu Gln Gln
 180 185 190

Leu Cys Ala Leu Ser Lys His Pro Thr Val Ala Phe Glu Asp Leu Gln
 195 200 205

Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp Phe Ser Gln
 210 215 220

Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu Ile Val Gly Ala Arg Asn
 225 230 235 240
 Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val Ser Leu Leu Gln Ala Thr
 245 250 255
 Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln Ser Lys Gly
 260 265 270
 Lys Thr Glu Glu Glu Cys Gln Asn Tyr Val Arg Val Leu Ile Val Ala
 275 280 285
 Gly Arg Lys Val Phe Met Cys Gly Thr Asn Ala Phe Ser Pro Met Cys
 290 295 300
 Thr Ser Arg Gln Val Gly Asn Leu Ser Arg Thr Thr Glu Lys Ile Asn
 305 310 315 320
 Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg His Asn Ser Thr Ala Val
 325 330 335
 Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile Asp Phe Ser
 340 345 350
 Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly Pro Pro Leu
 355 360 365
 Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro Asn Phe Val
 370 375 380
 Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu Arg Glu Asn
 385 390 395 400
 Ala Val Glu His Asp Cys Gly Arg Thr Val Tyr Ser Arg Val Ala Arg
 405 410 415
 Val Cys Lys Asn Asp Val Gly Gly Arg Phe Leu Leu Glu Asp Thr Trp
 420 425 430
 Thr Thr Phe Met Lys Ala Arg Leu Asn Cys Ser Arg Pro Gly Glu Val
 435 440 445
 Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala Phe His Leu Pro Glu Gln
 450 455 460
 Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn Val Asn Ser Ile Ala Ala
 465 470 475 480
 Ser Ala Val Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln Ala Phe Asn
 485 490 495
 Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp Leu Pro Ile
 500 505 510
 Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro Glu Thr Gly
 515 520 525
 Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala Gln Arg Leu
 530 535 540

Phe Leu Met Ser Glu Ala Val Gln Pro Val Thr Pro Glu Pro Cys Val
 545 550 555 560
 Thr Gln Asp Ser Val Arg Phe Ser His Leu Val Val Asp Leu Val Gln
 565 570 575
 Ala Lys Asp Thr Leu Tyr His Val Leu Tyr Ile Gly Thr Glu Ser Gly
 580 585 590
 Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu His Gly Cys
 595 600 605
 Tyr Leu Glu Glu Leu His Val Leu Pro Pro Gly Arg Arg Glu Pro Leu
 610 615 620
 Arg Ser Leu Arg Ile Leu His Ser Ala Arg Ala Leu Phe Val Gly Leu
 625 630 635 640
 Arg Asp Gly Val Leu Arg Val Pro Leu Glu Arg Cys Ala Ala Tyr Arg
 645 650 655
 Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys Gly Trp Asp
 660 665 670
 Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser Asn Met Ser
 675 680 685
 Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro Val Arg Asn Val Thr Arg
 690 695 700
 Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys Glu His Leu
 705 710 715 720
 Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg Ser Cys Asp
 725 730 735
 Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly Pro Ala Ile
 740 745 750
 His Ile Ala Asn Cys Ser Arg Asn Gly Ala Val Asp Pro Val Val Ile
 755 760 765
 Val Gly Arg Cys Ala Ala Thr Ser Cys Gly Ile Gly Phe Gln Val Arg
 770 775 780
 Gln Arg Ser Cys Ser Asn Pro Ala Pro Arg His Gly Gly Arg Ile Cys
 785 790 795 800
 Val Gly Lys Ser Arg Glu Glu Arg Phe Cys Asn Glu Asn Thr Pro Cys
 805 810 815
 Pro Val Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser Lys Cys Ser
 820 825 830
 Ser Asn Cys Gly Gly Met Gln Ser Arg Arg Arg Ala Cys Glu Asn
 835 840 845
 Gly Asn Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr Cys Asn Pro
 850 855 860
 Glu Gly Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr Pro Trp Leu

865	870	875	880
Pro Val Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln Arg Phe Arg			
885	890	895	
Phe Thr Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu Gln Phe Gly			
900	905	910	
Arg Arg Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly Ser Gly Ser			
915	920	925	
Cys Asp Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser Gly Ser Thr			
930	935	940	
Ser Pro His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly Pro Trp Ser			
945	950	955	960
Ser Cys Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg Lys Arg Thr			
965	970	975	
Cys Thr Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys Val Gly Asp			
980	985	990	
Ala Ala Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro Val Arg Gly			
995	1000	1005	
Ala Trp Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala Ser Cys			
1010	1015	1020	
Gly Gly Gly His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro Ala			
1025	1030	1035	
Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu			
1040	1045	1050	
Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp			
1055	1060	1065	
Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser Arg Ser			
1070	1075	1080	
Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala Gly			
1085	1090	1095	
Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val			
1100	1105	1110	
Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly			
1115	1120	1125	
Phe Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu			
1130	1135	1140	
Gly Ser Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His			
1145	1150	1155	
Cys Gln Arg Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr			
1160	1165	1170	
Pro Asn His Leu His Tyr Lys Gly Gly Gly Thr Pro Lys Asn Glu			
1175	1180	1185	

Lys Tyr Thr Pro Met Glu Phe Lys Thr Leu Asn Lys Asn Asn Leu
 1190 1195 1200

Ile Pro Asp Asp Arg Ala Asn Phe Tyr Pro Leu Gln Gln Thr Asn
 1205 1210 1215

Val Tyr Thr Thr Tyr Tyr Pro Ser Pro Leu Asn Lys His Ser
 1220 1225 1230

Phe Arg Pro Glu Ala Ser Pro Gly Gln Arg Cys Phe Pro Asn Ser
 1235 1240 1245

<210> 36

<211> 1150

<212> PRT

<213> Homo sapiens

<400> 36

Ala Ala Ala Pro Phe Pro Asp Arg Pro Pro Ala His Leu Val Ser Ser
 1 5 10 15

Arg Arg Ser Ala Pro Pro Gly Ser Arg Glu Pro Arg Gly Thr Gly His
 20 25 30

Leu His Pro Pro Leu Gly Gly Leu Leu Pro Cys Leu Pro Pro Gly Ala
 35 40 45

Arg Thr Ala Glu Gly Pro Ile Met Val Leu Ala Gly Pro Leu Ala Val
 50 55 60

Ser Leu Leu Leu Pro Ser Leu Thr Leu Leu Val Ser His Leu Ser Ser
 65 70 75 80

Ser Gln Asp Val Ser Ser Glu Pro Ser Ser Glu Gln Gln Leu Cys Ala
 85 90 95

Leu Ser Lys His Pro Thr Val Ala Phe Glu Asp Leu Gln Pro Trp Val
 100 105 110

Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp Phe Ser Gln Leu Ala Leu
 115 120 125

Asp Pro Ser Gly Asn Gln Leu Ile Val Gly Ala Arg Asn Tyr Leu Phe
 130 135 140

Arg Leu Ser Leu Ala Asn Val Ser Leu Leu Gln Ala Thr Glu Trp Ala
 145 150 155 160

Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln Ser Lys Gly Lys Thr Glu
 165 170 175

Glu Glu Cys Gln Asn Tyr Val Arg Val Leu Ile Val Ala Gly Arg Lys
 180 185 190

Val Phe Met Cys Gly Thr Asn Ala Phe Ser Pro Met Cys Thr Ser Arg
 195 200 205

Gln Val Gly Asn Leu Ser Arg Thr Thr Glu Lys Ile Asn Gly Val Ala

210	215	220
Arg Cys Pro Tyr Asp Pro Arg His Asn Ser Thr Ala Val Ile Ser Ser		
225	230	235
Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile Asp Phe Ser Gly Arg Asp		
245	250	255
Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly Pro Pro Leu Arg Thr Ala		
260	265	270
Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro Asn Phe Val Ala Ala Tyr		
275	280	285
Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu Arg Glu Asn Ala Val Glu		
290	295	300
His Asp Cys Gly Arg Thr Val Tyr Ser Arg Val Ala Arg Val Cys Lys		
305	310	315
Asn Asp Val Gly Gly Arg Phe Leu Leu Glu Asp Thr Trp Thr Thr Phe		
325	330	335
Met Lys Ala Arg Leu Asn Cys Ser Arg Pro Gly Glu Val Pro Phe Tyr		
340	345	350
Tyr Asn Glu Leu Gln Ser Ala Phe His Leu Pro Glu Gln Asp Leu Ile		
355	360	365
Tyr Gly Val Phe Thr Thr Asn Val Asn Ser Ile Ala Ala Ser Ala Val		
370	375	380
Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln Ala Phe Asn Gly Pro Phe		
385	390	395
Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp Leu Pro Ile Ala Asn Pro		
405	410	415
Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro Glu Thr Gly Pro Asn Glu		
420	425	430
Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala Gln Arg Leu Phe Leu Met		
435	440	445
Ser Glu Ala Val Gln Pro Val Thr Pro Glu Pro Cys Val Thr Gln Asp		
450	455	460
Ser Val Arg Phe Ser His Leu Val Val Asp Leu Val Gln Ala Lys Asp		
465	470	475
480		
Thr Leu Tyr His Val Leu Tyr Ile Gly Thr Glu Ser Gly Thr Ile Leu		
485	490	495
Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu His Gly Cys Tyr Leu Glu		
500	505	510
Glu Leu His Val Leu Pro Pro Gly Arg Arg Glu Pro Leu Arg Ser Leu		
515	520	525
Arg Ile Leu His Ser Ala Arg Ala Leu Phe Val Gly Leu Arg Asp Gly		
530	535	540

Val Leu Arg Val Pro Leu Glu Arg Cys Ala Ala Tyr Arg Ser Gln Gly
 545 550 555 560
 Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys Gly Trp Asp Gly Lys Gln
 565 570 575
 Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser Asn Met Ser Leu Trp Thr
 580 585 590
 Gln Asn Ile Thr Ala Cys Pro Val Arg Asn Val Thr Arg Asp Gly Gly
 595 600 605
 Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys Glu His Leu Asp Gly Asp
 610 615 620
 Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg Ser Cys Asp Ser Pro Arg
 625 630 635 640
 Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly Pro Ala Ile His Ile Ala
 645 650 655
 Asn Cys Ser Arg Asn Gly Ala Val Asp Pro Val Val His Arg Gly Pro
 660 665 670
 Leu Cys Ser His Val Leu Trp His Ala Ala Ser Arg Ser Ala Ser Glu
 675 680 685
 Val Ala Ala Thr Leu Leu Pro Ala Thr Gly Ala Ala Ser Ala Trp Ala
 690 695 700
 Arg Ala Trp Glu Glu Arg Phe Cys Asn Glu Asn Thr Pro Cys Pro Val
 705 710 715 720
 Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser Lys Cys Ser Ser Asn
 725 730 735
 Cys Gly Gly Gly Met Gln Ser Arg Arg Arg Ala Cys Glu Asn Gly Asn
 740 745 750
 Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr Cys Asn Pro Glu Gly
 755 760 765
 Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr Pro Trp Leu Pro Val
 770 775 780
 Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln Arg Phe Arg Phe Thr
 785 790 795 800
 Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu Gln Phe Gly Arg Arg
 805 810 815
 Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly Ser Gly Ser Cys Asp
 820 825 830
 Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser Gly Ser Thr Ser Pro
 835 840 845
 His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly Pro Trp Ser Ser Cys
 850 855 860

Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg Lys Arg Thr Cys Thr
 865 870 875 880

Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys Val Gly Asp Ala Ala
 885 890 895

Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro Val Arg Gly Ala Trp
 900 905 910

Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala Ser Cys Gly Gly Gly
 915 920 925

His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro Ala Pro Ser Pro Gly
 930 935 940

Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu Ala Leu Cys Ala Thr
 945 950 955 960

Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp Ser Glu Trp Ser Lys Cys
 965 970 975

Thr Asp Asp Gly Ala Gln Ser Arg Ser Arg His Cys Glu Glu Leu Leu
 980 985 990

Pro Gly Ser Ser Ala Cys Ala Gly Asn Ser Ser Gln Ser Arg Pro Cys
 995 1000 1005

Pro Tyr Ser Glu Ile Arg Val Ile Leu Pro Ala Ser Ser Met Glu
 1010 1015 1020

Glu Ala Thr Asp Cys Ala Gly Phe Asn Leu Ile His Leu Val Ala
 1025 1030 1035

Thr Gly Ile Ser Cys Phe Leu Gly Ser Gly Leu Leu Thr Leu Ala
 1040 1045 1050

Val Tyr Leu Ser Cys Gln His Cys Gln Arg Gln Ser Gln Glu Ser
 1055 1060 1065

Thr Leu Val His Pro Ala Thr Pro Asn His Leu His Tyr Lys Gly
 1070 1075 1080

Gly Gly Thr Pro Lys Asn Glu Lys Tyr Thr Pro Met Glu Phe Lys
 1085 1090 1095

Thr Leu Asn Lys Asn Asn Leu Ile Pro Asp Asp Arg Ala Asn Phe
 1100 1105 1110

Tyr Pro Leu Gln Gln Thr Asn Val Tyr Thr Thr Thr Tyr Tyr Pro
 1115 1120 1125

Ser Pro Leu Asn Lys His Ser Phe Arg Pro Glu Ala Ser Pro Gly
 1130 1135 1140

Gln Arg Cys Phe Pro Asn Ser
 1145 1150

<210> 37
 <211> 1211
 <212> PRT

<213> Homo sapiens

<400> 37

Ala Ala Ala Pro Phe Pro Asp Arg Pro Pro Ala His Leu Val Ser Ser
1 5 10 15

Arg Arg Ser Ala Pro Pro Gly Ser Arg Glu Pro Arg Gly Thr Gly His
20 25 30

Leu His Pro Pro Leu Gly Val Ser Gly Ser Ser Trp Cys Leu Ala Cys
35 40 45

Val Ser Trp Met Pro Cys Gly Phe Ser Pro Ser Pro Val Ala His His
50 55 60

Leu Val Pro Gly Pro Pro Asp Thr Pro Ala Gln Gln Leu Arg Cys Gly
65 70 75 80

Trp Thr Val Gly Gly Trp Leu Leu Ser Leu Val Arg Gly Leu Leu Pro
85 90 95

Cys Leu Pro Pro Gly Ala Arg Thr Ala Glu Gly Pro Ile Met Val Leu
100 105 110

Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser Leu Thr Leu Leu
115 120 125

Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser Glu Pro Ser Ser
130 135 140

Glu Gln Gln Leu Cys Ala Leu Ser Lys His Pro Thr Val Ala Phe Glu
145 150 155 160

Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp
165 170 175

Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu Ile Val Gly
180 185 190

Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val Ser Leu Leu
195 200 205

Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln
210 215 220

Ser Lys Gly Lys Thr Glu Glu Glu Cys Gln Asn Tyr Val Arg Val Leu
225 230 235 240

Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr Asn Ala Phe Ser
245 250 255

Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser Arg Thr Thr Glu
260 265 270

Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg His Asn Ser
275 280 285

Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile
290 295 300

Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly

305	310	315	320
Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro			
325	330	335	
Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu			
340	345	350	
Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr Val Tyr Ser Arg			
355	360	365	
Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg Phe Leu Leu Glu			
370	375	380	
Asp Thr Trp Thr Thr Phe Met Lys Ala Arg Leu Asn Cys Ser Arg Pro			
385	390	395	400
Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala Phe His Leu			
405	410	415	
Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn Val Asn Ser			
420	425	430	
Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln			
435	440	445	
Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp			
450	455	460	
Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro			
465	470	475	480
Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala			
485	490	495	
Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro Val Thr Pro Glu			
500	505	510	
Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His Leu Val Val Asp			
515	520	525	
Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu Tyr Ile Gly Thr			
530	535	540	
Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu			
545	550	555	560
His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro Pro Gly Arg Arg			
565	570	575	
Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala Arg Ala Leu Phe			
580	585	590	
Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu Glu Arg Cys Ala			
595	600	605	
Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys			
610	615	620	
Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser			
625	630	635	640

Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro Val Arg Asn
 645 650 655
 Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys
 660 665 670
 Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg
 675 680 685
 Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly
 690 695 700
 Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly Ala Val Asp Pro
 705 710 715 720
 Val Val Ile Val Gly Arg Cys Ala Ala Thr Ser Cys Gly Ile Gly Phe
 725 730 735
 Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro Arg His Gly Gly
 740 745 750
 Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe Cys Asn Glu Asn
 755 760 765
 Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser
 770 775 780
 Lys Cys Ser Ser Asn Cys Gly Gly Met Gln Ser Arg Arg Arg Ala
 785 790 795 800
 Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr
 805 810 815
 Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr
 820 825 830
 Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln
 835 840 845
 Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu
 850 855 860
 Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly
 865 870 875 880
 Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser
 885 890 895
 Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly
 900 905 910
 Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg
 915 920 925
 Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys
 930 935 940
 Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro
 945 950 955 960

Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala
 965 970 975
 Ser Cys Gly Gly His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro
 980 985 990
 Ala Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu
 995 1000 1005
 Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp
 1010 1015 1020
 Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser Arg Ser
 1025 1030 1035
 Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala Gly
 1040 1045 1050
 Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val
 1055 1060 1065
 Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly
 1070 1075 1080
 Phe Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu
 1085 1090 1095
 Gly Ser Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His
 1100 1105 1110
 Cys Gln Arg Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr
 1115 1120 1125
 Pro Asn His Leu His Tyr Lys Gly Gly Gly Thr Pro Lys Asn Glu
 1130 1135 1140
 Lys Tyr Thr Pro Met Glu Phe Lys Thr Leu Asn Lys Asn Asn Leu
 1145 1150 1155
 Ile Pro Asp Asp Arg Ala Asn Phe Tyr Pro Leu Gln Gln Thr Asn
 1160 1165 1170
 Ala Ser Ala Gly Tyr Pro Pro Leu Pro Gly Ser Leu Tyr Ser Thr
 1175 1180 1185
 Gln Gly Ile Pro Leu Val Arg Gly Ser Glu Tyr Trp Glu Leu Glu
 1190 1195 1200
 Ala Asp Leu Cys Leu Glu Val Leu
 1205 1210

<210> 38
 <211> 1203
 <212> PRT
 <213> Homo sapiens

<400> 38
 Ala Ala Ala Pro Phe Pro Asp Arg Pro Pro Ala His Leu Val Ser Ser
 1 5 10 15

Arg Arg Ser Ala Pro Pro Gly Ser Arg Glu Pro Arg Gly Thr Gly His
 20 25 30

Leu His Pro Pro Leu Gly Val Ser Gly Ser Ser Trp Cys Leu Ala Cys
 35 40 45

Val Ser Trp Met Pro Cys Gly Phe Ser Pro Ser Pro Val Ala His His
 50 55 60

Leu Val Pro Gly Pro Pro Asp Thr Pro Ala Gln Gln Leu Arg Cys Gly
 65 70 75 80

Trp Thr Val Gly Gly Trp Leu Leu Ser Leu Val Arg Gly Leu Leu Pro
 85 90 95

Cys Leu Pro Pro Gly Ala Arg Thr Ala Glu Gly Pro Ile Met Val Leu
 100 105 110

Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser Leu Thr Leu Leu
 115 120 125

Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser Glu Pro Ser Ser
 130 135 140

Glu Gln Gln Leu Cys Ala Leu Ser Lys His Pro Thr Val Ala Phe Glu
 145 150 155 160

Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro Gly Ala Arg Asp
 165 170 175

Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln Leu Ile Val Gly
 180 185 190

Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn Val Ser Leu Leu
 195 200 205

Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg Arg Ser Cys Gln
 210 215 220

Ser Lys Gly Lys Thr Glu Glu Cys Gln Asn Tyr Val Arg Val Leu
 225 230 235 240

Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr Asn Ala Phe Ser
 245 250 255

Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser Arg Thr Thr Glu
 260 265 270

Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg His Asn Ser
 275 280 285

Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile
 290 295 300

Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser Leu Gly Ser Gly
 305 310 315 320

Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro
 325 330 335

Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu

340	345	350
Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr Val Tyr Ser Arg		
355	360	365
Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg Phe Leu Leu Glu		
370	375	380
Asp Thr Trp Thr Thr Phe Met Lys Ala Arg Leu Asn Cys Ser Arg Pro		
385	390	395
400		
Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala Phe His Leu		
405	410	415
Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn Val Asn Ser		
420	425	430
Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln		
435	440	445
Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp		
450	455	460
Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro		
465	470	475
480		
Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala		
485	490	495
Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro Val Thr Pro Glu		
500	505	510
Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His Leu Val Val Asp		
515	520	525
Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu Tyr Ile Gly Thr		
530	535	540
Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu		
545	550	555
560		
His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro Pro Gly Arg Arg		
565	570	575
Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala Arg Ala Leu Phe		
580	585	590
Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu Glu Arg Cys Ala		
595	600	605
Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys		
610	615	620
Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser		
625	630	635
640		
Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro Val Arg Asn		
645	650	655
Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys		
660	665	670

Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg
 675 680 685

Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly
 690 695 700

Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly Ala Val Asp Pro
 705 710 715 720

Val Val Ile Val Gly Arg Cys Ala Ala Thr Ser Cys Gly Ile Gly Phe
 725 730 735

Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro Arg His Gly Gly
 740 745 750

Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe Cys Asn Glu Asn
 755 760 765

Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser
 770 775 780

Lys Cys Ser Ser Asn Cys Gly Gly Met Gln Ser Arg Arg Arg Ala
 785 790 795 800

Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr
 805 810 815

Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr
 820 825 830

Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln
 835 840 845

Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu
 850 855 860

Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly
 865 870 875 880

Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu Val Leu Leu Arg Ser
 885 890 895

Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly
 900 905 910

Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg
 915 920 925

Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys
 930 935 940

Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro
 945 950 955 960

Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala
 965 970 975

Ser Cys Gly Gly Gly His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro
 980 985 990

Ala Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu
 995 1000 1005

Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp
 1010 1015 1020

Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser Arg Ser
 1025 1030 1035

Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala Gly
 1040 1045 1050

Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Arg Val
 1055 1060 1065

Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Asp Cys Ala Gly
 1070 1075 1080

Phe Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu
 1085 1090 1095

Gly Ser Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His
 1100 1105 1110

Cys Gln Arg Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr
 1115 1120 1125

Pro Asn His Leu His Tyr Lys Gly Gly Gly Thr Pro Lys Asn Glu
 1130 1135 1140

Lys Tyr Thr Pro Met Glu Phe Lys Thr Leu Asn Lys Asn Asn Leu
 1145 1150 1155

Ile Pro Asp Asp Arg Ala Asn Phe Tyr Pro Leu Gln Gln Thr Asn
 1160 1165 1170

Val Tyr Thr Thr Thr Tyr Tyr Pro Ser Pro Leu Asn Lys His Ser
 1175 1180 1185

Phe Arg Pro Glu Ala Ser Pro Gly Gln Arg Cys Phe Pro Asn Ser
 1190 1195 1200

<210> 39
 <211> 1240
 <212> PRT
 <213> Homo sapiens

<400> 39
 Ala Ala Ala Pro Phe Pro Asp Arg Pro Pro Ala His Leu Val Ser Ser
 1 5 10 15

Arg Arg Ser Ala Pro Pro Gly Ser Arg Glu Pro Arg Gly Thr Gly His
 20 25 30

Leu His Pro Pro Leu Gly Val Ser Gly Ser Ser Trp Cys Leu Ala Cys
 35 40 45

Val Ser Trp Met Pro Cys Gly Phe Ser Pro Ser Pro Val Ala His His
 50 55 60

Leu Val Pro Gly Pro Pro Asp Thr Pro Ala Gln Gln Leu Arg Cys Gly
 65 70 75 80
 Trp Thr Val Gly Gly Trp Leu Leu Ser Leu Val Arg Gly Arg Lys Pro
 85 90 95
 Ser Gly Asp Phe Glu Trp Arg Gln Gly Trp Arg Gly Pro Gly Glu Glu
 100 105 110
 Asp Trp Pro Glu Ser Pro Ser Pro Lys Val Leu Met Asp Ser Ala Gly
 115 120 125
 Gly Leu Leu Pro Cys Leu Pro Pro Gly Ala Arg Thr Ala Glu Gly Pro
 130 135 140
 Ile Met Val Leu Ala Gly Pro Leu Ala Val Ser Leu Leu Leu Pro Ser
 145 150 155 160
 Leu Thr Leu Leu Val Ser His Leu Ser Ser Ser Gln Asp Val Ser Ser
 165 170 175
 Glu Pro Ser Ser Glu Gln Gln Leu Cys Ala Leu Ser Lys His Pro Thr
 180 185 190
 Val Ala Phe Glu Asp Leu Gln Pro Trp Val Ser Asn Phe Thr Tyr Pro
 195 200 205
 Gly Ala Arg Asp Phe Ser Gln Leu Ala Leu Asp Pro Ser Gly Asn Gln
 210 215 220
 Leu Ile Val Gly Ala Arg Asn Tyr Leu Phe Arg Leu Ser Leu Ala Asn
 225 230 235 240
 Val Ser Leu Leu Gln Ala Thr Glu Trp Ala Ser Ser Glu Asp Thr Arg
 245 250 255
 Arg Ser Cys Gln Ser Lys Gly Lys Thr Glu Glu Glu Cys Gln Asn Tyr
 260 265 270
 Val Arg Val Leu Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr
 275 280 285
 Asn Ala Phe Ser Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser
 290 295 300
 Arg Thr Thr Glu Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro
 305 310 315 320
 Arg His Asn Ser Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala
 325 330 335
 Ala Thr Val Ile Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg Ser
 340 345 350
 Leu Gly Ser Gly Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp
 355 360 365
 Leu Asn Glu Pro Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala
 370 375 380
 Tyr Phe Phe Leu Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr

385	390	395	400
Val Tyr Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg			
405	410	415	
Phe Leu Leu Glu Asp Thr Trp Thr Phe Met Lys Ala Arg Leu Asn			
420	425	430	
Cys Ser Arg Pro Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser			
435	440	445	
Ala Phe His Leu Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr			
450	455	460	
Asn Val Asn Ser Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser			
465	470	475	480
Ala Ile Ser Gln Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro			
485	490	495	
Arg Ala Ala Trp Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys			
500	505	510	
Gly Thr Leu Pro Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser			
515	520	525	
Leu Gln Asp Ala Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro			
530	535	540	
Val Thr Pro Glu Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His			
545	550	555	560
Leu Val Val Asp Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu			
565	570	575	
Tyr Ile Gly Thr Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala			
580	585	590	
Ser Arg Ser Leu His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro			
595	600	605	
Pro Gly Arg Arg Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala			
610	615	620	
Arg Ala Leu Phe Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu			
625	630	635	640
Glu Arg Cys Ala Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg			
645	650	655	
Asp Pro Tyr Cys Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu			
660	665	670	
Glu Asp Ser Ser Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys			
675	680	685	
Pro Val Arg Asn Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro			
690	695	700	
Trp Gln Pro Cys Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu			
705	710	715	720

Cys Arg Ala Arg Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu
 725 730 735
 Asp Cys Leu Gly Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly
 740 745 750
 Gly Arg Gly Pro Arg Gly Ala Ser Trp Ala Ala Val Gln Ala Arg Pro
 755 760 765
 Val Ala Ser Gly Phe Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala
 770 775 780
 Pro Arg His Gly Gly Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg
 785 790 795 800
 Phe Cys Asn Glu Asn Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser
 805 810 815
 Trp Gly Ser Trp Ser Lys Cys Ser Ser Asn Cys Gly Gly Met Gln
 820 825 830
 Ser Arg Arg Arg Ala Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly
 835 840 845
 Val Glu Phe Lys Thr Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg
 850 855 860
 Asn Thr Pro Trp Thr Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly
 865 870 875 880
 Ala Arg Gln Glu Gln Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala
 885 890 895
 Asp Pro His Gly Leu Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr
 900 905 910
 Cys Pro Ala Asp Gly Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu
 915 920 925
 Val Leu Leu Arg Ser Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly
 930 935 940
 Trp Ala Ala Trp Gly Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu
 945 950 955 960
 Gly Phe Arg Val Arg Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn
 965 970 975
 Gly Gly Leu Pro Cys Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn
 980 985 990
 Pro Gln Ala Cys Pro Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp
 995 1000 1005
 Ser Pro Cys Ser Ala Ser Cys Gly Gly Gly His Tyr Gln Arg Thr
 1010 1015 1020
 Arg Ser Cys Thr Ser Pro Ala Pro Ser Pro Gly Glu Asp Ile Cys
 1025 1030 1035

Leu Gly Leu His Thr Glu Glu Ala Leu Cys Ala Thr Gln Ala Cys
1040 1045 1050

Pro Glu Gly Trp Ser Pro Trp Ser Glu Trp Ser Lys Cys Thr Asp
1055 1060 1065

Asp Gly Ala Gln Ser Arg Ser Arg His Cys Glu Glu Leu Leu Pro
1070 1075 1080

Gly Ser Ser Ala Cys Ala Gly Asn Ser Ser Gln Ser Arg Pro Cys
1085 1090 1095

Pro Tyr Ser Glu Ile Arg Val Ile Leu Pro Ala Ser Ser Met Glu
1100 1105 1110

Glu Ala Thr Asp Cys Ala Gly Phe Asn Leu Ile His Leu Val Ala
1115 1120 1125

Thr Gly Ile Ser Cys Phe Leu Gly Ser Gly Leu Leu Thr Leu Ala
1130 1135 1140

Val Tyr Leu Ser Cys Gln His Cys Gln Arg Gln Ser Gln Glu Ser
1145 1150 1155

Thr Leu Val His Pro Ala Thr Pro Asn His Leu His Tyr Lys Gly
1160 1165 1170

Gly Gly Thr Pro Lys Asn Glu Lys Tyr Thr Pro Met Glu Phe Lys
1175 1180 1185

Thr Leu Asn Lys Asn Asn Leu Ile Pro Asp Asp Arg Ala Asn Phe
1190 1195 1200

Tyr Pro Leu Gln Gln Thr Asn Val Tyr Thr Thr Thr Tyr Tyr Pro
1205 1210 1215

Ser Pro Leu Asn Lys His Ser Phe Arg Pro Glu Ala Ser Pro Gly
1220 1225 1230

Gln Arg Cys Phe Pro Asn Ser
1235 1240